background
supraregion
prescrib
algorithm
pa
antiretrovir
arv
drug
impos
unit
follow
consult
process
april
audit
arv
prescrib
perform
polici
chang
result
compar
evalu
arv
manag
patient
outcom
centr
throughout
period
chang
relev
chang
also
occur
time
newer
arv
becam
avail
commiss
nh
england
method
retrospect
case
record
review
patient
start
arv
first
time
centr
jan
april
pa
introduc
assess
whether
treatment
consist
bhiva
guidelin
pa
undetect
hiv
viral
load
vl
still
first
line
treatment
persist
start
arv
cost
save
achiev
first
audit
differ
prescrib
pattern
consult
also
assess
follow
introduct
pa
longer
consid
necessari
prescrib
member
multidisciplinari
team
mdt
includ
result
record
patient
examin
first
second
audit
complianc
bhiva
guidelin
high
first
audit
minor
differ
consult
prescrib
practic
follow
introduct
pa
first
line
regimen
kivexaefavirenz
pa
regimen
justif
document
mdt
undetect
vl
month
treatment
increas
persist
rate
similar
largest
chang
prescrib
increas
use
lamivudineabacavir
integras
inhibitor
ini
singl
commonli
prescrib
regimen
atripla
first
audit
triumeq
second
cost
save
approxim
per
patient
per
year
conclus
signific
chang
prescrib
practic
note
unit
past
year
improv
rapid
virolog
control
note
patient
first
line
regimen
new
pa
unlik
reason
like
increas
use
ini
especi
triumeq
cost
save
pa
introduct
modest
weigh
increas
need
mdt
discuss
even
straightforward
prescrib
decis
background
atvrel
nephrolithiasi
well
report
approxim
incid
case
per
patient
year
atazanavir
atv
relat
cholelithiasi
recent
describ
report
case
year
old
whitebritish
male
present
cholang
due
atv
contain
gallston
method
follow
diagnosi
patient
start
antiretrovir
therapi
present
truvada
atvritonavir
year
admiss
count
cellsmm
nondetect
viral
load
copiesml
patient
present
right
upper
quadrant
pain
fever
jaundic
treat
biliari
sepsi
magnet
reson
cholangiopancreatogram
mrcp
confirm
gallston
possibl
sludg
distal
common
bile
duct
duct
dilat
endoscop
retrograd
pancreatogram
ercp
despit
sphincterotomi
mm
common
bile
duct
stone
could
remov
two
mm
balloon
burst
contact
stone
third
balloon
impact
stone
attempt
stent
insert
fail
second
ercp
three
day
later
stone
success
remov
dormia
basket
consequ
concern
regard
atv
gallston
medic
chang
truvada
darunavirritonavir
result
stone
sent
atv
drug
level
analysi
use
valid
hplcm
methodolog
macroscop
singl
brown
stone
dissolv
ml
normal
salin
could
weigh
base
size
estim
specif
graviti
estim
weight
rang
mg
stone
atv
concentr
estim
lgmg
comparison
typic
concentr
atv
mg
formul
nonpregn
hiv
patient
steadyst
report
geometr
cmin
ngml
cmax
ngml
conclus
case
repres
first
measur
atv
stone
concentr
patient
present
gallston
still
longterm
atv
suggest
much
higher
stone
concentr
atv
previous
report
gastroscopist
point
view
would
highlight
unusu
featur
sever
balloon
burst
easili
contact
stone
patient
remain
atv
longer
period
vigil
atv
associ
cholelithiasi
maintain
even
stop
drug
ercp
oper
may
find
atv
contain
bile
duct
stone
better
remov
dormia
basket
rather
balloon
clinic
outcom
naiv
patient
start
darunavir
cobicistatbas
art
experi
clinic
set
f
clark
cousin
n
lomax
warren
attridg
cardiff
royal
infirmari
uk
background
fix
dose
combin
pill
contain
darunavir
cobisistat
market
rezolsta
approv
use
welsh
hiv
clinic
august
offer
fix
dose
proteas
inhibitor
option
reduct
pill
burden
patient
howev
patient
provid
may
concern
efficaci
safeti
toler
impact
measur
renal
function
method
patient
start
first
line
antiretrovir
arv
therapi
contain
rezolsta
june
novemb
identifi
pharmaci
record
data
collect
demograph
baselin
characterist
arv
drug
histori
data
also
collect
clinic
paramet
along
renal
function
patient
report
side
effect
result
note
identifi
elig
inclus
mani
patient
male
median
age
year
median
time
diagnosi
start
month
rang
median
nadir
count
cellsmm
rang
patient
document
archiv
resist
prior
start
patient
commenc
tenofovir
contain
backbon
undetect
viral
load
achiev
week
patient
median
week
median
chang
estim
gfr
week
mlmin
patient
report
side
effect
includ
rash
nausea
vomit
diarrhoea
headach
howev
resolv
within
week
patient
switchedstop
treatment
due
sideeffect
patient
start
rezolsta
base
art
prior
resist
test
result
result
known
patient
switch
therapi
reduc
drug
interact
switch
str
choic
patient
continu
initi
rezolsta
base
art
conclus
major
patient
use
rezolsta
achiev
undetect
viral
load
within
week
switch
patient
suggest
regimen
differ
side
effect
profil
pill
burden
option
continu
rezolsta
base
art
patient
start
prior
resist
test
result
switch
due
transmit
drug
resist
toler
short
live
side
effect
wide
observ
absenc
egfr
chang
seen
patient
cohort
lead
clinician
low
threshold
concern
monitor
renal
function
data
support
benefit
start
simplifi
regimen
rezolsta
also
offer
safe
financi
viabl
option
healthcar
provid
method
patient
start
rezolsta
march
novemb
identifi
pharmaci
record
case
note
review
data
collect
demograph
baselin
characterist
antiretrovir
drug
histori
indic
switch
data
also
collect
clinic
paramet
switch
along
renal
function
patient
report
side
effect
result
note
identifi
elig
inclus
patient
male
median
age
year
patient
document
archiv
resist
patient
tenofovirbas
backbon
reason
switch
rezolsta
vari
major
patient
switch
simplif
patient
switch
due
low
level
viraemia
previou
regimen
patient
switch
due
side
effect
previou
regimen
patient
switch
due
ritonavir
allergi
loss
virolog
control
occur
patient
patient
improv
egfr
averag
mlmin
patient
declin
egfr
averag
mlmin
first
blood
test
side
effect
includ
go
diarrhoea
nausea
vomit
rash
vivid
dream
sweat
dri
mouth
headach
muscl
pain
howev
major
shortliv
week
patient
stop
take
rezolsta
due
nausea
size
tablet
muscl
pain
hepat
c
interact
person
prefer
altern
regimen
poor
memoryconcentr
conclus
patient
experi
switch
rezolsta
unev
return
previou
regimen
switch
anoth
regimen
toler
drug
improv
patient
outcom
wide
observ
minim
chang
egfr
seen
patient
cohort
lead
clinician
low
threshold
concern
monitor
renal
function
data
support
benefit
simplifi
regimen
rezolsta
also
offer
safe
financi
viabl
option
healthcar
provid
earli
uk
ireland
patient
access
tenofovir
alafenamidebas
product
compassion
use
programm
c
robinson
g
reilli
smith
piontkowski
gilead
scienc
ltd
london
uk
gilead
scienc
inc
foster
citi
usa
background
pre
reimburs
access
benefit
patient
unmet
need
follow
present
phase
clinic
trial
result
tenofovir
alafenamid
taf
base
product
gilead
scienc
approach
earli
access
gilead
made
avail
product
elvitegravircobicistatemtrictabin
taf
genvoya
emtricitabinetaf
descovi
rilpivirineemtrictabinetaf
odefsey
compassion
use
programm
cup
taf
product
studi
treatment
switch
adult
adolesc
renal
impair
egfr
mlmin
measur
renal
marker
bone
miner
densiti
show
improv
taf
compar
tenofovir
disoproxil
fumar
tdf
regimen
method
case
cup
use
assess
individu
basi
intern
clinic
review
databas
establish
includ
gender
age
rational
request
comorbid
comed
resist
current
viral
count
hbvhcv
coinfect
recent
laboratori
result
databas
scrutinis
review
demograph
applic
clinic
rational
result
patient
access
taf
base
product
via
cup
demograph
breakdown
compar
uk
hiv
popul
common
clinic
rational
compassion
use
declin
renal
function
tenofovir
disoproxil
fumar
tdf
preexist
renal
impair
tdf
nrti
continu
high
cv
risk
previou
cv
event
abc
use
desir
hcp
hla
b
posit
abc
contraind
declin
renal
function
hbvhiv
coinfect
hbvhiv
therapi
requir
tdf
base
regimen
suitabl
osteopeniaosteoporosi
patient
conclus
larg
scale
cup
demonstr
taf
contain
product
address
signific
unmet
medic
need
taf
contain
drug
commiss
across
uk
ireland
patient
impair
renal
function
reduc
bmd
taf
offer
safer
tenofovirbas
treatment
option
cup
taf
base
product
seem
particular
benefit
older
patient
multipl
comorbid
seen
compassion
use
programm
access
limit
signific
unmet
need
howev
clinic
studi
show
clinic
relev
bone
renal
advantag
adolesc
older
patient
hiv
clinic
cohort
reaudit
qip
cormack
croydon
univers
hospit
uk
background
depart
look
hiv
posit
outpati
high
preval
area
signific
econom
depriv
shown
affect
treatment
outcom
audit
initi
qualiti
improv
project
review
improv
antiretrovir
regimen
suitabl
patient
reaudit
cohort
method
prospect
case
note
review
databas
complet
hiv
posit
patient
book
attend
hiv
physician
time
patient
lost
follow
die
nonhiv
relat
caus
normal
vl
copiesml
haart
transfer
care
move
area
transfer
specialist
care
nonattend
rate
outpati
clinic
cohort
diagnos
late
aid
defin
ill
adi
baselin
viral
load
copiesml
diagnos
year
ago
year
year
year
newli
diagnos
year
result
haart
home
deliveri
patient
strongli
advis
take
haart
medic
reason
declin
still
engag
care
asymptomat
readi
start
elit
control
vl
without
haart
haart
vl
copiesml
copiesml
copiesml
copi
ml
patient
nnrtinrti
gener
avail
nnrti
far
patient
offer
switch
gener
nnrti
option
done
proteas
inhibitor
integras
inhibitor
patient
novel
haart
due
comorbid
eg
nnrti
compar
previou
audit
number
patient
haart
increas
nnrti
use
decreas
still
commonli
use
art
class
cohort
proteas
inhibitor
use
decreas
integras
use
increas
conclus
high
rate
retent
care
low
rate
nonattend
virolog
suppress
remain
high
cohort
follow
prescrib
chang
home
deliveri
major
gener
option
avail
result
patient
identifi
median
age
rang
white
british
boostedpi
monotherapi
rest
dual
therapi
boost
pi
median
durat
treatment
week
monodu
therapi
maintain
virolog
suppress
stop
due
detect
viraemia
develop
new
resist
rest
revert
tripl
therapi
achiev
virolog
suppress
move
dual
monotherapi
due
archiv
resist
discontinu
later
due
persist
viraemia
new
resist
stop
due
advers
event
lipodystrophi
diarrhoea
hyperlipidaemia
drug
interact
neurocognit
impair
detect
csf
viral
loadsymptom
resolv
chang
back
tripl
therapi
patient
took
monodu
therapi
week
transfer
care
baselin
investig
unavail
least
doubl
exceed
normal
limit
triglycerid
week
declin
egfr
week
statist
signific
differ
egfr
triglycerid
mono
dual
therapi
group
conclus
monodu
therapi
boost
pi
demonstr
compar
effect
side
effect
within
cohort
provid
altern
treatment
strategi
simplifi
treatment
avoid
nrtirel
toxic
reduc
cost
virolog
failur
new
drug
resist
remain
concern
long
term
data
requir
support
routin
clinic
practic
randomis
trial
bictegravir
dolutegravir
ftctaf
initi
hiv
therapi
pe
sax
e
dejesu
ward
p
benson
x
wei
k
white
h
martin
cheng
e
quirk
antonucci
brigham
women
hospit
harvard
medic
school
boston
usa
orlando
immunolog
center
usa
dupont
circl
physician
washington
dc
usa
well
medic
berkley
usa
gilead
scienc
foster
citi
usa
gilead
scienc
london
uk
background
bictegravir
bic
novel
unboost
oncedaili
insti
demonstr
potent
activ
monotherapi
studi
vitro
activ
instiresist
virus
method
treatment
hivinfect
adult
random
receiv
blind
treatment
daili
bic
mg
dolutegravir
dtg
mg
open
label
emtricitabin
mgtenofovir
alafenamid
mg
ftctaf
week
primari
endpoint
proport
hiv
rna
cml
use
snapshot
analysi
noninferior
assess
ci
safeti
secondari
endpoint
result
patient
enrol
random
bicftctaf
dtgftctaf
subject
male
asymptomat
hiv
infect
median
rna
virolog
success
rna
c
ml
bic
arm
dtg
arm
respect
tabl
viral
resist
detect
bicftctaf
arm
treatmentrel
seriou
advers
event
death
one
subject
bic
arm
discontinu
due
urticaria
follow
visit
median
chang
estim
glomerular
filtrat
gfrcg
mlmin
bic
mlmin
dtg
discontinu
due
renal
advers
event
conclus
bicftctaf
dtgftctaf
demonstr
high
virolog
respons
rate
treatment
well
toler
signific
safeti
signal
detect
either
arm
estim
gfrcg
chang
consist
known
inhibit
tubular
creatinin
transport
bic
dtg
evalu
bic
treatment
hiv
infect
warrant
week
week
rna
copiesml
continu
week
b
differ
percentag
bicftctaf
vs
dtgftctaf
week
background
switch
integras
inhibitor
ini
base
art
reduc
toxic
drug
interact
lack
compar
data
three
current
ini
guid
use
method
multicentr
retrospect
evalu
patient
art
hiv
vl
cml
switch
dualnrti
backbon
ini
dolutegravir
dtg
cobicistatboost
elvitegravir
evg
raltegravir
ral
uk
ireland
main
outcom
viral
suppress
vl
cml
miss
vl
data
ini
switch
account
way
without
vl
measur
exclud
si
ii
without
vl
measur
consid
vl
cml
mf
si
iii
without
vl
measur
switch
ini
consid
vl
cml
mf
sf
nrti
chang
ignor
reason
discontinu
emerg
resist
also
summaris
result
centr
provid
data
patient
switch
ral
dtg
evg
switch
signific
differ
gender
male
median
age
year
white
ethnic
main
hiv
risk
sex
men
differ
percent
cellsll
week
compar
proport
achiev
vl
cml
tabl
ini
switch
ignor
howev
consid
ini
switch
miss
vl
failur
signific
observ
differ
tabl
mf
sf
week
discontinu
ral
dtg
evg
comparison
hiv
vl
detect
switch
take
ral
dtg
evg
genotyp
resist
develop
report
patient
discontinu
initi
ini
side
effectstox
common
indic
stop
ini
switch
simplif
common
ral
conclus
switch
high
rate
viral
suppress
discontinu
driven
mainli
side
effectstox
twice
daili
dose
ral
seem
prompt
small
number
switch
conveni
vl
result
centr
provid
data
patient
start
dtg
evg
start
art
signific
differ
gender
male
median
age
year
main
hiv
risk
sex
men
white
ethnic
proport
cellsll
respect
week
switchfailur
analysi
show
significantli
higher
percentag
viral
respons
evg
week
discontinu
ral
dtg
evg
respect
p
comparison
switch
ral
simplifi
singl
tablet
regimen
vl
cml
discontinu
initi
ini
hiv
vl
detect
switch
week
take
ral
switch
week
dtg
switch
week
evg
genotyp
avail
stop
ral
dtg
evg
respect
vl
cml
resist
associ
mutat
observ
ral
take
dtg
base
art
conclus
inibas
art
treatment
patient
associ
high
rate
viral
suppress
discontinu
ral
seem
driven
patientdoctor
choic
daili
art
background
due
benefit
antiretrovir
treatment
art
hiv
popul
age
uk
one
three
peopl
access
hiv
care
year
dolutegravir
dtg
base
regimen
dbr
well
toler
art
adult
studi
shown
superior
efficaci
versu
darunavirritonavir
drvr
flamingo
fix
dose
combin
tenofoviremtricitabineefavirenz
singl
atazanavirritonavir
atzr
tenofoviremtricitabin
tdfftc
ariawomen
studi
noninferior
efficaci
versu
raltegravir
ral
nrti
analysi
present
safeti
efficaci
dbr
phase
iiiiiib
studi
age
group
method
data
four
studi
collat
examin
flamingo
investig
allow
select
nrti
abacavir
lamivudin
tdfftc
singl
aria
dtg
use
versu
tdfftc
efavirenz
singl
tablet
atvr
respect
subject
assign
dbr
evalu
age
subgroup
year
older
advers
event
ae
respons
rate
fda
snapshot
comorbid
comed
summaris
group
result
subject
identifi
year
vs
year
high
efficaci
low
ae
rate
consist
across
subgroup
tabl
grade
nervou
system
ns
psychiatr
ae
uncommon
rate
ae
lead
discontinu
remain
low
subject
take
dbr
conclus
analysi
studi
show
dtg
daili
effect
well
toler
treatment
option
older
patient
year
consist
overal
studi
result
major
patient
group
year
signific
efficaci
long
term
safeti
differ
tafbas
str
naiv
adult
emtricitabin
ecf
week
w
ecftaf
statist
noninferior
ecftdf
proport
subject
rna
copi
c
ml
signific
improv
renal
bone
safeti
endpoint
describ
follow
blind
data
method
arv
particip
random
receiv
ecftaf
taf
ecftdf
tdf
viral
suppress
fda
snapshot
analysi
predefin
bone
renal
safeti
toler
endpoint
report
result
hivinfect
adult
random
treat
women
nonwhit
viral
load
cml
taf
met
prespecifi
criteria
noninferior
superior
tdf
fda
snapshot
algorithm
tabl
mean
sd
decreas
bmd
significantli
less
taf
group
lumbar
spine
total
hip
tabl
multipl
measur
renal
safeti
significantli
better
particip
random
taf
case
renal
tubulopathi
taf
arm
vs
tdf
particip
taf
renalrel
discontinu
vs
tdf
p
conclus
particip
ecftaf
significantli
higher
rate
virolog
suppress
cml
ecftdf
driven
fewer
particip
ecftaf
data
ecftaf
continu
statist
superior
bone
renal
safeti
profil
compar
ecftdf
demonstr
signific
safeti
advantag
ecftdf
year
treatment
creatinin
ratio
cmlcopiesml
egfrestim
glomerular
filtrat
rate
upcrurin
protein
creatinin
ratio
rbpcrurin
retinol
bind
protein
creatinin
ratio
evalu
time
first
document
hiv
test
result
date
first
art
prescript
virolog
respons
analys
demograph
hiv
viral
load
vl
count
art
regimen
hepat
b
hbv
c
hcv
statu
recent
infect
test
algorithm
rita
antigen
result
reason
noniniti
defin
lost
follow
ltfu
contact
unit
month
despit
attempt
contact
via
email
text
telephon
result
elig
patient
studi
period
male
median
age
year
count
hiv
vl
avail
median
count
cellscc
rang
hiv
vl
copi
rnaml
rang
diagnosi
patient
antigen
test
avail
recent
infect
enrol
research
studi
patient
hbv
coinfect
hcv
coinfect
patient
start
treatment
studi
period
declin
treatment
move
centr
ltfu
remain
patient
start
art
studi
period
median
time
first
hiv
diagnosi
art
initi
day
rang
analys
quarter
proport
new
hiv
patient
initi
art
time
first
hiv
test
art
initi
show
signific
chang
time
commenc
integras
inhibitor
base
regimen
patient
result
avail
post
art
start
undetect
vl
conclus
first
year
updat
bhiva
guidanc
public
note
rapid
initi
art
excel
virolog
outcom
newli
diagnos
hiv
individu
howev
half
start
art
ltfu
indic
critic
need
novel
strategi
improv
retent
care
success
antiretrovir
therapi
nonurban
hiv
cohort
method
elig
inclus
review
individu
activ
followup
receiv
combin
antiretrovir
therapi
least
month
decemb
count
hiv
viral
load
data
collect
retrospect
review
data
retriev
clinic
case
note
laboratori
report
includ
data
demograph
current
antiretrovir
combin
whether
current
antiretrovir
combin
individu
first
combin
subsequ
combin
cell
count
viral
load
result
studi
period
result
individu
elig
individu
male
femal
median
age
cohort
last
review
year
rang
year
individu
cohort
acquir
hiv
infect
via
heterosexu
contact
individu
receiv
combin
antiretrovir
therapi
month
undetect
hiv
viral
load
receiv
nnrti
base
regimen
pi
base
regimen
integras
base
regimen
conclus
analysi
demonstr
major
individu
receiv
antiretrovir
therapi
cohort
undetect
hiv
viral
load
review
help
demonstr
individu
manag
smaller
nonurban
hiv
cohort
continu
achiev
success
treatment
outcom
compar
larger
treatment
centr
nation
data
background
impact
switch
efvftctdf
mg
week
week
review
respect
treatment
group
n
commenc
tafftvelvc
due
desir
singl
tablet
regimen
median
vl
group
copiesml
week
copiesml
blq
week
patient
fulli
suppress
week
regard
renal
paramet
median
creatinin
week
mmoll
mmoll
week
upcr
week
mgmmol
mgmmol
week
patient
report
side
effect
includ
patient
report
gi
symptom
rash
sleep
disturb
anxieti
palpit
dizzi
eye
irrit
side
effect
led
discontinu
patient
rash
directli
attribut
taf
conclus
result
indic
tenofovir
alafenamid
well
toler
cohort
discontinu
report
virolog
control
satisfactori
treatment
naiv
experienc
patient
compar
report
phase
studi
ongo
problem
cush
syndrom
result
drugdrug
interact
steroid
proteas
inhibitor
retrospect
case
seri
strategi
avoid
r
simon
castelino
ali
r
kulasegaram
guy
st
thoma
nh
foundat
trust
london
uk
background
cush
syndrom
secondari
adren
suppress
wide
report
hiv
posit
patient
due
drugdrug
interact
ritonavir
boost
proteas
inhibitor
corticosteroid
howev
incid
result
harm
patient
continu
occur
method
retrospect
case
seri
conduct
hiv
cohort
london
teach
hospit
strategi
futur
avoid
incid
consid
put
practic
result
report
case
see
tabl
discuss
coordin
multidisciplinari
approach
involv
hiv
specialist
pharmacist
requir
collabor
across
specialti
avoid
incid
result
harm
patient
strategi
implement
includ
present
specialti
department
meet
nation
confer
public
trust
guidelin
avail
intranet
dissemin
inform
via
electron
safeti
bulletin
patient
safeti
card
given
patient
ritonavircobicistat
collabor
specialti
includ
question
antiretrovir
therapi
surgic
checklist
prior
steroid
inject
also
aim
includ
trust
induct
new
staff
cliniciandefin
slow
progress
hiv
contribut
factor
therapi
case
median
time
sinc
hiv
diagnosi
year
rang
count
nonprogressor
undetect
viral
load
case
reason
initi
therapi
clearli
document
har
remaind
main
reason
therapi
patient
prefer
sever
psycholog
social
problem
factor
case
includ
comorbid
mental
health
diagnosi
substanc
misus
intoler
side
effect
factor
case
recent
interrupt
care
includ
transfer
care
factor
case
case
clinician
defer
art
allow
treatment
opportunist
infect
case
patient
chose
defer
art
due
recent
myocardi
infarct
conclus
singlecentr
studi
give
insight
patient
may
initi
art
generaliz
uk
centr
limit
studi
necessarili
focus
patient
retain
care
limit
note
review
rather
interview
patient
directli
slowprogress
hiv
key
factor
influenc
decis
initi
art
within
cohort
clinician
ensur
inform
patient
benefit
risk
commenc
treatment
document
discuss
clearli
patient
transfer
care
clinician
endeavour
provid
continu
care
detail
handov
includ
detail
discuss
decis
regard
treatment
sever
psycholog
social
problem
remain
import
factor
howev
number
remain
small
background
small
popul
cell
harbour
integr
copi
hiv
latent
reservoir
persist
despit
effect
antiretrovir
therapi
art
barrier
hiv
cure
rariti
cell
absenc
uniqu
cellsurfac
marker
make
studi
popul
difficult
addit
provir
sequenc
analysi
complic
excess
human
genom
materi
reaction
present
novel
hiv
dna
captur
assay
combin
next
gen
sequenc
technolog
retriev
near
fulllength
hiv
sequenc
well
integr
site
patient
sampl
method
agil
sureselect
xt
protocol
modifi
enrich
hiv
provir
dna
uniqu
biotinyl
rna
bait
homolog
hiv
hybridis
lg
tcell
dna
hour
enrich
achiev
posit
select
use
streptavidinco
bead
improv
captur
specif
wash
step
perform
captur
dna
sequenc
use
illumina
miseq
platform
read
map
de
novo
reconstruct
hiv
genom
integr
site
analysi
perform
two
step
first
read
map
hiv
refer
profil
ltr
read
contain
ltr
end
motif
ltr
sequenc
remov
remain
human
sequenc
map
genom
use
novoalign
determin
integr
locu
result
near
fulllength
sequenc
obtain
mix
uninfect
infect
cell
line
hiv
infect
patient
rang
total
hiv
dna
measur
qpcr
copi
per
million
tcell
depth
sequenc
coverag
achiev
sampl
posit
correl
hivdna
mean
sequenc
coverag
patient
sampl
consist
current
literatur
primari
cell
integr
site
map
intron
region
human
genom
conclus
present
first
next
genbas
enrich
protocol
allow
near
fulllength
provir
hiv
dna
sequenc
analysi
broad
rang
hiv
total
dna
integr
site
identif
preliminari
studi
six
patient
support
current
understand
high
frequenc
delet
present
reservoir
hiv
preferenti
integr
within
intron
region
highli
express
gene
combin
qualit
sequencebas
correct
qpcr
like
provid
accur
reflect
true
reservoir
size
addit
comprehens
map
annot
integr
site
could
also
help
identifi
cell
like
constitut
reservoir
work
support
bhiva
research
award
j
frater
major
reactivat
latent
hiv
provirus
genet
distinct
evid
ongo
evolut
hp
mok
n
norton
fun
j
hirst
will
lever
univers
cambridg
uk
background
two
mechan
propos
contribut
mainten
hiv
latent
reservoir
homeostat
prolifer
latent
infect
cell
low
level
viral
replic
lymphoid
tissu
studi
sequenc
reactivat
latent
virus
obtain
stabli
treat
patient
assess
import
mechan
method
rest
cell
isol
regular
interv
patient
underw
limit
dilut
activ
cocultur
cell
day
supernat
harvest
viral
rna
region
gag
env
analys
sanger
sequenc
control
artefact
cultur
sequenc
cell
infect
underw
limit
dilut
cultur
sequenc
process
pairwis
comparison
perform
obtain
pdistanc
pair
patient
deriv
viral
sequenc
consid
distinct
pdistanc
higher
correspond
region
sequenc
infect
cell
seek
evid
viral
evolut
consensu
creat
viral
sequenc
obtain
first
sampl
sequenc
sampl
obtain
subsequ
compar
baselin
consensu
obtain
sequenc
reactiv
latent
virus
singl
patient
distinct
sequenc
could
distinguish
gag
region
remain
sequenc
segreg
five
group
howev
env
region
sequenc
analys
one
clonal
group
two
sequenc
remain
reactiv
latent
virus
distinct
threshold
pdistanc
two
sequenc
consid
distinct
set
maxim
rather
averag
pdistanc
observ
refer
set
reactiv
latent
virus
would
still
consid
distinct
observ
increas
pdistanc
week
sampl
compar
baselin
sampl
suggest
accumul
mutat
ever
achiev
undetect
viral
load
high
tasp
clinic
need
group
vs
trend
toward
higher
rate
virolog
failur
defin
bhiva
clinic
group
vs
start
art
clinic
need
like
disengag
care
defin
attend
clinic
month
compar
start
tasp
vs
number
sti
tasp
group
higher
compar
clinic
group
month
month
art
vs
vs
respect
howev
fall
number
sti
tasp
group
year
follow
art
compar
year
prior
vs
cohort
patient
start
art
tasp
maintain
high
level
virolog
suppress
less
like
disengag
start
clinic
need
fall
incid
sti
art
group
find
suggest
concern
tasp
unfound
realtim
partner
notif
feedback
r
betournay
j
paparello
menonjohansson
guy
st
thoma
nh
foundat
trust
london
uk
sxt
health
cic
london
uk
background
least
fifth
partner
newli
diagnos
hiv
posit
patient
infect
sexual
transmit
infect
sti
two
third
sti
partner
notif
pn
shown
effect
public
health
strategi
done
effect
reduc
cost
diagnos
infect
new
tool
develop
support
pn
deliveri
captur
patient
report
outcom
sti
clinic
howev
test
hiv
clinic
therefor
introduc
servic
hiv
clinic
test
util
deliv
pn
report
outcom
method
analysi
perform
follow
week
usag
pn
tool
focu
number
index
patient
total
partner
contact
contact
number
partner
told
test
either
report
patient
captur
via
healthcar
worker
hcw
verif
use
pn
tool
key
perform
indic
kpi
target
sti
set
partner
seen
test
within
four
week
everi
index
patient
ie
use
benchmark
result
pn
data
captur
index
patient
femal
heterosexu
black
white
mix
ethnic
msm
white
mix
asian
black
ethnic
heterosexu
male
black
white
asian
ethnic
nine
patient
demograph
captur
nine
differ
infect
hiv
chlamydia
gonorrhoea
hepat
c
trichomona
vaginali
lymphogranuloma
venereum
hepat
b
shigella
two
infect
diagnos
index
patient
total
number
partner
contact
contact
contact
told
seen
test
via
pn
tool
clinic
report
partner
report
patient
shortest
time
partner
told
hcw
verif
minut
largest
distanc
index
patient
partner
test
clinic
km
kpi
overal
sinc
launch
tool
time
write
last
four
week
conclus
pn
tool
sign
one
third
partner
seen
test
well
support
hiv
clinic
report
outcom
achiev
kpi
nine
differ
infect
work
requir
roll
pn
tool
optim
number
contact
told
support
high
public
health
valu
partner
seen
test
effect
bing
drink
recreat
drug
use
viral
nonsuppress
among
peopl
hiv
antiretrovir
treatment
uk
kall
nardon
v
delpech
j
lewi
l
coyer
shahmanesh
r
gilson
h
ward
e
pufal
public
health
england
london
uk
london
school
hygien
tropic
medicin
london
uk
univers
colleg
london
uk
imperi
colleg
london
uk
background
viral
suppress
among
peopl
hiv
vital
individu
public
health
despit
excel
qualiti
care
high
rate
viral
suppress
uk
remain
fraction
peopl
antiretrovir
therapi
art
viral
suppress
heavi
alcohol
use
recreat
drug
use
known
influenc
art
adher
downstream
effect
viral
nonsuppress
unclear
examin
effect
bing
drink
drug
use
viral
nonsuppress
nation
weight
sampl
peopl
access
hiv
care
method
crosssect
survey
data
posit
voic
pilot
maynovemb
link
clinic
data
nation
hiv
cohort
person
access
care
odd
ratio
or
associ
bing
drink
drink
men
women
one
occas
least
monthli
drug
use
use
recreat
drug
past
year
viral
nonsuppress
hiv
rna
test
result
copiesml
past
year
calcul
use
logist
regress
adjust
selfreport
adher
analys
restrict
person
art
month
result
survey
respond
includ
men
sex
men
msm
heterosexu
men
women
populationpreval
bing
drink
drug
use
highest
preval
msm
respect
preval
viral
nonsuppress
viral
nonsuppress
higher
bing
drinker
compar
nonbing
drinker
vs
adjust
drug
use
age
hiv
risk
group
employ
statu
bing
drinker
doubl
odd
viral
nonsuppress
compar
nonbing
drinker
ci
drug
user
also
significantli
higher
preval
viral
nonsuppress
nondrug
user
vs
howev
adjust
evid
associ
viral
nonsuppress
found
ci
adjust
art
adher
chang
result
conclus
monthli
frequent
bing
drink
associ
viral
nonsuppress
among
art
associ
fulli
explain
postul
mechan
art
adher
screen
lifestyl
behaviour
may
impact
health
includ
alcohol
consumpt
form
import
part
hiv
care
research
need
explor
causal
mechan
background
approxim
pregnanc
report
annual
unit
kingdom
uk
women
diagnos
hiv
women
live
hiv
wlhiv
may
encount
signific
psychosoci
challeng
journey
motherhood
even
though
uk
rate
vertic
transmiss
current
peersupport
shown
benefici
impact
wellb
pregnant
wlhiv
build
londonbas
mentor
mother
programm
describ
expans
across
uk
present
preliminari
evalu
method
collabor
hivspecif
thirdsector
organis
aim
train
wlhiv
across
uk
mentor
mother
mm
innov
train
packag
facilit
two
experienc
trainer
one
mm
compris
coach
clinic
psychosoci
aspect
pregnanc
hiv
combin
creativ
write
workshop
encourag
traine
reflect
upon
pregnanc
journey
result
april
octob
project
train
women
live
hiv
mm
eight
uk
region
median
age
women
complet
train
year
rang
black
african
ethnic
overal
feedback
mm
particip
project
posit
rate
differ
compon
train
either
good
excel
nearli
mentor
mother
report
knowledg
hiv
pregnanc
confid
action
plan
improv
key
challeng
achiev
plan
number
particip
workshop
reason
nonattend
includ
childcar
commit
concern
confidenti
review
approach
throughout
project
attempt
mitig
issu
subsequ
session
conclus
end
train
peer
mentor
mother
readi
provid
support
least
five
wlhiv
longer
term
evalu
ongo
network
mentor
mother
invalu
resourc
complement
clinic
care
manag
hiv
pregnanc
across
uk
adher
cost
save
use
pill
glide
antiretrovir
therapi
busari
n
tickner
raghunanan
c
foster
imperi
colleg
healthcar
nh
trust
london
uk
background
transit
liquid
tablet
prepar
difficult
young
children
liquid
formul
expens
bulki
addit
adolesc
often
struggl
pill
swallow
impact
adher
pill
glide
lubric
fruit
flavour
spray
facilit
tablet
swallow
audit
pilot
use
pill
glide
cohort
perinat
infect
children
pahiv
antiretrovir
therapi
art
method
retrospect
case
note
pharmaci
dispens
review
pahiv
children
year
art
prescrib
pill
glide
junedec
data
collect
includ
demograph
art
adher
reason
pill
glide
use
outcom
cost
save
analysi
perform
pill
glide
cost
per
bottl
dose
recommend
spray
per
pill
result
children
femal
black
african
median
age
rang
year
receiv
pill
glide
success
transit
tabletsimprov
adherencetoler
patient
switch
liquid
tablet
averag
annual
cost
save
per
patient
predict
rise
switch
kivexa
gener
abacavirlamivudin
conclus
pill
glide
assist
transit
liquid
tablet
small
cohort
cost
save
explor
nonadher
adolesc
report
swallow
difficulti
warrant
subsequ
pill
glide
use
paediatr
tb
rheumatolog
bone
marrow
transplant
servic
within
trust
complex
establish
antiretrovir
therapi
femal
childbear
age
subsequ
success
use
maraviroc
pregnanc
e
mccarti
todd
royal
victoria
hospit
belfast
uk
background
signific
advanc
antiretrovir
therapi
art
new
drug
class
greater
choic
drug
inclass
new
treatment
combinationssingl
tablet
regim
meant
less
common
clinic
practic
experi
difficulti
construct
suitabl
regim
particularli
absenc
drug
resist
complex
comorbid
present
case
outlin
complex
treat
year
femal
signific
side
effectstox
across
number
arv
class
subsequ
becam
pregnant
case
report
year
old
caucasian
femal
diagnos
infect
follow
routin
gum
screen
nadir
count
l
rna
viral
load
diagnosi
copiesml
resist
profil
show
wild
type
viru
major
mutat
neg
patient
histori
depress
ongo
issu
bulimia
struggl
diagnosi
signific
input
requir
psycholog
agre
april
commenc
treatment
tdfftcdrvr
within
day
develop
widespread
erythroderm
rash
necessit
hospit
admiss
arv
stop
treat
oral
steroid
antihistamin
reluctantli
agre
recomm
arv
abc
juli
three
month
later
present
generalis
anxieti
disord
report
difficulti
cope
everyday
task
social
withdraw
symptom
attribut
dolutegravir
settl
soon
switch
review
week
later
widespread
maculopapular
rash
hyperbilirubinaemia
bilirubin
lmol
l
atzr
switch
raltegravir
alongsid
backbon
within
week
report
palpit
panic
attack
anxieti
altern
agent
excludedrilpivirin
unsuit
due
food
requir
context
bulimia
etravirin
associ
risk
rash
tropic
prescrib
maraviroc
mg
bd
well
toler
side
effect
one
year
later
present
clinic
week
pregnant
opt
stay
maraviroc
despit
limit
safeti
data
pregnanc
went
deliv
healthi
babi
boy
fullterm
conclus
even
context
wide
choic
avail
arv
regim
complex
still
aris
construct
effect
welltoler
regim
especi
context
pregnanc
limit
safeti
data
exist
newer
drug
complic
triplet
pregnanc
poorli
compliant
hivposit
woman
case
report
sm
afzal
n
bodas
univers
hospit
north
midland
stokeontr
uk
introduct
rate
hiv
mothertochildtransmiss
uk
improv
dramat
due
combin
success
matern
antiretrovir
arv
therapi
plan
deliveri
formulafeed
unfortun
chaotic
lifestyl
may
prevent
women
adher
therapi
increas
risk
vertic
transmiss
date
document
case
success
seroneg
multipl
pregnanc
poorli
compliant
hivposit
women
present
case
trizygot
triplet
pregnanc
poorlycompli
hivposit
patient
case
report
x
old
hiv
posit
woman
known
poor
arv
adher
variabl
engag
servic
recent
admiss
pneumocysti
jiroveci
pneumonia
present
clinic
four
week
pregnant
point
singl
mother
two
children
includ
one
child
special
need
univers
student
parttim
employe
poorli
control
hiv
cellsll
vl
copiesml
keen
reengag
servic
x
resum
daili
regim
truvada
boost
darunavir
difficulti
treatment
adher
engag
partli
due
confidenti
concern
multidisciplinari
team
support
includ
commun
volunt
input
treatment
intensifi
twice
daili
boost
darunavir
addit
raltegravir
viral
load
remain
detect
copiesml
pregnanc
complic
loss
one
triplet
first
trimest
one
admiss
possibl
spontan
ruptur
membran
srom
week
breech
present
twin
although
twin
b
perform
spontan
cephal
version
x
improv
adher
closer
deliveri
viral
load
week
gestat
copiesml
deliv
two
healthi
babi
via
elect
caesarean
section
week
gestat
twin
neg
hiv
dna
pcr
level
birth
week
week
age
twin
receiv
zidovudin
prophylaxi
four
week
current
develop
well
formula
feed
conclus
case
highlight
import
multidisciplinari
team
approach
manag
adher
contracept
confidenti
psychosoci
obstetr
paediatr
challeng
multipl
pregnanc
amongst
poorli
adher
hivposit
women
hiv
clinic
improv
collabor
commun
voluntari
sector
optimis
patient
care
dolutegravir
pregnanc
retrospect
case
review
r
simon
r
kulasegaram
guy
st
thoma
nh
foundat
trust
london
uk
background
data
dolutegravir
use
pregnanc
limit
manufactur
advis
avoid
exposur
unless
risk
outweigh
benefit
bhiva
guidelin
suggest
establish
option
ideal
use
method
retrospect
case
review
posit
pregnant
women
prescrib
dolutegravir
triumeq
abacavirlamivudinedolutegravir
conduct
april
januari
london
teach
hospit
demograph
data
efficaci
toler
matern
infant
outcom
collect
result
pregnant
women
prescrib
dolutegravir
women
deliv
date
remain
pregnanc
third
trimest
outcom
women
present
bhiva
median
age
rang
blackafrican
ethnic
women
prescrib
triumeq
one
dolutegravir
combin
truvada
darunavir
ritonavir
women
conceiv
dolutegravir
remain
women
start
switch
median
gestat
age
week
rang
week
reason
use
includ
previou
poor
adher
need
rapid
virolog
suppress
gastrointestin
side
effect
regimen
median
baselin
hiv
viral
load
copiesml
rang
women
achiev
full
virolog
suppress
median
time
suppress
day
rang
women
deliv
date
hiv
viral
load
copiesml
deliveri
remain
women
viral
load
last
measur
dolutegravir
well
toler
discontinu
vagin
deliveri
plan
caesarean
section
remain
emerg
caesarean
section
obstetr
reason
median
gestat
age
deliveri
week
rang
one
preterm
deliveri
week
patient
emerg
caesarean
foetal
distress
uncontrol
matern
hypertens
preexist
pregnanc
median
birthweight
g
rang
g
foetal
abnorm
note
babi
born
uk
hiv
dna
pcr
neg
conclus
small
case
seri
suggest
use
dolutegravir
pregnanc
effect
well
toler
appear
safe
howev
addit
data
cohort
studi
clinic
trial
antiretrovir
pregnanc
registri
requir
four
year
followup
hiv
infect
children
adolesc
requir
measl
rubella
chickenpox
vaccin
pregnanc
demonstr
alter
ifnc
respons
flu
cmv
disrupt
dc
nk
tcell
profil
cocker
n
imami
johnson
dermont
w
khan
imperi
colleg
london
uk
chelsea
westminst
hospit
london
uk
background
pregnanc
induc
alter
immun
cell
function
phenotyp
support
develop
fetu
protect
pathogen
disrupt
immun
function
associ
higher
rate
viral
coinfect
increas
incid
pregnanc
complic
studi
aim
investig
impact
antivir
respons
peripher
blood
mononuclear
cell
pbmc
profil
pregnanc
method
nonpregn
pregnant
pregnant
women
antiretrovir
therapi
art
recruit
pbmc
isol
ifnc
elispot
assay
perform
gag
nef
respons
test
individu
flow
cytometr
analysi
pbmc
undertaken
determin
express
activ
differenti
exhaust
marker
dendrit
cell
dc
natur
killer
cell
nk
cell
statist
analysi
carri
use
prism
version
intergroup
variat
assess
mannwhitney
test
statist
signific
defin
p
result
increas
pregnant
ifnc
respons
compar
nonpregn
pregnant
group
flu
respect
cmv
respons
lower
pregnant
group
nonpregn
flu
cmv
group
show
reduc
respons
compar
pregnant
group
antigen
eighti
per
cent
women
ifnc
respond
gag
nef
respond
phenotyp
comparison
pregnant
group
show
increas
frequenc
exhaust
cell
women
reduc
anerg
nk
popul
rais
plasmacytoid
dc
myeloid
dc
ratio
conclus
despit
art
persist
shown
gag
nef
respons
group
differ
observ
reflect
prolong
immun
activ
disrupt
function
regul
furthermor
similar
pbmc
profil
previous
associ
pregnanc
complic
find
demonstr
impact
viral
persist
innat
acquir
immun
implic
confound
factor
complic
treat
pregnanc
warrant
depth
function
analysi
cohort
matern
carriag
group
b
streptococcu
hivposit
women
subsequ
neonat
infect
watt
dempsey
k
macleod
kirkham
univers
manchest
uk
st
mari
hospit
manchest
uk
manchest
royal
infirmari
uk
background
group
b
streptococcu
gb
lead
caus
neonat
sepsi
earli
onset
gb
diseas
occur
within
day
age
link
intrapartum
gb
exposur
nation
earli
onset
gb
diseas
occur
neonat
gb
carriag
rate
pregnanc
infect
day
age
late
onset
diseas
thought
relat
intrapartum
transmiss
unlik
usa
canada
uk
gb
screen
programm
studi
suggest
increas
gb
carriag
hivinfect
women
increas
gb
diseas
hivexpos
uninfect
neonat
audit
assess
gb
carriag
hivinfect
women
gb
diseas
hivexpos
uninfect
neonat
guid
antenat
manag
method
retrospect
audit
hivinfect
pregnant
women
deliv
st
mari
hospit
manchest
march
novemb
matern
inform
review
includ
gb
carriag
high
vagin
swab
midstream
urin
sampl
intrapartum
antibiot
prophylaxi
neonat
record
review
gb
statu
includ
csf
blood
cultur
result
women
hiv
diagnos
pregnanc
women
treatment
prior
concept
women
test
gb
pregnanc
carriag
rate
high
vagin
swab
women
diagnos
hiv
pregnanc
higher
gb
carriag
differ
baselin
viral
load
count
pregnanc
whole
cohort
carri
gb
also
observ
reduct
gb
carriag
antiretrovir
prior
concept
intrapartum
antibiot
prophylaxi
use
appropri
case
babi
test
posit
gb
either
earli
late
onset
diseas
investig
blood
cultur
csf
cultur
day
blood
cultur
csf
cultur
day
conclus
cohort
gb
carriag
rate
compar
nation
figur
viral
load
treatment
prior
concept
affect
gb
carriag
rate
case
earli
late
onset
gb
diseas
support
current
uk
practic
routin
screen
gb
carriag
contradict
studi
suggest
increas
gb
carriag
hivinfect
women
increas
gb
diseas
hivexpos
uninfect
neonat
predict
futur
cardiovascular
risk
adolesc
perinat
acquir
hiv
r
karunaratn
c
foster
imperi
colleg
healthcar
nh
trust
london
uk
background
earli
data
suggest
perinat
hivinfect
pahiv
young
peopl
may
increas
risk
cardiovascular
cv
diseas
adulthood
attribut
prolong
exposur
hiv
antiretrovir
therapi
art
whilst
cv
risk
algorithm
commonli
use
adult
compar
tool
young
peopl
less
develop
pathobiolog
determin
atherosclerosi
youth
pday
coronari
arteri
ca
abdomin
aorta
aa
risk
score
weight
aggreg
modifi
risk
factor
dyslipidaemia
cigarett
smoke
hypertens
obes
hyperglycaemia
valid
us
adolesc
popul
minim
data
pahiv
cohort
method
pday
score
calcul
adolesc
age
year
art
use
retrospect
observ
cohort
data
electron
record
novemb
januari
pday
score
strongli
associ
presenc
intens
subclin
coronari
abdomin
atherosclerosi
autopsi
year
later
baselin
pday
risk
score
adolesc
associ
increas
risk
atherosclerosi
middl
age
result
pahiv
adolesc
median
age
year
iqr
femal
black
african
median
count
cellsll
iqr
viral
load
cml
bmi
hypertens
th
centil
ageheight
current
smoker
total
cholesterol
mmolsl
median
hdl
mmoll
iqr
median
non
hdl
mmoll
iqr
aa
ca
pday
score
aa
ca
pday
score
aa
ca
pday
score
highest
ca
score
mean
aa
score
ci
median
mean
ca
score
ci
median
ca
conclus
pday
score
cohort
suggest
consider
increas
burden
atherosclerot
cardiovascular
risk
factor
uk
pahiv
adolesc
twice
us
pahiv
popul
pday
score
may
valuabl
identifi
individu
highest
risk
develop
atherosclerot
lesion
therapi
may
target
manag
modifi
reduc
risk
factor
burden
risk
cardiovascular
diseas
later
adulthood
referr
commun
adolesc
mental
health
servic
camh
perinat
infect
adolesc
cohort
p
seeri
freeman
c
foster
imperi
nh
healthcar
trust
london
uk
background
earli
data
suggest
increas
mental
health
diagnos
perinat
infect
adolesc
uninfect
sibl
compar
peer
studi
aim
characteris
differ
mental
health
mh
present
paediatr
set
elucid
clinic
psychosoci
featur
seen
method
retrospect
case
note
audit
referr
mental
health
servic
adolesc
age
year
result
adolesc
refer
mental
health
servic
median
age
year
iqr
femal
black
african
ethnic
known
learn
disabl
ld
experienc
parent
separ
due
death
divorc
migrat
ten
known
social
servic
look
children
lac
annual
incid
new
mental
health
referr
within
adolesc
cohort
year
mean
rang
highest
primari
reason
camh
referr
psychosi
suicid
autism
conduct
disord
mood
disord
consist
depress
anxieti
mix
five
histori
selfharm
referr
vl
copiesml
median
count
cellsll
iqr
requir
acut
admiss
tabl
admiss
mha
section
psychiatr
servic
paediatr
ward
latter
first
psychot
episod
requir
assess
organ
caus
three
outpati
ever
engag
camh
remaind
receiv
psycholog
support
paediatr
hiv
servic
conclus
despit
good
virolog
control
new
mental
health
present
peak
year
multipl
known
risk
factor
poor
subsequ
engag
camh
care
plan
transit
adult
servic
requir
highli
vulner
complex
popul
test
children
hivposit
parent
nt
forget
father
cormack
croydon
univers
hospit
uk
background
nt
forget
children
state
hiv
statu
children
known
hivposit
adult
uk
known
matter
clinic
urgenc
method
analysi
hiv
posit
mother
father
seen
hiv
outpati
clinic
consult
carri
hiv
cohort
predominantli
blackafrican
femal
exist
case
note
review
confirm
children
detail
hiv
statu
verifi
system
note
possibl
result
mother
children
born
hiv
posit
adult
report
hiv
neg
children
still
age
year
children
need
test
mother
verifi
hiv
neg
birthdat
children
verifi
hiv
neg
verifi
hiv
posit
verifi
test
still
activ
health
advisor
ha
followup
report
neg
live
abroad
father
children
hiv
posit
father
adult
children
need
test
mother
verifi
hiv
neg
birthdat
children
verifi
hiv
neg
verifi
hiv
posit
verifi
test
child
refer
test
provid
referr
children
report
neg
could
confirm
live
abroad
children
report
contact
father
overal
hiv
posit
parent
children
age
year
children
requir
test
verifi
test
verifi
posit
activ
followup
test
report
neg
live
abroad
children
report
contact
father
conclus
overal
rate
verifi
test
children
high
test
trace
children
hiv
posit
father
challeng
rate
verifi
test
much
lower
util
antiretrovir
drug
level
effect
hiv
viral
load
clinic
outcom
pregnanc
n
astil
n
ekong
simonini
schoeman
j
wilson
leed
teach
hospit
trust
uk
background
bhiva
pregnanc
guidelin
consid
recommend
therapeut
drug
monitor
tdm
patient
proteas
inhibitor
pi
particularli
combin
tenofovir
atazanavir
data
pharmacokinet
antiretrovir
arv
pregnanc
scanti
evid
tdm
improv
outcom
conflict
therefor
evalu
tdm
result
pregnanc
assess
util
aim
identifi
rate
subtherapeut
drug
level
associ
factor
assess
effect
viral
load
vl
clinic
outcom
method
retrospect
casenot
review
tdm
perform
pregnant
women
result
tdm
perform
pregnanc
year
median
gestat
tdm
week
rang
week
diagnos
hiv
prepregn
conceiv
art
baselin
vl
subtherapeut
drug
level
diagnos
hiv
prepregn
conceiv
art
atazanavir
subtherapeut
atazanavir
tenofovir
subtherapeut
atazanavir
tenofovir
subtherapeut
darunavir
subtherapeut
neviripin
mr
subtherapeut
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
compar
subtherapeut
drug
level
atazanavir
versu
third
agent
factor
associ
subtherapeut
drug
level
art
dose
chang
made
formul
chang
aid
complianc
tdm
perform
near
start
treatment
repeat
arrang
poor
attend
adjust
possibl
deliveri
effect
tdm
level
vl
clinic
outcom
shown
tabl
conclus
high
rate
subtherapeut
drug
level
identifi
atazanavir
particularli
combin
tenofovir
associ
subtherapeut
level
detect
vl
tdm
clinic
outcom
howev
art
adjust
made
subtherapeut
level
altern
avail
longer
initi
atazanvirtenofovir
contain
regimen
pregnanc
p
olupotolupot
nsubuga
j
meadway
mbale
region
referr
hospit
uganda
busitema
univers
mbale
uganda
medicin
muheza
london
uk
background
earli
infant
diagnosi
eid
hiv
expos
infant
aim
provid
earliest
opportun
diagnosi
track
elimin
mother
child
transmiss
hiv
emtct
subsequ
enrol
infant
found
pcrposit
avail
antiretrovir
therapi
art
implement
ugandan
nation
hiv
prevent
strategi
includ
eid
assess
trend
eid
eastren
uganda
nhp
method
studi
eid
incorpor
retrospect
quantit
prospect
qualit
studi
qualit
studi
done
focu
group
discuss
fgd
key
inform
interview
kii
incept
novemb
implement
june
nhp
qualit
data
captur
sourc
document
written
narr
voic
record
retrospect
data
abstract
eid
regist
year
correspond
end
nhp
respect
ethic
permiss
conduct
studi
obtain
result
high
level
knowledg
support
polici
maker
healthcar
provid
implement
nhp
health
worker
support
modifi
breastfeed
haart
mother
newborn
knowledg
eid
among
pregnant
postnat
mother
low
begin
markedli
increas
end
nhp
period
newborn
hiv
infect
respect
conclus
mark
support
nhp
polici
maker
healthcar
provid
right
begin
implement
togeth
increas
knowledg
eid
among
mother
attend
antenat
care
could
contribut
mark
fall
mtct
period
progress
requir
haemodialysi
may
nonepileptiform
attack
disord
depress
asthma
recent
treat
syphili
septemb
admit
dialysi
becom
unrespons
hypertens
mmhg
suffer
singl
selftermin
seizur
ct
head
show
deep
white
matter
hypodens
haemorrhag
infarct
blood
pressur
bp
extrem
labil
gtn
labetalol
infus
commenc
ongo
seizur
activ
warrant
intub
mri
brain
show
extens
ischaem
chang
within
cerebr
cerebellar
hemispher
consist
pre
watersh
infarct
lumbar
punctur
open
pressur
cm
h
protein
mgl
glucos
mmoll
wbc
rbc
microscopi
cultur
virolog
syphili
serolog
neg
prolong
period
ventil
bp
control
remain
difficult
receiv
methylprednisolon
iv
immunoglobulin
cover
vascul
differenti
diagnosi
although
imag
serolog
suggest
hypertens
screen
neg
syphili
serolog
confirm
respons
recent
treatment
eventu
clinic
condit
improv
return
ward
despit
oral
antihypertens
agent
episod
hypertens
mmhg
result
sudden
cortic
blind
increas
signal
within
right
medial
pariet
occipit
lobe
mri
consist
pre
uptitr
oral
antihypertens
regular
ultrafiltr
fluid
restrict
facilit
bp
control
correl
natur
histori
pre
vision
complet
return
discharg
day
conclus
pre
rare
condit
aetiolog
remain
unclear
infrequ
report
hiv
fewer
case
report
last
year
hypertens
one
well
document
caus
treatment
includ
mainten
normotens
demonstr
case
case
tuberculosisassoci
immun
reconstitut
inflammatori
syndrom
iri
manag
receptor
antagonist
background
treatment
coinfect
mycobacterium
tuberculosi
tb
hiv
rel
common
phenomenon
within
infecti
diseas
set
within
cohort
patient
increas
risk
iri
upon
initi
highli
activ
antiretrovir
therapi
haart
howev
case
steroid
either
effect
use
long
period
treatment
option
less
clear
may
includ
immun
modul
therapi
case
studi
ethiopian
femal
patient
present
fever
night
sweat
weight
loss
associ
wide
spread
lymphadenopathi
time
present
live
uk
year
report
medic
problem
diagnos
hiv
dissemin
tb
baselin
count
initi
present
condit
worsen
mri
brain
imag
show
widespread
lesion
cerebr
tb
confirm
cerebrospin
fluid
examin
patient
commenc
antiretrovir
antituberculosi
treatment
initi
respond
well
develop
iri
massiv
cervic
intraabdomin
lymphadenopathi
iri
respons
steroid
howev
due
ongo
inflammatori
respons
requir
protract
cours
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
patient
subsequ
develop
secondari
renal
amyloidosi
result
underli
inflammatori
process
patient
receiv
month
antitb
therapi
good
effect
onset
iri
steroid
use
reduc
inflamm
control
renal
amyloid
good
effect
unfortun
steroid
unabl
wean
due
recurr
symptom
associ
iri
also
due
steroidassoci
side
effect
montelukast
use
tri
attempt
suppress
iri
limit
effect
iri
unusu
manifest
due
protract
length
last
around
year
anakinra
receptor
antagonist
subsequ
use
switch
proinflammatori
process
patient
viral
load
eventu
undetect
year
first
diagnosi
despit
good
complianc
medic
due
sever
resist
mutat
conclus
iri
difficult
manag
context
patient
complex
morbid
result
hiv
infect
case
describ
highlight
use
immun
therapi
manag
iri
order
control
inflammatori
process
avoid
longterm
steroid
review
renal
histolog
infect
individu
tenofovir
disoproxil
fumar
tdf
could
glomerular
involv
cevik
c
leen
raha
western
gener
hospit
edinburgh
uk
chalmer
sexual
health
centr
edinburgh
uk
background
although
deterior
renal
function
multifactori
accord
knowledg
patient
receiv
tdf
contain
regimen
increas
risk
renal
impair
particular
concern
tdf
especi
wide
use
prep
pep
data
suggest
tdf
target
proxim
tubular
mitochondria
howev
exact
mechan
tdf
nephrotox
still
clear
histopatholog
character
proxim
renal
tubular
injuri
dysmorph
mitochondria
present
analysi
renal
biopsi
individu
receiv
tdf
contain
regimen
aim
improv
understand
nephrotox
hiv
method
identifi
infect
individu
renal
biopsi
perform
past
year
western
gener
hospit
includ
individu
tdf
contain
regimen
time
renal
biopsi
data
retrospect
collat
electron
patient
record
patholog
record
descript
statist
perform
result
individu
renal
biopsi
includ
femal
tdf
contain
regimen
median
age
year
diagnos
hiv
preart
era
individu
renal
biopsi
due
renal
impair
proteinuria
individu
due
proteinuria
individu
biopsyproven
tdf
nephrotox
also
interstiti
nephriti
mild
mesangioprolif
glomerulonephr
hivassoci
immun
complex
glomerulonephr
lupu
like
glomerulonephr
individu
tdf
relat
toxic
individu
proteinuria
haematuria
time
renal
biopsi
histopatholog
tdf
relat
toxic
consist
tubular
injuri
eosinophil
inclus
posit
trichom
stain
tubular
mitochondri
injuri
confirm
electron
microscopi
em
nondiagnost
em
except
one
complet
resolut
proteinuria
renal
impair
discontinu
tdf
one
individu
requir
haemodialysi
eventu
resolv
one
individu
ckd
conclus
although
tdf
toxic
describ
tubular
injuri
cohort
individu
also
haematuria
resolv
discontinu
tdf
haematuria
would
consist
glomerular
injuri
howev
previous
report
tdf
relat
renal
toxic
review
introduct
acut
kidney
injuri
aki
alert
hiv
care
picken
william
e
kingdon
brighton
sussex
univers
hospit
brighton
uk
background
human
immunodefici
viru
hiv
leav
patient
risk
acut
kidney
injuri
aki
chronic
kidney
diseas
ckd
bidirect
relationship
western
set
kidney
problem
popul
heavili
attribut
medic
nephrotox
hivrel
kidney
diseas
coinfect
hepat
b
c
low
count
high
viral
load
contribut
patient
risk
renal
diseas
aki
suscept
increas
age
comorbid
coinfect
hypertens
diabet
cardiovascular
diseas
acut
hospit
admiss
aki
prompt
identif
aki
like
favour
influenc
shortterm
outcom
sequela
object
sought
investig
epidemiolog
aki
centr
tertiari
hiv
practic
region
renal
unit
describ
popul
hivv
patient
develop
aki
sinc
introduct
ice
patholog
aki
alert
system
method
retrospect
analysi
aki
centr
serv
patient
hiv
larg
teach
hospit
aki
case
ascertain
mean
nation
aki
detect
algorithm
run
local
middlewar
softwar
icesunquest
b
review
code
data
search
case
aki
code
consult
care
hivv
inpati
c
excel
databas
hivv
inpati
data
collect
decemb
nov
medic
note
review
crossrefer
clinic
diagnos
aki
conclus
aki
unusu
event
experi
differ
method
identifi
aki
episod
limit
overlap
nation
aki
algorithm
requir
comparison
old
current
result
possibl
storag
result
differ
ident
led
underestim
preval
aki
work
underway
identifi
caus
aki
outcom
cohort
venn
diagram
illustr
distribut
case
patient
aki
identifi
retrospect
studi
review
thrombot
diseas
haart
era
friday
h
coleman
g
brook
kapembwa
murphi
london
northwest
healthcar
nh
trust
uk
background
hiv
infect
recognis
prothrombot
state
preval
venou
thromboembol
vte
among
hiv
infect
patient
rang
per
year
two
tenfold
increas
risk
venou
thrombosi
comparison
gener
popul
age
mani
aspect
vte
hiv
infect
describ
detail
literatur
howev
littl
inform
hepat
vein
thrombosi
hvt
hiv
infect
popul
object
case
seri
review
proport
peopl
vte
hvt
cohort
emphas
need
prevent
recogn
need
vigor
treatment
complic
method
retrospect
review
hiv
posit
patient
diagnos
thrombot
diseas
last
year
conduct
analysi
includ
demograph
data
associ
comorbid
risk
factor
thrombot
diseas
antiretrovir
therapi
count
viral
load
result
cohort
patient
thrombot
diseas
studi
period
year
femal
male
age
year
nadir
count
less
time
thrombot
event
count
greater
undetect
viral
load
patient
diagnosi
hiv
year
patient
apart
antiretrovir
arv
prior
vte
least
year
patient
proteas
pi
base
regimen
nonpi
base
regimen
case
risk
factor
vte
risk
factor
includ
recent
surgeri
antiphospholipid
syndrom
combin
oral
contracept
use
immobl
liver
abscess
nephrot
syndrom
type
vte
includ
hepat
vein
thrombosi
deep
vein
thrombosi
dvt
combin
dvt
pulmonari
embol
pe
patient
commenc
warfarin
without
risk
factor
investig
thoroughli
underli
caus
found
patient
found
multipl
comorbid
conclus
preval
thrombot
diseas
hiv
cohort
year
period
hvt
seen
frequent
compar
dvt
pe
patient
develop
hvt
virolog
suppress
appar
predispos
factor
prolong
pi
use
physician
care
hiv
posit
patient
abl
recognis
treat
vte
complic
treat
chronic
hiv
infect
audit
care
monitor
patient
coinfect
hiv
hepat
c
gum
edinburgh
need
better
document
identifi
h
pollitt
raha
chalmer
centr
edinburgh
uk
background
hepat
c
coinfect
hiv
patient
increas
risk
liver
cirrhosi
hepatocellular
carcinoma
hcc
henc
import
coinfect
patient
screen
monitor
appropri
present
audit
gum
depart
edinburgh
method
use
bhiva
guidelin
manag
hiv
hepat
c
coinfect
formul
data
field
aim
audit
well
compli
guidelin
use
inform
differ
system
use
local
paper
note
look
back
last
year
document
data
field
includ
age
gender
date
hcv
diagnosi
date
hiv
diagnosi
gp
awar
hiv
hcv
diagnosi
mode
transmiss
latest
count
current
arv
regimen
date
arv
start
arv
start
hcv
diagnos
arv
start
hcv
treat
type
length
treatment
treatment
stop
acut
hcv
treatment
start
within
month
special
input
referr
drug
alcohol
servic
referr
mental
health
hev
screen
hav
serolog
vaccin
hbv
serolog
vaccin
fibroscan
lft
liver
biopsi
risk
reduct
discuss
cirrhot
last
liver
ultrasound
afp
endoscopi
refer
liver
transplant
hcv
treatment
annual
fibrosi
assess
result
number
patient
identifi
coinfect
hiv
hcv
care
nontreat
patient
annual
fibrosi
assess
conclus
hiv
patient
document
hepat
c
care
spread
differ
system
paper
note
collat
data
ensur
patient
receiv
appropri
care
monitor
therefor
timeconsum
unwieldi
result
audit
show
need
cohes
way
document
result
plan
patient
ensur
safe
clinic
care
effect
handov
clinician
address
aim
introduc
better
system
document
result
audit
unusu
caus
isol
secondari
ovarian
failur
due
cerebr
toxoplasmosi
african
woman
aid
k
yoganathan
sadiq
k
yoganathan
singleton
hospit
swansea
uk
morriston
hospit
swansea
uk
abstract
primari
ovarian
failur
common
isol
secondari
ovarian
failur
due
gonadotrophin
defici
rare
case
isol
gonadotrophin
defici
due
congenit
cerebr
toxoplasmosi
describ
children
report
case
year
old
hiv
posit
african
woman
develop
secondari
amenorrhoea
follow
success
treatment
cerebr
toxoplasmosi
investig
reveal
develop
isol
gonodotropin
defici
due
pituitari
lesion
rest
pituitari
function
dynam
test
normal
best
knowledg
similar
case
report
adult
cerebr
toxoplasmosi
case
report
admit
three
week
histori
fever
headach
rigor
februari
examin
reveal
pyrexi
alert
gc
score
hiv
test
posit
count
cellsmm
hiv
rna
level
million
copiesml
hiv
genotyp
subtyp
c
mutat
serolog
test
toxoplasma
reveal
elisa
igmneg
dye
test
iuml
toxoplasma
igm
isaga
neg
toxoplasma
ig
gposit
mri
scan
show
focal
ring
enhanc
lesion
keep
underli
abscess
empir
treat
cerebr
toxoplasmosi
headach
subsid
remain
afebril
week
later
develop
secondari
amenorrhea
month
initi
present
pregnanc
test
neg
regular
period
prior
current
ill
two
healthi
children
endocrin
test
show
low
oestradiol
due
isol
gonadotrophin
defici
discuss
patient
present
symptom
rais
intracrani
pressur
without
focal
neurolog
sign
high
toxoplasma
antibodi
titr
along
focal
ring
enhanc
lesion
brain
highli
suggest
cerebr
toxoplasmosi
respons
anti
toxoplasma
therapi
confirm
diagnosi
cerebr
toxoplasmosi
complic
cerebr
toxoplasmosi
depend
site
brain
lesion
patient
develop
secondari
amenorrhoea
month
develop
cerebr
toxoplasmosi
conclus
clinician
made
awar
potenti
complic
pituitari
dysfunct
patient
cerebr
toxoplasmosi
central
nervou
system
complic
hiv
infect
primari
brain
lymphoma
progress
multifoc
leucoencephalopathi
result
patient
new
hiv
diagnosi
follow
audit
period
hbsab
result
baselin
visit
diagnos
chronic
hbv
infect
vaccin
indic
vaccin
regim
month
indic
booster
dose
ultrarapid
cours
given
receiv
least
one
vaccin
dose
within
month
hiv
diagnosi
complet
appropri
vaccin
cours
audit
period
accord
local
guidelin
requir
vaccin
complet
dose
audit
period
receiv
less
dose
vaccin
regim
introduc
guidelin
updat
signific
improv
uptak
high
dose
vaccin
regim
compar
low
dose
regim
vs
patient
complet
vaccin
cours
hbsab
result
test
postvaccin
conclus
implement
new
guidelin
uptak
hbv
vaccin
significantli
improv
due
consult
educ
present
new
guidelin
introduct
new
hbv
vaccin
proforma
low
rate
hbv
vaccin
complet
especi
vaccin
regim
popul
newli
diagnos
hiv
individu
vaccin
pathway
remind
schedul
hbv
vaccin
appoint
may
improv
rate
hbv
vaccin
complet
anal
intraepitheli
neoplasia
cohort
hivposit
individu
retrospect
data
analysi
lawrenc
j
vera
richardson
gilbert
r
marchant
c
morgan
lawson
unit
brighton
uk
royal
sussex
counti
hospit
brighton
uk
background
men
sex
men
msm
live
hiv
increas
risk
human
papillomaviru
hpv
associ
cancer
includ
anal
squamou
cell
cancer
scc
diagnosi
anal
intraepitheli
neoplasia
present
opportun
initi
monitor
cur
treatment
characterist
patient
diagnos
poorli
understood
factor
associ
progress
scc
project
aim
describ
case
larg
urban
cohort
peopl
live
hiv
uk
method
identifi
case
among
patient
attend
singl
hiv
outpati
care
centr
review
case
note
histopatholog
result
case
diagnos
identifi
white
msm
median
age
year
rang
nadir
cellsmm
median
month
sinc
diagnosi
antiretrovir
therapi
art
previou
anorect
sti
hpv
gonorrhoea
hsv
chlamydia
document
current
smoker
patient
present
anal
lump
major
iii
treat
imiquimod
surgic
excis
imiquimod
electrocauteri
imiquimod
one
patient
surveil
patient
repeat
histolog
progress
scc
improv
iii
ii
receiv
addit
imiquimod
resolv
entir
patient
progress
scc
rang
one
nine
year
compar
age
median
rang
nadir
cellsmm
broader
cohort
diagnos
hiv
past
month
conclus
emerg
issu
msm
live
hiv
effect
art
larg
proport
patient
anal
sti
diagnosi
small
cohort
patient
progress
scc
research
need
clarifi
patient
risk
develop
scc
hiv
infect
recept
anal
intercours
strong
risk
factor
anal
scc
thu
highest
incid
found
hivposit
men
sex
men
msm
anal
human
papillomaviru
hpv
underli
caus
roughli
case
aim
describ
case
scc
larg
urban
cohort
peopl
live
hiv
uk
method
identifi
case
anal
scc
amongst
patient
attend
singl
uk
hiv
outpati
clinic
spite
diagnos
treat
review
case
note
histopatholog
result
scc
case
identifi
gener
increas
diagnos
year
white
msm
median
age
year
rang
nadir
cellsmm
averag
time
year
sinc
hiv
diagnosi
antiretrovir
therapi
art
document
sexual
transmit
infect
sti
histori
previous
diagnos
anorect
sti
hpv
gonorrhoea
chlamydia
herp
simplex
viru
common
present
symptom
anal
lump
pain
rectal
bleed
local
diseas
local
node
metastat
diseas
previou
diagnos
treat
centr
treat
chemoradiotherapi
radiotherapi
alon
surgeri
patient
need
surgeri
unsuccess
chemoradiotherapi
diagnos
success
scc
treatment
patient
die
two
death
attribut
scc
conclus
anal
scc
emerg
issu
msm
live
hiv
effect
art
found
larg
proport
patient
anorect
hpv
diagnos
anal
scc
minor
previous
diagnos
research
experi
establish
impact
anal
cancer
screen
reduct
anal
scc
popul
urgent
need
intend
analys
histopatholog
sampl
centr
consid
annual
digit
rectal
examin
screen
tool
atyp
guillainbarr
e
syndrom
consid
hiv
background
guillainbarr
e
syndrom
gb
acut
immun
mediat
ill
caus
rapidli
progress
polyneuropathi
weak
gb
uncommon
manifest
hiv
describ
two
case
patient
diagnos
treat
gb
found
acut
hiv
case
year
old
femal
present
week
histori
lethargi
difficulti
mobilis
bilater
leg
weak
alter
sensat
right
leg
hand
examin
reveal
reduc
power
alter
sensat
arreflexia
lower
upper
limb
mri
normal
neurophysiolog
test
reveal
sensori
motor
polyneuropathi
demyelin
csf
show
rais
protein
pleocytosi
subsequ
hiv
test
posit
year
old
man
present
week
histori
pain
behind
knee
lower
limb
weak
recurr
fall
alter
sensat
feet
week
previous
report
night
sweat
weight
loss
lethargi
examin
reveal
lower
leg
weak
impair
sensat
absent
knee
ankl
reflex
mri
spine
normal
csf
reveal
high
protein
nerv
conduct
studi
show
sensori
motor
abnorm
without
demyelin
featur
investig
reveal
posit
hiv
test
case
count
high
indic
preserv
immun
function
treatment
ivig
show
minim
clinic
improv
improv
note
initi
antiretrovir
therapi
discuss
patient
present
possibl
gb
progress
symmetr
muscl
weak
arreflexia
high
csf
protein
level
unexpect
find
pleocytosi
unusu
nerv
conduct
result
led
suspicion
hiv
hiv
present
neuropathi
first
present
distal
sensori
polyneuropathi
toxic
neuropathi
common
associ
hiv
gb
incid
low
incid
gb
hiv
popul
similar
nonhiv
popul
gb
typic
occur
earli
cours
hiv
infect
seroconvers
count
high
present
cours
manag
gb
hiv
seroposit
seroneg
patient
similar
evid
improv
antiretrovir
therapi
hiv
posit
patient
background
hivassoci
tb
contribut
substanti
burden
tbassoci
morbid
mortal
surviv
improv
earli
antiretrovir
therapi
art
follow
initi
tb
therapi
investig
qualiti
hiv
care
among
individu
diagnos
simultan
tb
hiv
method
comprehens
cohort
data
adult
year
diagnos
hiv
uk
link
nation
enhanc
tb
surveil
system
followup
end
individu
consid
simultan
diagnos
coinfect
tb
hiv
diagnosi
within
three
month
time
lag
hiv
diagnosi
first
test
date
proxi
link
care
arv
initi
first
viral
load
vl
copiesml
calcul
result
adult
diagnos
hiv
subsequ
link
hiv
care
coinfect
tb
median
time
hiv
diagnosi
hiv
care
among
coinfect
person
day
iqr
link
care
within
month
figur
similar
without
tb
diagnosi
day
linkag
differ
count
observ
median
time
art
initi
day
day
coinfect
person
respect
similar
without
tb
diagnosi
strata
among
coinfect
adult
start
art
sooner
counterpart
without
tb
median
day
vs
day
among
diagnos
start
art
within
day
tb
diagnosi
within
day
follow
art
initi
vl
avail
tbhiv
adult
achiev
viral
suppress
within
month
rang
month
regardless
count
similar
hivdiagnos
adult
without
tb
assum
miss
vlfailur
figur
drop
respect
miss
valu
like
reflect
poor
data
qualiti
viral
failur
conclus
linkag
hiv
care
follow
hiv
diagnosi
prompt
regardless
tb
coinfect
differ
art
initi
strata
reflect
guidelin
uptak
overal
prompt
among
coinfect
person
viral
suppress
follow
art
initi
high
observ
differ
time
art
initi
continu
reduc
test
treat
guidelin
coinfect
diagnos
hiv
audit
mortal
among
hiv
patient
coventri
da
allan
h
taha
bopitiya
croxford
timperley
coventri
warwickshir
partnership
nh
trust
uk
nation
infect
servic
public
health
england
london
uk
univers
hospit
coventri
warwickshir
uk
background
accuraci
report
vital
statist
crucial
legal
requir
death
report
nation
death
regist
aim
assess
accuraci
death
report
mortal
among
hiv
patient
impact
late
diagnosi
mortal
method
retrospect
case
note
review
death
hiv
patient
jan
dec
death
data
obtain
public
health
england
phe
receiv
death
report
clinician
death
regist
phe
data
compar
death
data
obtain
trust
electron
patient
record
hospit
paper
note
result
death
report
death
regist
hospit
two
patient
die
coventri
resid
outsid
coventri
one
age
death
report
phe
one
patient
report
dead
clinic
outsid
coventri
conclus
audit
highlight
seriou
error
death
report
registr
occur
develop
action
plan
success
implement
ensur
accur
death
report
registr
hiv
patient
audit
plan
complet
audit
cycl
work
need
improv
life
expect
peopl
hiv
reduc
late
diagnosi
contribut
number
death
audit
surveil
hepatocellular
carcinoma
hcc
highrisk
individu
live
hiv
patel
gilleec
bradshaw
brighton
sussex
univers
hospit
nh
trust
uk
background
bhiva
recommend
hcc
screen
high
risk
patient
monthli
hepat
ultrasound
us
alphafetoprotein
afp
convers
easl
recommend
screen
us
alon
due
minim
addit
benefit
afp
concern
fals
posit
result
audit
local
hcc
surveil
practic
guidelin
method
retrospect
note
review
hiv
centr
patient
hbv
serolog
perform
first
registr
patient
cirrhosi
andor
hbvinfect
identifi
search
fibroscan
imag
patholog
databas
us
afp
result
review
year
result
seventi
five
patient
posit
hbsag
test
year
prior
period
interest
hcc
surveil
data
avail
twentyon
patient
hbvinfect
cirrhosi
therefor
patient
includ
median
age
year
rang
male
median
cell
count
cellsmm
rang
undetect
hiv
vl
hbvinfect
patient
receiv
tenofovir
contain
arv
regimen
patient
nontenofovir
contain
regimen
entecavir
lamivudin
alon
antihbv
therapi
one
therapi
twentyeight
undetect
hbv
vl
patient
cirrhosi
six
hcvinfect
anoth
caus
cirrhosi
includ
alcohol
fortytwo
patient
least
liver
scan
us
ct
two
scan
show
hcc
fortytwo
patient
afp
level
elev
patient
thirtysix
patient
afp
scan
us
ct
twenti
cirrhot
patient
hbv
coinfect
patient
scan
cirrhot
patient
elev
afp
read
rang
hbv
coinfect
patient
elev
afp
read
kll
hbv
coinfect
patient
normal
us
result
cirrhot
patient
abnorm
afp
level
patient
like
hcc
diagnosi
us
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
conclus
elig
patient
appropri
screen
hcc
use
us
although
lower
noncirrhot
hbvinfect
cirrhot
individu
afp
identifi
lesion
also
identifi
us
fals
posit
patient
test
clinician
focu
effort
improv
surveil
us
especi
hbvinfect
patient
bone
densiti
measur
amongst
young
adult
perinat
acquir
hiv
infect
routin
care
f
fyle
c
foster
fidler
imperi
colleg
london
uk
st
mari
hospit
london
uk
background
antiretrovir
therapi
art
enabl
young
peopl
live
perinatallyacquir
hiv
pahiv
reach
adulthood
increas
focu
longterm
complic
hiv
art
factor
impact
bone
miner
densiti
bmd
includ
hiv
viraemia
arttenofovir
tdf
steroiddepot
contracept
failur
thrive
ftt
hiv
encephalopathi
hyperton
diplegia
describ
routin
bmd
scan
cohort
pahiv
young
adult
desensitis
emtricitabin
tenofovir
outpati
set
patient
presum
allerg
reaction
case
report
v
gordon
brawley
bagu
nh
grampian
aberdeen
uk
background
year
old
woman
diagnos
hiv
posit
count
commenc
treatment
darunavirritonavir
mg
od
truvada
tab
od
three
week
initi
develop
sever
maculopapular
rash
trunk
limb
system
featur
mucos
involv
treatment
stop
system
steroid
initi
symptom
resolv
combin
efavirenz
truvada
commenc
symptom
recur
emtricitabin
ftc
tenofovir
disoproxil
fumar
tdf
suspect
like
caus
regimen
switch
raltegravir
mg
bd
darunavirritonavir
mg
mg
od
remain
regimen
without
advers
effect
ask
option
simplifi
regimen
due
multipl
lifestyl
factor
rechalleng
desensitis
titrat
ftc
tdf
discuss
patient
subsequ
arrang
method
darunavirritonavir
raltegravir
continu
patient
frequent
pharmacist
review
personalis
care
plan
address
case
advers
effect
ftc
mgml
suspens
prescrib
follow
regimen
mg
day
increas
mg
everi
day
day
maximum
dose
mg
equival
mg
ftc
capsul
one
month
ftc
wash
agre
attempt
tdf
desensitis
tdf
titrat
use
mggscoop
granul
day
period
start
mg
day
increas
mg
everi
day
mg
dose
increas
mg
everi
four
day
mg
result
titrat
complet
unev
conclus
ftc
tdf
rechalleng
success
case
highlight
immens
potenti
valu
manag
option
increas
rang
antivir
avail
patient
directact
antivir
therapi
hivhcv
coinfect
patient
significantli
reduc
liver
fibrosi
prospect
cohort
studi
easdon
edward
nelson
imperi
colleg
london
uk
background
hivhepat
c
hcv
coinfect
associ
higher
rate
mortal
morbid
hcv
monoinfect
issu
includ
rapid
progress
fibrosi
excess
inflamm
reduc
respons
highli
activ
antiretrovir
treatment
haart
method
patient
hivhcv
coinfect
fibrosi
treat
directact
antivir
daa
therapi
routin
fibroscan
marker
immun
respons
haart
pre
post
therapi
result
octob
octob
patient
hcvhiv
coinfect
fibroscan
consist
fibrosi
receiv
daa
therapi
male
mean
age
receiv
haart
viral
load
less
copiesml
viral
load
less
copiesml
mean
count
prior
daa
therapi
rang
cellsll
rang
meanmedian
fibroscan
score
kpa
meanmedian
metavir
score
within
cirrhot
rang
percent
patient
daa
therapi
week
harvoni
plu
ribavirin
rbv
patient
week
abbvi
plu
rbv
patient
week
sofosbuvir
plu
peginterferon
plu
rbv
patient
week
harvoni
patient
week
sofosbuvir
plu
daclatasvir
plu
rbv
patient
one
patient
achiev
svr
mean
count
mean
week
post
therapi
cellsll
mean
mean
decreas
count
cellsll
mean
increas
meanmedian
fibroscan
score
mean
week
post
therapi
kpa
mean
decreas
kpa
p
individu
remain
cirrhot
read
conclus
success
daa
therapi
possibl
hcvhiv
coinfect
popul
signific
improv
marker
liver
fibrosi
signific
chang
count
efavirenz
trotman
k
michi
l
ratcliff
royal
liverpool
hospit
uk
background
efavirenz
shown
reduc
toler
compar
newer
agent
driven
cn
toxic
downgrad
prefer
altern
third
agent
bhiva
guidelin
also
associ
advers
effect
lipid
would
consid
prefer
option
patient
hypercholesterolaemia
increas
cardiovascular
risk
review
current
use
efavirenz
cohort
recent
guidanc
method
perform
retrospect
case
note
review
patient
current
take
efavirenz
collect
data
demograph
time
efavirenz
comorbid
virolog
suppress
discuss
regard
side
effect
switch
option
applic
result
male
femal
age
rang
year
patient
age
ethnic
british
african
ethnic
origin
major
patient
take
follow
efavirenz
efavirenz
durat
time
efavirenz
rang
month
year
patient
virolog
supress
count
rang
median
comorbid
type
type
cardiovascular
diseas
previou
mi
stroke
case
switch
away
efavirenz
view
side
effect
discuss
declin
patient
case
switch
triall
patient
return
efavirenz
base
regim
patient
switch
current
plan
memori
problem
metabol
derang
discuss
document
conclus
patient
efavirenz
tend
age
take
efavirenz
base
regim
least
year
expect
rate
virolog
suppress
high
howev
high
proport
patient
comorbid
may
benefit
switch
altern
third
agent
whilst
patient
declin
toler
switch
import
consid
altern
particularli
cohort
age
effect
lowdos
oral
vitamin
bone
miner
densiti
chang
hiv
patient
h
taha
da
bopitiya
coventri
warwickshir
partnership
trust
uk
background
high
preval
vitamind
defici
abnorm
bone
miner
densiti
bmd
report
hiv
patient
aim
find
effect
low
dose
oral
vitamind
replac
vitamind
level
parathyroid
hormon
pth
level
bmd
spine
hip
hiv
patient
vitamind
defici
method
compar
effect
low
dose
vitamind
iu
daili
tablet
hivinfect
patient
vitamind
defici
collect
inform
demographi
viral
load
count
risk
factor
fractur
treatment
histori
measur
oh
pth
intact
pth
inorgan
phosphat
correct
calcium
alkalin
phosphatas
alp
bmd
spine
hip
baselin
month
month
statist
analysi
done
oneway
anova
follow
dunn
multipl
comparison
test
result
total
patient
mean
age
year
black
african
femal
count
cellsdl
plasma
vl
log
copiesml
durat
ill
exposur
antiretrovir
month
includ
analysi
patient
tenofovir
higher
pth
efavirenz
lower
vitamind
differ
bmd
spine
hip
month
follow
patient
vitamin
replac
signific
increas
vitamind
level
vs
reduct
pth
vs
alkalin
phosphatas
vs
increas
correct
calcium
vs
bmd
hip
vs
bmd
spine
vs
patient
vitamind
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
replac
increas
vitamind
vs
correct
calcium
vs
level
pth
alp
bmd
hip
spine
chang
multivari
analysi
includ
signific
variabl
vitamind
replac
independ
associ
increas
vitamind
level
ci
decreas
pth
level
ci
chang
correct
calcium
alkalin
phosphatas
bmd
hip
spine
conclus
month
follow
replac
low
dose
daili
oral
vitamind
treatment
experienc
hiv
patient
vitamind
defici
increas
vitamind
level
reduc
pth
level
chang
bmd
hip
spine
follow
evid
consist
approach
manag
elit
control
start
studi
l
bull
n
rockwood
barber
chelsea
westminst
hospit
nh
foundat
trust
london
uk
background
recent
studi
demonstr
benefit
earlier
initi
antiretrovir
therapi
art
chronic
hiv
infect
regardless
count
elit
control
hiv
infect
defin
spontan
sustain
mainten
hiv
rna
copiesml
absenc
art
data
regard
benefit
earlier
initi
art
elit
control
ec
less
robust
although
studi
demonstr
ongo
immun
activ
rais
cardiovascular
risk
possibl
hospitalis
ec
compar
individu
art
want
investig
current
manag
ec
low
level
viraem
llv
patient
within
cohort
method
databas
interrog
identifi
ec
llv
patient
defin
vl
copiesml
seen
year
dec
dec
case
note
examin
identifi
discussionadvic
start
art
respect
contemporari
data
result
patient
seen
allot
time
frame
ec
llv
three
elit
control
seen
diagnosi
seen
leav
patient
analysi
median
time
diagnosi
ec
month
llv
patient
month
median
percentag
median
ratio
ratio
ec
document
discuss
regard
rational
start
treatment
last
year
declin
patient
llv
document
discuss
regard
start
art
last
year
four
declin
one
current
consid
associ
ratio
whether
patient
offer
treatment
conclus
line
current
guidelin
amongst
cohort
clear
consensu
treat
peopl
well
control
hiv
receiv
art
discrep
whether
discuss
take
place
treatment
physician
suggest
minimum
document
discuss
treatment
patient
treatment
least
year
treatment
recommend
ratio
indic
start
data
perhap
predict
certain
amount
retic
amongst
ec
toward
start
treatment
may
warrant
explor
hepat
b
exposur
immun
infect
newli
diagnos
hiv
infect
men
sex
men
analysi
k
manavi
univers
hospit
birmingham
nh
foundat
trust
uk
background
uk
men
sex
men
msm
immunis
hepat
b
viru
hbv
infect
nice
guidelin
recommend
screen
immunis
hbv
infect
wide
rang
set
notwithstand
recommend
data
show
rate
exposur
chronic
infect
among
msm
may
still
high
aim
present
studi
investig
longitudin
rate
exposur
hbv
infect
chronic
hbv
immun
hbv
infect
newli
diagnos
hiv
infect
msm
method
newli
diagnos
patient
routin
undergo
screen
hepat
b
serolog
hepat
b
surfac
antigen
hbsag
hepat
b
core
antibodi
hbcab
hepat
b
surfac
antibodi
hbsab
baselin
hepat
b
serolog
result
msm
diagnos
januari
januari
includ
kendal
tau
use
compar
proport
studi
decad
result
msm
diagnos
hiv
infect
studi
period
hbcab
posit
consid
expos
hbv
rate
exposur
declin
statist
signific
declin
kendal
tau
declin
mark
among
msm
neg
hbcab
immun
hbsab
iul
immun
state
patient
unknown
studi
period
rate
immun
hbv
increas
differ
signific
kendal
tau
chronic
hbv
infect
identifi
msm
studi
period
rate
chronic
infect
remain
low
stabl
time
period
kendal
tau
conclus
year
observ
cohort
rate
chronic
hbv
infect
remain
low
msm
newli
diagnos
hiv
rate
exposur
hbv
infect
declin
significantli
reduct
account
improv
immunis
msm
hbv
hiv
qt
long
long
raff
k
simmon
shaw
gilleec
churchil
brighton
sussex
univers
hospit
nh
trust
uk
background
signific
prolong
qt
interv
electrocardiogram
ecg
caus
sudden
cardiac
death
number
antiretrovir
arv
drug
shown
prolong
qt
interv
particular
concern
use
combin
qt
prolong
medic
manual
calcul
qt
interv
correct
heart
rate
qtc
recommend
evalu
risk
medic
evalu
knowledg
arv
prescrib
regard
qt
prolong
medic
abil
calcul
qtc
method
use
conveni
sampl
deleg
autumn
bhiva
ask
complet
anonym
questionnair
includ
calcul
qtc
interv
use
bazett
formula
american
heart
associ
definit
normal
qtc
use
women
ms
men
ms
gold
standard
correct
qtc
calcul
use
teach
tangent
method
result
thirtythre
clinician
complet
questionnair
professor
consult
registrar
abl
correctli
defin
normal
qtc
underestim
valu
overestim
valu
state
idea
state
would
check
googl
review
product
characterist
identifi
arv
qtc
prolong
effect
seen
efavirenz
correctli
identifi
rilpivirin
atazanavir
darunavir
saquinavir
ritonavir
clinician
correctli
identifi
agent
identifi
agent
without
includ
addit
agent
answer
includ
drug
known
qtc
prolong
effect
select
cobicistat
agent
frequent
incorrectli
identifi
caus
qtc
prolong
clinician
calcul
qtc
sampl
ecg
averag
answer
ms
answer
rang
wide
ms
gave
gold
standard
answer
ms
within
ms
conclus
signific
variat
seen
hiv
clinician
manual
calcul
qtc
consist
find
report
elsewher
includ
among
cardiologist
cohort
gener
underestim
qtc
implic
patient
safeti
poor
knowledg
arv
caus
qtc
prolong
may
also
impact
choic
arv
regimen
uk
british
hiv
associ
audit
identifi
low
rate
monitor
cardiovascular
risk
observ
data
implic
proteas
inhibitor
increas
cardiovascular
renal
risk
evid
mix
littl
uk
data
preval
cardiovascular
risk
peopl
live
hiv
take
proteas
inhibitor
aim
describ
burden
risk
cohort
method
conduct
point
preval
audit
hiv
posit
patient
proteas
inhibitor
therapi
cohort
art
extract
data
databas
local
laboratori
data
use
calcul
edinburgh
cv
risk
bmi
proxi
metabol
syndrom
renal
risk
result
baselin
demograph
similar
wider
cohort
popul
male
white
ethnic
origin
black
ethnic
origin
case
acquir
sex
men
via
heterosexu
sex
mean
age
resist
viru
reason
pi
use
nadir
less
patient
ritonavirboost
darunavir
proteas
inhibitor
use
patient
tenofovir
contain
regimen
current
smoker
preval
record
diagnosi
comorbid
includ
hypertens
chronic
kidney
diseas
diabet
prior
cardiovascular
diseas
patient
cardiovascular
risk
greater
mean
bmi
patient
bmi
greater
mean
renal
score
without
chronic
kidney
diseas
conclus
limit
lack
valid
tool
cardiovascular
risk
qrisk
favour
gp
bhiva
hiv
patient
studi
end
event
myocardi
infarct
compar
patient
third
agent
increas
risk
observ
may
reflect
popul
trend
within
proteas
inhibitor
therapi
real
world
audit
uk
patient
receiv
proteas
inhibitor
indic
high
burden
cardiovascular
renal
risk
addit
bmi
proxi
metabol
syndrom
signific
highlight
urgent
need
improv
monitor
manag
reevalu
pi
use
patient
wildtyp
viru
background
hepatocellular
carcinoma
hcc
lead
caus
liverrel
mortal
peopl
live
hiv
coinfect
hepatotrop
virus
acceler
cours
chronic
liver
diseas
albi
grade
novel
biomark
liver
dysfunct
hcc
howev
prognost
signific
yet
evalu
patient
coinfect
hiv
method
use
uniand
multivari
analys
studi
albi
grade
predictor
overal
surviv
os
larg
multicentr
cohort
patient
hivassoci
hcc
recruit
centr
countri
within
liver
cancer
hiv
studi
group
result
total
patient
predominantli
hcv
coinfect
balanc
represent
barcelona
clinic
liver
cancer
bclc
stage
recruit
hcc
diagnosi
antiretrovir
therapi
median
durat
year
albi
grade
stratifi
patient
group
significantli
differ
overal
surviv
grade
median
surviv
month
ci
grade
month
ci
grade
month
ci
p
advanc
albi
grade
also
correl
lower
count
higher
hiv
viraemia
p
conclus
larg
multicentr
retrospect
studi
valid
albi
grade
biomark
surviv
hivassoci
hcc
relationship
albi
hivcorrel
immunesuppress
unveil
progress
liver
dysfunct
import
pathophysiolog
mechan
justifi
aggress
cours
observ
hivassoci
hcc
lowest
acquisit
drug
cost
directli
act
antivir
daa
treatment
hepat
c
hcv
high
cure
rate
difficult
treat
hivhcv
popul
k
agarw
k
child
sawier
c
taylor
johansen
r
kulasegaram
j
paparello
king
colleg
hospit
london
uk
guy
st
thoma
nh
foundat
trust
london
uk
background
rct
daa
hivhcv
coinfect
equival
sustain
virolog
respons
svr
rate
hcv
alon
recent
data
suggest
outsid
trial
patient
hivhcv
may
experi
lower
svr
rate
method
data
gather
patient
hivhcv
undergo
treatment
rx
daa
centr
london
discuss
multidisciplinari
team
mdt
decid
rx
type
durat
use
ribavirin
rbv
option
sofosbuvirledipasvir
sofldp
paritaprevirritonavirombitasvir
pro
plu
dasabuvir
prod
sofosbuvir
daclatasvir
sofdac
sof
rbv
pegyl
interferon
pegifn
accord
nhse
genotyp
base
guidelin
continu
variabl
express
median
iqr
result
patient
start
daa
rx
reach
svr
timepoint
demograph
see
tabl
total
group
art
alter
regimen
prior
daa
due
drugdrug
interact
ddi
group
reach
week
post
rx
svr
cirrhot
includ
decompens
post
olt
undetect
hiv
rna
previou
null
respond
pegifn
hcv
reinfect
success
treat
pegifn
receiv
ribavirin
rbv
rbv
level
mgl
baselin
hcv
rna
tabl
achiev
week
post
rx
svr
one
relaps
young
woman
noncirrhot
treat
week
sofl
rbv
conclus
data
demonstr
patient
hivhcv
advanc
liver
diseas
achiev
excel
svr
rate
joint
manag
hiv
liver
physician
essenti
consid
rx
durat
use
rbv
optimis
ddi
iuml
cirrhot
result
patient
sign
renal
tubular
damag
low
serum
phosphat
mmoll
start
phosphat
supplement
one
abacavir
abc
base
tdfbase
regimen
patient
abc
three
tdf
transient
hypophosphataemia
continu
regimen
switch
altern
abcbas
suitabl
nucleotid
spare
regimen
phosphat
level
stabilis
switch
six
remain
tdfbase
regimen
phosphat
supplement
four
later
switch
genvoyaa
tenofovir
alafenamid
fumar
taf
base
regimen
two
elig
taf
switch
time
review
one
offer
genvoya
next
appoint
one
complex
treatment
histori
numer
art
wish
switch
nonstandard
regimen
genvoya
appropri
recent
switch
descovi
preliminari
result
patient
switch
genvoya
indic
switch
may
stabilis
phosphat
level
even
supplement
withdrawn
mean
serum
phosphat
improv
conclus
taf
offer
simpl
strategi
manag
hypophosphataemia
associ
tdfrelat
renal
dysfunct
clinician
vigil
monitor
phosphat
allow
identifi
chang
associ
kidney
dysfunct
earli
take
action
patient
still
asymptomat
renal
dysfunct
still
revers
consequ
advanc
marker
subclin
atherosclerot
diseas
hiv
infect
patient
method
sixti
adult
stabl
hiv
infect
art
ldlcholesterol
mmoll
recruit
three
uk
hiv
centr
particip
randomis
receiv
dietari
advic
reduc
satur
fat
intak
energi
intak
adopt
mediterranean
portfolio
diet
addit
cholesterollow
food
nut
stanol
soya
oat
bean
month
measur
food
intak
bodi
composit
arteri
stiff
inflamm
cvr
fast
blood
lipid
conduct
baselin
month
betweengroup
chang
cv
risk
factor
assess
use
ancova
adjust
baselin
valu
depend
variabl
analysi
intent
treat
ethic
approv
grant
result
baselin
characterist
group
compar
age
mean
ae
year
gender
femal
smoke
statu
nonsmok
ethnic
black
african
white
european
lipid
profil
mean
ldl
ae
mmoll
adher
portfolio
compon
vari
mean
ae
month
particip
show
greater
increas
mediterranean
diet
score
point
ci
p
reduct
ldlcholesterol
mmoll
ci
cholesterol
hdl
ratio
ci
systol
blood
pressur
mm
hg
ci
p
arteri
stiff
bodi
mass
index
waist
circumfer
level
physic
activ
high
sensit
creactiv
protein
significantli
differ
group
advers
effect
observ
plasma
level
vitamin
gut
function
health
relat
qualiti
life
health
wellb
conclus
dietet
advic
follow
mediterranean
diet
contain
plant
stanol
nut
oat
bean
soya
protein
produc
greater
improv
diet
qualiti
cvr
greater
reduct
ldlcholesterol
standard
guidelin
reduc
satur
fat
intak
reduct
ldlcholesterol
magnitud
would
translat
reduct
major
vascular
event
monitor
fractur
risk
bone
miner
densiti
hivposit
individu
singlecentr
audit
hadley
lawrenc
gilleec
brighton
sussex
medic
school
uk
lawson
unit
brighton
uk
background
hivposit
individu
uk
get
older
increasingli
import
monitor
bone
health
reduc
bone
miner
densiti
bmd
associ
chronic
hiv
infect
antiretrovir
therapi
art
tradit
risk
factor
bhiva
recommend
assess
via
frax
score
diagnosi
prior
start
art
everi
three
year
thereaft
frax
valid
hiv
unclear
hiv
consid
caus
secondari
osteoporosi
dual
energi
xray
absorptiometri
dxa
scan
recommend
increas
risk
women
men
year
bhiva
nation
audit
highlight
poor
perform
nation
method
review
case
note
patient
attend
singl
hiv
clinic
octob
compar
local
audit
record
risk
factor
low
bmd
frax
score
calcul
dxa
result
calcul
frax
score
without
hiv
includ
caus
secondari
osteoporosi
result
case
includ
femal
mean
age
rang
mean
durat
infect
month
cell
mm
art
ever
taken
tdf
viral
load
cml
document
common
risk
factor
white
ethnic
age
smoke
alcohol
intak
lday
two
patient
previou
fractur
one
osteoporosi
treatment
bone
health
discuss
case
frax
score
calcul
diagnosi
start
art
patient
last
year
previou
dxa
scan
calcul
frax
score
without
hiv
caus
secondari
osteoporosi
risk
low
intermedi
dxa
recommend
includ
hiv
caus
secondari
osteoporosi
increas
risk
low
intermedi
high
dxa
recommend
conclus
find
similar
bhiva
nation
audit
figur
significantli
improv
local
figur
patient
bone
health
discuss
howev
huge
room
improv
clinician
need
discuss
bone
health
regularli
calcul
frax
score
per
bhiva
guidelin
launch
specialist
women
clinic
focus
bone
health
amongst
issu
work
multidisciplinari
team
integr
bone
health
care
multidrug
resist
tb
mdrtb
hiv
patient
characterist
outcom
resourc
limit
set
j
meadway
waiswa
obbo
p
olupotolupot
medicin
muheza
london
uk
mbale
region
referr
hospit
mbale
uganda
busitema
univers
mbale
uganda
background
multidrugresist
tuberculosi
mdrtb
grow
public
health
problem
pauciti
data
resourcelimit
set
mani
countri
adopt
capac
build
toward
improv
mdrtb
detect
hospit
sinc
strategi
includ
train
health
worker
introduct
genexpert
mtbrifa
molecular
test
tb
earli
diagnosi
tb
infrastructur
adjust
studi
mdrtb
hiv
hivpati
describ
patient
characterist
set
method
assess
record
patient
manag
drug
resist
tb
period
june
novemb
audit
obtain
data
patient
demograph
hiv
statu
previou
histori
tb
resist
type
time
cultur
convers
regimen
durat
treatment
outcom
use
basic
static
analys
data
result
total
patient
complet
record
children
year
adult
year
major
male
hiv
posit
patient
mdrtb
histori
previou
tb
drug
resist
mainli
rifampicin
follow
rifampicin
isoniazid
note
poli
resist
period
cure
die
rest
still
treatment
conclus
poor
treatment
initi
tb
infect
hiv
infect
predispos
factor
mdrtb
metabol
syndrom
nafld
recognis
comorbid
hiv
littl
known
interact
chronic
hiv
infect
nafld
aim
characteris
cohort
nafld
hiv
monoinfect
identifi
risk
factor
associ
diseas
method
prospect
pilot
studi
perform
collect
comprehens
clinic
data
consecut
patient
refer
dedic
clinic
two
centr
marchdecemb
patient
underw
liver
ultrasound
transient
elastographi
patient
liver
stiff
ls
kpa
invit
biopsi
nafld
defin
steatosi
ultrasound
scan
andor
control
attenu
paramet
dbm
absenc
excess
alcohol
caus
chronic
liver
diseas
univari
analysi
continu
median
iqr
mannwhitney
discret
chisquar
fisher
exact
test
variabl
perform
compar
age
sex
match
control
liver
diseas
factor
associ
signific
fibrosi
liver
stiff
kpa
andor
biopsi
confirm
also
explor
result
patient
seen
hepat
steatosi
seen
exclud
secondari
caus
steatosi
alcohol
hcv
testosteron
supplement
hbv
coinfect
patient
enrol
popul
characterist
male
age
year
bmi
waist
circumfer
cm
diabet
durat
hiv
infect
year
nrti
exposur
month
exposur
ddrug
nadir
undetect
viral
load
signific
fibrosi
defin
liver
stiff
kpa
liver
biopsi
show
nash
fibrosi
compar
control
nafld
associ
increas
bmi
p
waist
circumfer
p
hyperlipidaemia
associ
drug
exposur
includ
ddrug
nadir
count
durat
infect
age
bmi
ferritin
ggt
associ
signific
fibrosi
conclus
age
obes
key
player
develop
nafldrel
fibrosi
hiv
monoinfect
patient
independ
hivrel
paramet
observ
lesson
learn
newli
implement
intertrust
joint
hivendocrinolog
multidisciplinari
team
meet
k
fernando
b
jose
cobridg
health
centr
stokeontr
uk
univers
hospit
north
midland
nh
trust
stokeontr
uk
background
nonaid
comorbid
increasingli
recognis
age
well
control
hivinfect
popul
chronic
immun
activ
earlier
art
initi
coinfect
drug
interact
recognis
contributori
factor
hiv
servic
provid
care
cohort
outpati
due
commiss
chang
sexual
healthhiv
servic
reloc
commun
nh
trust
provid
result
geograph
separ
acut
trust
aim
servic
gap
identifi
regard
specialist
input
issu
metabolicendocrinolog
natur
aim
bridg
creat
crosstrust
work
method
april
joint
hivendocrinolog
mdt
meet
conven
case
requir
specialist
input
identifi
weekli
department
hivinfecti
diseas
mdt
meet
endocrinologist
acut
trust
attend
servic
quarterli
basi
patient
record
review
jointli
hiv
physician
result
fiftyf
patient
discuss
date
age
rang
year
take
art
count
cellsmm
rang
cellsmm
undetect
hiv
viral
load
frequent
rais
issu
discuss
dyslipidaemia
patient
known
diabet
discuss
due
suboptim
diabet
control
diabet
dyslipidaemia
andor
potenti
artdiabet
drug
interact
rang
group
mmol
mol
new
diagnos
diabet
prediabet
possibl
reactiv
hypoglycaemia
identifi
patient
diagnos
cush
syndromeadren
suppress
secondari
inhal
fluticason
ritonavir
interact
diagnos
includ
subclin
hypothyroid
hypogonad
observ
import
pattern
present
metabolicendocrinolog
comorbid
endocrinolog
input
prove
great
benefit
particularli
manag
complex
riskassoci
present
includ
adren
suppress
errat
diabet
control
joint
work
also
allow
consist
link
acut
trust
inpati
consult
furthermor
wider
learn
opportun
increas
awar
amongst
nonhiv
specialist
colleagu
acut
trust
promot
particularli
regard
opportun
hiv
test
parkinson
diseas
hivposit
individu
case
seri
singl
uk
centr
l
taylor
lawrenc
gilleec
royal
sussex
counti
hospit
brighton
uk
lawson
unit
brighton
uk
background
hivposit
individu
reach
normal
lifespan
increasingli
encount
diseas
associ
age
includ
parkinson
diseas
pd
littl
known
pd
context
hiv
one
report
individu
franc
show
chang
pd
incid
clinic
cours
individu
report
specif
hallucin
increas
impuls
behaviour
four
individu
experienc
unusu
motor
deterior
interact
antiretrovir
therapi
art
pd
treatment
found
publish
data
uk
aim
describ
case
diagnos
singl
hiv
outpati
clinic
uk
case
four
male
pd
identifi
total
patient
ever
access
singl
hiv
clinic
two
parkinson
plu
syndrom
one
progress
supranuclear
palsi
one
lewi
bodi
dementia
age
pd
present
rang
year
time
hiv
diagnosi
pd
diagnosi
rang
year
individu
diagnos
neurologist
normal
mr
imag
brain
bar
mild
ventricular
promin
one
case
differenti
diagnosi
includ
hiv
dementia
three
individu
experienc
postur
hypotens
two
case
preced
diagnosi
previous
link
hiv
parkinson
one
individu
datscan
lumbar
punctur
due
diagnost
uncertainti
show
signific
chang
basal
ganglia
indic
pd
minim
csf
viral
escap
copiesml
manag
chronic
hiv
impact
pd
diagnosi
one
individu
confus
exacerb
dolutegravir
three
individu
swallow
difficulti
impact
drug
administr
individu
csf
viral
escap
art
intensifi
increas
cn
penetr
individu
experienc
progress
diseas
issu
power
attorney
next
kin
becam
import
disclosur
hiv
statu
conclus
similar
previou
case
seri
onset
pd
four
men
live
hiv
occur
preval
similar
gener
popul
clear
link
hiv
infect
increas
hallucin
impuls
motor
deterior
found
also
found
art
dopamin
treatment
interact
patient
challeng
manag
hiv
pd
includ
neuropsychiatr
side
effect
art
swallow
difficulti
issu
surround
capac
studi
includ
adult
hbeagposit
chb
enrol
phase
trial
studi
compar
taf
mg
qd
vs
tdf
mg
qd
associ
hbeag
loss
week
host
viral
treatmentrel
factor
includ
ontreat
virolog
suppress
roch
coba
taqman
lower
limit
detect
iuml
determin
use
logist
regress
analys
result
among
includ
patient
median
age
yr
asian
median
baselin
bl
alt
hbv
dna
ul
iqr
iuml
iqr
respect
patient
lost
hbeag
patient
hbeag
seroconvers
week
hbeag
loss
similar
taf
tdf
treatment
group
vs
p
compar
subject
persist
hbeagposit
hbeag
loss
older
median
age
vs
yr
higher
median
bl
alt
vs
ul
higher
preval
presum
cirrhosi
fibrotest
vs
lower
median
bl
serum
hbv
dna
vs
iuml
p
patient
hbeag
loss
greater
median
declin
hbv
dna
week
vs
iuml
p
week
vs
iuml
p
multivari
analysi
independ
predictor
hbeag
loss
includ
older
age
per
yr
ci
p
higher
bl
alt
per
ul
p
lower
hbv
dna
per
iuml
p
hbv
dna
suppress
week
signific
conclus
minor
subject
treat
taf
tdf
experi
hbeag
loss
week
treatment
older
age
higher
bl
serum
alt
lower
hbv
dna
associ
higher
rate
respons
preval
cardiovascular
risk
factor
women
age
hiv
analysi
data
poppi
studi
pharmacokinet
clinic
observ
peopl
fifti
tariq
bagkeri
c
sabin
l
garvey
l
burgess
winston
asbo
johnson
j
anderson
william
univers
colleg
london
uk
imperi
colleg
london
uk
chelsea
westminst
hospit
london
uk
royal
free
hospit
london
uk
homerton
univers
hospit
london
uk
mortim
market
centr
london
uk
background
increas
number
older
women
access
hiv
servic
uk
postmenopaus
hiv
women
combin
effect
oestrogen
deplet
hiv
may
place
particular
risk
cardiovascular
diseas
cvd
describ
preval
cvd
risk
factor
women
age
particip
poppi
studi
explor
effect
hiv
menopaus
statu
method
analysi
base
data
hiv
women
age
similarlyag
hivwomen
women
report
stop
menstruat
defin
postmenopaus
chisquar
test
compar
proport
cvd
risk
group
result
median
rang
age
hiv
hivwomen
year
respect
among
hiv
women
median
count
cellsll
antiretrovir
therapi
signific
differ
preval
key
cvd
risk
factor
accord
hiv
statu
either
overal
women
postmenopaus
total
tabl
postmenopaus
hiv
hivwomen
receiv
lipidlow
drug
lld
p
receiv
antihypertens
p
among
hiv
women
addit
women
met
establish
criteria
lld
antihypertens
hivwomen
respect
receiv
either
class
drug
signific
betweengroup
differ
conclus
within
small
cohort
report
similar
cvd
risk
factor
among
hiv
agematch
hivwomen
howev
substanti
number
women
high
cvd
risk
andor
hypertens
receiv
medic
condit
clinician
awar
cvd
risk
women
age
hiv
ensur
treat
accord
bhiva
guidelin
conclus
nci
observ
cohort
unselect
natur
cohort
may
make
accur
real
life
approxim
goodwin
c
leen
l
panton
kerr
univers
edinburgh
uk
nh
lothian
edinburgh
uk
background
abnorm
liver
function
test
common
hiv
posit
patient
may
due
antiretrovir
therapi
hepat
b
c
coinfect
nonalcohol
fatti
liver
diseas
nafld
increasingli
diagnos
patient
previou
studi
shown
preval
nafld
higher
normal
popul
nafld
coexist
viral
hepat
could
caus
faster
progress
fibrosi
studi
investig
preval
persist
rais
alt
characterist
associ
hiv
posit
cohort
method
patient
persist
rais
alt
identifi
caus
investig
demograph
laboratori
paramet
collect
identifi
factor
associ
nafld
hiv
monoinfect
hbvhcv
coinfect
patient
includ
ultrasonographi
transient
elastographi
use
identifi
nafld
liver
fibrosi
result
hiv
posit
patient
found
persist
rais
alt
patient
exclud
investig
due
alcohol
excess
autoimmun
liver
diseas
area
deceas
remain
patient
bmi
classifi
obes
patient
met
criteria
metabol
syndrom
small
proport
patient
undergon
investig
rais
alt
clinician
data
patient
underw
investig
liver
diseas
present
patient
underw
liver
ultrasound
find
suggest
degre
nafld
patient
bmi
amount
dyslipidemia
patient
underw
transient
elastographi
liver
stiff
valu
indic
signific
liver
stiff
data
avail
next
coupl
month
conclus
surprisingli
low
preval
transamin
cohort
compar
previou
studi
studi
found
transamin
frequent
inadequ
investig
clinician
research
requir
preval
nafld
within
hiv
popul
especi
within
uk
patient
need
long
term
follow
order
evalu
prognosi
nafldnash
within
hiv
popul
prostat
cancer
peopl
live
hiv
outcom
era
haart
method
larg
prospect
maintain
databas
patient
diagnos
era
combin
antiretrovir
therapi
cart
nonaid
defin
cancer
identifi
patient
median
age
year
rang
diagnosi
prostat
cancer
result
time
cancer
diagnosi
median
cell
count
mm
cart
undetect
hiv
viral
load
patient
present
symptom
nation
psa
screen
programm
median
serum
psa
present
ngml
gleason
score
biopsi
rang
correl
histolog
grade
tumour
cell
count
cancer
diagnosi
three
patient
metastat
diseas
diagnosi
whilst
patient
localis
diseas
nineteen
patient
localis
diseas
treat
radic
therapi
cur
intent
radic
prostatectomi
extern
beam
radiotherapi
requir
subsequ
salvag
surgeri
twelv
patient
localis
diseas
receiv
radic
therapi
monitor
close
surveil
case
localis
tumour
low
grade
gleason
median
followup
year
maximum
year
year
overal
surviv
ci
one
patient
present
metastat
diseas
die
conclus
outcom
treatment
localis
prostat
cancer
plwh
excel
would
strongli
suggest
plwh
localis
prostat
cancer
offer
treatment
strategi
patient
hiv
seroneg
includ
access
radic
prostatectomi
metastat
set
given
myriad
complex
drug
interact
suscept
opportunist
infect
recommend
plwh
need
chemotherapi
manag
clinician
interest
field
realworld
assess
renal
safeti
among
patient
hiv
infect
expos
tenofovir
alafenamid
megar
p
rafferti
w
dinsmor
c
donnelli
c
emerson
e
mccarti
quah
royal
victoria
hospit
belfast
uk
background
tripl
therapi
compris
nrti
backbon
choic
agent
remain
standard
care
treat
hiv
choos
nrti
backbon
often
involv
balanc
potenti
renal
bone
toxic
increas
cardiovascular
cv
risk
risk
unaccept
complex
nucleosid
spare
regim
altern
studi
shown
tenofovir
alafenamid
taf
less
detriment
renal
bone
health
tenofovir
disoproxil
fumar
tdf
would
ideal
choic
situat
present
data
earli
clinic
experi
taf
patient
abnorm
renal
paramet
risk
factor
method
patient
prescrib
taf
maynovemb
renal
indic
identifi
clinic
record
retrospect
chart
review
conduct
data
collect
includ
relev
risk
factor
previou
arv
therapi
renal
marker
interv
post
taf
initi
result
patient
prescrib
taf
base
regim
renal
indic
mean
age
year
rang
caucasian
black
african
patient
treatment
experienc
switch
tdfftc
backbon
backbon
nrti
spare
regimen
post
switch
taf
regimen
tafftcelvc
tafftc
agent
patient
regard
comorbid
hypertens
known
cv
diseas
increas
cv
risk
reason
initi
taf
identifi
elev
upcr
patient
increas
creatinin
patient
noteabl
patient
previou
renal
toxic
tdf
addit
high
cv
risk
renal
paramet
record
week
median
creatinin
clearanc
crcl
mlmin
mlmin
mlmin
respect
median
upcr
mgmmol
mgmmol
mgmmol
respect
patient
previou
tdf
toxic
crcl
mlmin
week
mlmin
week
patient
virolog
suppress
week
conclus
earli
clinic
experi
taf
mildmoder
renal
impair
similar
outcom
larg
phase
iii
trial
data
suggest
improv
crcl
upcr
patient
identifi
renal
risk
whilst
appear
ideal
choic
nrti
backbon
older
patient
underli
renal
dysfunct
comorbid
eg
diabet
data
need
establish
place
treatment
tenofovir
relat
tubulopathi
fanconi
syndrom
reflect
specialist
hiv
menopaus
servic
chirwa
n
taghinejadi
g
macaulay
n
nwokolo
c
bellon
n
panay
chelsea
westminst
hospit
nh
foundat
trust
london
uk
background
women
live
hiv
wlwh
uk
age
data
suggest
wlwh
may
undergo
earlier
menopaus
suffer
associ
illhealth
women
without
hiv
moreov
potenti
interact
antiretrovir
hormon
replac
therapi
hrt
underscor
need
develop
experi
manag
grow
cohort
women
establish
monthli
hiv
menopaus
servic
overseen
gynaecologist
hiv
physician
describ
characterist
wlwh
attend
clinic
result
wlhiv
attend
median
age
first
attend
refer
hiv
clinician
black
mean
year
hiv
diagnosi
rang
median
baselin
count
cellsll
previou
aid
defin
ill
antiretrovir
therapi
art
median
last
count
cellsll
viral
load
copiesml
commonest
symptom
hot
flush
menstrual
irregular
labil
mooddepress
vagin
dryness
median
durat
symptom
clinic
attend
month
patient
altern
diagnos
sought
diagnosi
menopaus
made
earli
menopaus
onset
year
prematur
ovarian
insuffici
menopaus
onset
year
women
dexa
scan
osteopenia
osteoporosi
initi
hrt
alreadi
hrt
except
patient
either
express
concern
hrt
risk
longer
symptom
time
clinic
attend
transderm
oestrogen
oral
progesteron
frequent
use
hrt
regimen
women
seen
follow
describ
improv
symptom
median
time
hrt
month
hrt
associ
complic
instanc
art
modif
conclus
menopaus
women
like
low
nadir
reflect
number
year
sinc
hiv
diagnosi
african
descent
commonest
present
vasomotor
symptom
high
proport
osteopenia
osteoporosi
long
delay
onset
menopaus
symptom
offer
treatment
may
due
misdiagnosi
attribut
symptom
hiv
uptak
hrt
high
method
retrospect
analysi
peopl
live
hiv
obstruct
lung
diseas
old
age
year
nasopharyng
sampl
test
respiratori
viral
pathogen
januari
multiplex
pcr
identifi
adenoviru
coronaviru
enteroviru
human
metapneumoviru
influenza
parainfluenza
respiratori
syncyti
viru
rhinoviru
result
sampl
identifi
plwh
old
hiv
group
predominantli
male
caucasian
median
age
count
cellsmm
hiv
load
undetect
old
group
predominantli
femal
caucasian
median
age
proport
sampl
respiratori
viral
pathogen
detect
differ
significantli
plwh
old
group
vs
remain
true
analysi
restrict
hospitalis
symptom
consist
viral
respiratori
ill
vs
within
posit
sampl
rhinoviru
overal
frequent
isol
viru
popul
follow
influenza
influenza
b
parainfluenza
influenza
vs
parainfluenza
vs
frequent
detect
old
group
plwh
posit
sampl
multivari
analysi
show
age
year
ci
femal
gender
low
count
cellsmm
increas
significantli
associ
hospitalis
hospitalis
patient
posit
sampl
plwh
like
abnorm
cxr
vs
less
like
admit
icu
vs
median
length
admiss
day
rang
old
group
day
hiv
group
conclus
singl
centr
studi
plwh
less
like
old
patient
influenza
parainfluenza
detect
data
suggest
may
reflect
part
differ
age
two
popul
plwh
low
blood
count
associ
hospitalisationhighlight
import
effect
antiretrovir
therapi
continu
longterm
popul
age
retin
vascular
calibr
hivposit
men
year
compar
similar
age
hivneg
younger
hivposit
control
l
haddow
r
laverick
r
gilson
william
c
sabin
leung
peto
j
vera
f
post
boffito
winston
univers
colleg
london
uk
moorfield
eye
hospit
london
uk
brighton
sussex
medic
school
brighton
uk
king
colleg
hospit
london
uk
st
stephen
aid
trust
london
uk
imperi
colleg
london
uk
background
peopl
live
hiv
may
increas
risk
cerebr
small
vessel
diseas
csvd
determin
associ
hiv
statu
retin
vascular
measur
use
retin
vascular
photographi
noninvas
method
measur
csvd
method
white
nondiabet
men
multicentr
poppi
cohort
compris
three
demograph
match
group
hivposit
hiv
age
year
hiv
year
hivneg
hiv
year
recruit
ophthalm
substudi
hiv
particip
virolog
suppress
optic
disc
centr
fundu
photograph
use
calcul
central
retin
arteri
crae
venou
crve
calibr
well
arterioven
ratio
avr
measur
one
randomlychosen
eye
per
particip
compar
group
use
anova
associ
hiv
statu
avr
estim
use
multivari
linear
regress
model
adjust
age
factor
associ
avr
bivari
model
p
result
includ
hiv
year
median
age
interquartil
rang
hiv
year
year
count
hiv
median
tenyear
risk
cardiovascular
diseas
framingham
hiv
year
hiv
year
year
respect
signific
differ
blood
pressur
bp
bodi
mass
index
lipid
seven
hiv
year
selfreport
histori
stroketia
compar
group
smoke
preval
hiv
year
respect
differ
group
retin
vascular
measur
tabl
multivari
model
incorpor
age
systol
bp
stroke
syphili
histori
recreat
drug
use
hiv
statu
associ
increas
avr
confid
interv
result
overal
preval
hypogonad
found
secondari
hypogonad
common
observ
patient
primari
hypogonad
found
reflect
effect
hivaid
hypothalam
pituitari
gonad
hpg
axi
well
direct
testicular
injuri
patient
symptomat
histor
hypogonad
statist
signific
associ
hypogonad
level
immunodefici
found
increas
preval
sever
hypogonad
count
decreas
significantli
lower
level
free
testosteron
dhea
found
case
sever
immunosuppress
direct
correl
count
level
free
testosteron
well
dhea
found
indirectli
reflect
neg
impact
high
viral
load
testicular
well
adren
androgen
anaemia
also
found
significantli
patient
hypogonad
lhfshprolactin
level
higher
patient
mark
immunodefici
associ
count
signific
mean
testosteron
fsh
level
significantli
higher
patient
art
similar
associ
hormon
could
ascertain
conclus
hypogonad
primari
well
secondari
common
endocrinolog
disord
hivinfect
male
popul
delay
initi
art
low
count
major
determin
background
hcvhiv
coinfect
lead
increas
morbid
mortal
directli
act
antivir
daa
high
rate
cure
even
hivhcv
coinfect
patient
complex
drugdrug
interact
must
manag
examin
poverti
level
treatment
outcom
hcv
monoand
hcvhiv
coinfect
patient
cohort
method
retrospect
studi
patient
start
daa
sociodemograph
health
data
collect
includ
sustain
virolog
respons
week
end
treatment
result
patient
hcv
monoinfect
hcvhiv
coinfect
patient
document
treatment
outcom
time
write
patient
predominantli
male
white
mean
age
year
patient
monoinfect
depriv
quintil
versu
hivhcv
coinfect
cirrhosi
present
monoinfect
coinfect
patient
genotyp
predomin
genotyp
monoinfect
coinfect
patient
hcvhiv
coinfect
patient
treatment
naiv
whilst
hcv
monoinfect
patient
previou
treatment
hcvhiv
coinfect
patient
receiv
daa
includ
prod
harvoni
week
hcv
viral
load
iuml
sofriba
per
nh
england
guidanc
time
outcom
shown
background
central
nervou
system
cn
toxic
common
combin
antiretrovir
therapi
efavirenz
efv
use
concern
exist
regard
overt
cn
toxic
directli
recogn
peopl
hiv
pwh
efv
clinician
could
impact
qualiti
life
aim
studi
determin
whether
cn
symptom
improv
pwh
without
overt
complain
cn
toxic
switch
efv
method
pwh
receiv
atripla
least
week
hiv
rna
copiesml
selfreport
cn
symptom
associ
efv
enrol
prospect
studi
switch
eviplera
neuropsychiatr
cn
toxic
evalu
use
cn
sleep
questionnair
median
cn
score
deriv
sum
toxic
grade
collect
cn
questionnair
cn
side
effect
tabl
median
sleep
score
calcul
baselin
week
primari
endpoint
switch
eviplera
cognit
function
assess
baselin
week
use
comprehens
batteri
result
patient
median
age
interquartil
rang
iqr
predominantli
male
white
ethnic
recruit
week
analysi
signific
reduct
total
cn
score
observ
week
trend
toward
improv
week
respons
patient
aim
studi
investig
immun
respons
hepat
b
vaccin
cohort
hiv
infect
patient
method
newli
diagnos
hiv
infect
patient
underw
routin
screen
hbv
infect
baselin
clinic
visit
nonimmun
patient
routin
offer
immunis
hbv
infect
vaccin
cours
compris
engerix
ml
administ
intramuscularli
zero
month
one
month
six
immunis
patient
undergo
annual
screen
hepat
b
surfac
antibodi
present
analysi
patient
neg
hepat
b
surfac
antigen
hepat
b
surfac
antibodi
hepat
b
core
antibodi
includ
studi
data
newli
diagnos
patient
attend
clinic
januari
januari
review
serolog
inform
patient
complet
vaccin
cours
includ
studi
immun
respons
vaccin
defin
presenc
hepat
b
surfac
antibodi
titr
equal
greater
iuml
month
first
dose
engerix
result
newli
hiv
infect
patient
met
studi
inclus
criteria
includ
men
sex
men
msm
heterosexu
individu
six
intraven
drug
user
ivdu
six
individu
infect
mother
child
transmiss
hiv
patient
receiv
first
dose
hepat
b
vaccin
second
third
dose
vaccin
administ
patient
respect
one
year
start
vaccin
cours
patient
receiv
plan
three
dose
vaccin
immun
hepat
b
conclus
cohort
hiv
infect
individu
post
vaccin
immun
hbv
compar
healthi
individu
without
hiv
infect
doubl
dose
hepat
b
vaccin
administ
standard
schedul
offer
hiv
infect
patient
effect
individualis
diet
exercis
advic
reduc
type
diabet
risk
peopl
live
hiv
pilot
investig
duncan
b
peter
l
goff
guy
st
thoma
hospit
london
uk
king
colleg
london
uk
background
burden
diabet
increas
peopl
live
hiv
plwh
histor
diet
exercis
intervent
aim
mitig
risk
cardiovascular
diseas
cvd
plwh
treat
antiretrovir
arv
demonstr
littl
effect
insulin
resist
studi
recruit
hiv
patient
prediabet
aim
investig
effect
new
diet
exercis
intervent
diabet
risk
method
patient
attend
urban
hiv
clinic
stabl
arv
impair
fast
glucos
mmoll
invit
take
part
month
appoint
particip
advis
chang
diet
exercis
order
meet
goal
base
mediterranean
diet
diabet
prevent
trial
advic
individualis
meet
cultur
socioeconom
need
pre
post
intervent
diabet
risk
measur
use
frequentlysampl
liquid
meal
toler
test
rang
secondari
outcom
measur
data
analys
use
spss
ttest
estim
effect
result
particip
recruit
complet
intervent
achiev
median
goal
statist
signific
improv
mean
chang
glucos
insulin
fast
level
reduct
respect
postprandi
increment
area
curv
reduct
respect
signific
reduct
mean
valu
weight
waist
systol
blood
pressur
fast
triglycerid
cvd
risk
signific
increas
mean
hdl
life
satisfact
score
signific
chang
ldl
frailti
gut
symptom
conclus
despit
potenti
hiv
infect
arv
increas
diabet
risk
diet
exercis
chang
significantli
reduc
risk
addit
intervent
significantli
reduc
central
obes
hypertens
triglycerid
cvd
risk
given
cohort
heavili
treat
statin
absenc
effect
ldl
surpris
variabl
achiev
goal
warrant
investig
facilit
barrier
behaviour
chang
given
effect
intervent
plwh
financi
pressur
face
nh
futur
randomis
control
trial
might
investig
less
expens
method
intervent
deliveri
result
implement
realtim
pcr
method
diagnost
opportunist
infect
hivinfect
person
kiev
region
centr
prevent
control
aid
stepchenkova
yurchenko
karnet
kiev
region
centr
prevent
control
aid
ukrain
object
improv
laboratori
diagnost
opportunist
hivassoci
infect
hivinfect
patient
medic
supervis
kiev
region
centr
prevent
control
aid
materi
method
realtim
pcr
method
test
blood
sampl
bodi
fluid
research
carri
realtim
pcr
equip
rotorgen
testkit
amplisens
russia
result
discuss
kiev
citi
one
affect
hiv
epidemi
region
ukrain
medic
supervis
kiev
region
centr
prevent
control
aid
patient
rapid
spread
epidem
increas
reach
hivinfect
patient
antiretrovir
therapi
antiretrovir
therapi
kiev
region
centr
prevent
control
aid
use
adult
presenc
opportunist
hivassoci
patient
lead
complic
reduc
effect
arv
therapi
immunolog
clinic
ineffici
presenc
diseas
patient
alway
possibl
determin
convent
laboratori
method
therefor
laboratori
diagnosi
opportunist
hivassoci
infect
realtim
pcr
method
allow
assign
necessari
treatment
time
increas
effect
arv
therapi
pcr
depart
clinic
laboratori
kiev
region
centr
prevent
result
coinfect
patient
identifi
distinct
infect
reinfect
genotyp
g
cirrhot
male
msm
like
ivdu
acquir
patient
treat
local
use
treatment
episod
infect
receiv
pegyl
interferon
ifn
ribavirin
subsequ
regimen
ifnribavirinsimeprevir
ifnribavirinsofosbuvir
abbvi
abbvi
harvoni
ribavirin
svr
henc
patient
treat
date
achiev
remain
infect
patient
schedul
commenc
treatment
immin
await
fund
ifnspar
therapi
treat
elsewher
left
region
poorli
engag
servic
side
effect
ifncontain
regimen
numer
one
occas
therapi
discontinu
noncirrhot
patient
stop
interferon
week
remain
sofosbuvirribavirin
complet
week
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
neg
dose
reduct
ribavirin
undertaken
accord
level
haemolysi
preserv
haemoglobin
one
patient
develop
antibodi
posit
autoimmun
myositi
cessat
treatment
probabl
precipit
ifn
antiretrovir
therapi
art
commenc
prior
hepat
c
treatment
case
care
taken
avoid
drug
interact
di
treat
direct
act
antivir
daa
discuss
hub
mdt
per
commiss
arrang
patient
requir
transient
switch
art
avoid
di
whilst
allow
lowest
cost
acquisit
hepat
c
therapi
art
tailor
avoid
di
prepar
daa
therapi
highlight
advantag
integr
infecti
diseas
servic
conclus
cohort
demonstr
remark
efficaci
real
world
data
patient
treat
daa
therapi
transform
outcom
recent
year
well
demonstr
along
abil
effect
manag
complex
coinfect
dgh
set
idl
servic
excel
patient
engag
side
effect
major
drug
interact
high
reinfect
rate
cohort
observ
weight
gain
patient
use
integras
inhibitor
emerg
class
side
effect
bhaduri
robert
worcestershir
health
care
trust
uk
worcestershir
nh
acut
trust
uk
background
hiv
servic
host
semi
urban
cohort
patient
patient
use
integras
inhibitor
insti
part
antiretrovir
regim
patient
complain
weight
gain
regim
explor
observ
across
class
drug
method
case
note
patient
use
insti
scrutinis
evid
weight
gain
identifi
patient
evid
signific
weight
gain
result
case
year
old
caucasian
femal
comorbid
rheumatoid
arthriti
ra
switch
atripla
stribild
month
exposur
elvitegravir
kg
weight
gain
note
switch
dolutegravirtruvada
weight
increas
kg
month
remain
stabl
viral
load
suppress
addit
steroid
requir
ra
patient
switch
dolutegravir
evotaz
weight
reduct
kg
month
case
year
old
black
african
male
commenc
atripla
switch
triumeq
due
worsen
renal
function
weight
increas
kg
month
stabl
count
viral
suppress
case
year
old
caucasian
male
commenc
truvadadarunavirritonavir
later
darunavir
switch
dolutegravir
weight
gain
kg
year
stabl
viral
suppress
dolutegravir
switch
nevirapin
complet
revers
weight
gain
case
year
old
caucasian
male
diagnos
mm
truvadaraltegravir
switch
triumeqdarunavir
owe
resist
weight
gain
kg
month
stabl
viral
load
suppress
case
year
old
caucasian
male
diagnos
viral
load
copiesml
commenc
truvadadarunavir
switch
triumeq
simplif
month
later
weight
gain
kg
note
increas
viral
suppress
conclus
case
seri
patient
describ
associ
weight
gain
insti
exposur
across
differ
insti
case
demonstr
revers
switch
insti
actg
studi
highlight
effect
raltegravir
exposur
weight
gain
persist
despit
adjust
immun
statu
two
case
weight
gain
may
compound
late
diagnosi
immun
reconstitut
overal
data
support
recent
literatur
insti
exposur
weight
gain
furthermor
suggest
possibl
class
effect
weight
gain
insti
project
aim
review
demograph
patient
reason
late
present
obstacl
time
diagnosi
suggest
improv
primari
secondari
tertiari
care
servic
reduc
rate
late
diagnosi
method
retrospect
analysi
case
note
adult
patient
diagnos
late
hiv
june
june
patient
baselin
count
cellsmm
select
gum
clinic
infecti
diseas
unit
citi
result
set
note
identifi
across
two
site
met
criteria
avail
give
final
cohort
patient
baselin
count
rang
cellsmm
median
cellsmm
patient
identifi
men
sex
men
msm
heterosexu
bisexu
test
due
symptomat
unwel
case
rout
transmiss
clearli
document
msm
suspect
rout
transmiss
case
heterosexu
test
indic
condit
diagnosi
includ
sexual
transmit
infect
chlamydia
cervic
intraepitheli
neoplasia
stage
iii
mononucleosislik
syndrom
aid
defin
condit
includ
kaposi
sarcoma
pneumocysti
pneumonia
hiv
encephalopathi
conclus
msm
heterosexu
popul
risk
late
diagnosi
well
outsid
uk
signific
proport
patient
present
sever
aid
defin
condit
suggest
miss
hiv
test
opportun
health
servic
suggest
earlier
test
would
led
fewer
late
diagnos
less
hivrel
morbid
local
evalu
requir
method
expedit
hiv
test
includ
promot
provis
home
hiv
test
improv
access
hiv
test
atrisk
group
educ
healthcar
profession
around
hiv
risk
sexual
histori
take
awar
hiv
indic
condit
optim
use
hiv
prevent
strategi
partner
notif
prepost
exposur
prophylaxi
may
also
contribut
reduct
late
diagnos
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
aid
edinburgh
case
seri
ongo
diagnost
challeng
raha
c
mutch
mackenzi
chalmer
centr
edinburgh
uk
region
infecti
diseas
unit
edinburgh
uk
background
year
region
infecti
diseas
unit
edinburgh
ridu
four
death
due
aid
present
review
patient
method
case
note
review
result
multipl
risk
factor
delay
diagnosi
identifi
ie
men
sex
men
msm
movement
health
board
within
outwith
uk
patient
present
nonspecif
symptom
initi
misdiagnos
common
present
patient
continu
present
indic
hiv
test
yet
diagnosi
often
delay
worsen
outcom
initi
present
aid
commonli
nonspecif
common
symptom
vital
maintain
high
degre
suspicion
lack
sexual
health
histori
part
routin
medic
clerkin
contribut
delay
hiv
diagnosi
risk
factor
identifi
remain
vital
educ
clinician
recognis
featur
suggest
hivaid
increas
awar
bhiva
guidelin
test
barrier
hiv
test
patient
confirm
oesophag
candidiasi
f
carlin
royal
liverpool
univers
hospit
uk
background
earlier
hiv
diagnosi
associ
improv
health
outcom
reduc
admiss
health
cost
reduc
rate
transmiss
bhiva
bashh
bi
test
guidanc
recommend
test
patient
oesophag
candidiasi
occur
frequent
hiv
posit
individu
lower
count
aim
find
mani
patient
oesophag
candida
gastroscopi
ogd
test
hiv
identifi
possibl
barrier
test
method
data
hospit
endoscopi
unit
first
month
review
case
candida
ogd
patient
includ
base
endoscopi
find
histolog
lab
result
case
note
check
look
evid
hiv
test
within
three
month
ogd
discuss
offer
test
ogd
result
collect
brief
survey
conduct
within
gastroenterolog
team
regard
barrier
test
result
patient
identifi
candida
exclud
due
neg
histolog
equal
split
men
women
hiv
test
one
ogd
report
recommend
hiv
test
surgic
patient
test
gp
referr
amu
gener
medicin
gastroenterolog
referr
test
patient
test
also
symptom
unexplain
anaemia
weight
loss
hepat
b
c
list
indic
condit
uk
nation
guidelin
hiv
test
patient
like
receiv
hiv
test
yr
old
oesophag
candidiasi
often
attribut
inhal
caus
could
found
patient
activ
malign
less
like
test
note
mani
malign
common
hiv
posit
individu
barrier
test
includ
lack
knowledg
guidelin
recommend
concern
regard
cost
test
requir
specialist
test
counsel
patient
includ
time
constraint
appropri
follow
conclus
patient
confirm
oesophag
candida
test
hiv
highlight
miss
opportun
diagnosi
mani
healthcar
profession
awar
nation
guidelin
hiv
test
indic
condit
test
recommend
highlight
need
increas
regular
staff
educ
across
hospit
specialti
gener
practic
rais
awar
guidelin
promot
hiv
test
part
routin
practic
method
death
among
hiv
patient
occur
report
london
hiv
care
centr
data
collect
demograph
diagnosi
inform
caus
place
death
recent
load
vl
art
statu
report
adher
clinician
ask
whether
death
expect
defin
patient
expect
die
eg
receiv
plan
end
life
care
termin
condit
unexpect
eg
late
present
admit
diagnosi
respons
treatment
death
categoris
use
code
protocol
result
death
report
among
hiv
patient
care
site
among
men
median
age
death
year
men
women
peopl
die
hospit
home
peopl
art
adher
last
clinic
visit
art
cellsmm
vl
copiesml
half
death
unexpect
expect
death
die
hospit
median
time
diagnosi
death
year
peopl
die
within
year
caus
death
among
everyon
die
within
one
year
unexpect
death
seen
tabl
caus
known
major
death
aid
nonaid
cancer
aidsdefin
ill
account
death
occur
within
one
year
diagnosi
unexpect
death
present
oi
significantli
lower
count
p
higher
viral
load
p
less
like
engag
care
p
ivdu
mode
acquisit
hcv
coinfect
individu
like
admit
nonhiv
relat
ill
p
p
respect
heterosexu
risk
group
like
present
oi
oi
vs
non
oi
p
discuss
improv
care
packag
ivdu
hcv
coinfect
cohort
need
develop
optimis
patient
care
prevent
hospit
admiss
healthcar
cost
also
need
improv
screen
immedi
art
given
ongo
rate
oi
seen
cohort
factor
associ
delay
linkag
care
follow
hiv
diagnosi
western
europ
result
individu
includ
analysi
men
women
mean
baselin
cellsll
rang
mean
hiv
vl
copiesml
rang
median
time
hiv
diagnosi
art
initi
day
individu
start
art
within
day
within
month
rapid
art
initi
associ
lower
baselin
ci
high
baselin
viral
load
ci
primari
hiv
infect
diagnosi
mean
time
art
individu
diagnos
primari
hiv
day
rang
rapid
art
initi
associ
age
gender
ethnic
coinfect
hepat
b
c
conclus
half
individu
start
art
within
day
hiv
diagnosi
factor
associ
rapid
art
initi
includ
low
high
vl
primari
hiv
infect
investig
delay
art
initi
underway
hiv
partner
notif
audit
bashh
standard
background
hiv
diagnosi
care
improv
howev
still
grow
epidem
reduc
sever
approach
need
taken
includ
increas
hiv
test
rate
estim
peopl
live
hiv
uk
unawar
infect
risk
transmiss
higher
peopl
highli
activ
retrovir
therapi
haart
also
import
identifi
may
alreadi
hiv
posit
start
hiv
post
exposur
prophylaxi
pep
reduc
risk
induc
resist
antiretrovir
therapi
hiv
poct
provid
faster
result
standard
serolog
test
may
accept
patient
suffer
needl
phobia
anxiou
await
result
therefor
use
prior
prescrib
pep
anticip
increas
hiv
test
method
ascertain
util
perform
aler
hiv
poct
pilot
local
sexual
health
depart
hiv
poct
perform
start
pep
needl
phobic
anxiou
await
standard
serolog
result
anoth
signific
reason
proforma
complet
hiv
poct
logbook
complet
result
total
patient
hiv
poct
sever
risk
factor
hiv
transmiss
includ
msm
hiv
posit
partner
partner
high
preval
area
common
reason
hiv
poct
pre
pep
anxieti
await
standard
serolog
signific
reason
hiv
poct
result
neg
antibodi
posit
confirm
standard
serolog
hiv
test
confirm
confirmatori
serolog
taken
conclus
hiv
poct
confirmatori
serolog
taken
confirm
apart
account
confirm
test
perform
untrain
staff
member
futur
hiv
poct
would
perform
train
staff
hiv
poct
confirmatori
serolog
taken
due
needl
phobia
result
would
appear
aler
hiv
poct
sensit
specif
test
introduc
aler
hiv
poct
would
decreas
clinic
risk
may
increas
take
hiv
test
may
accept
patient
needl
phobia
may
cost
effect
reduc
followup
attend
result
high
risk
patient
hiv
test
emerg
depart
import
distinct
target
popul
sexual
health
clinic
commun
care
clinic
gp
secondari
care
diagnos
partner
notif
ed
popul
heterosexu
none
popul
vs
signific
differ
gender
ethnic
group
ed
popul
seroconvert
median
count
significantli
differ
two
group
vs
admit
inpati
follow
present
ed
one
present
ed
within
month
prior
diagnos
ed
popul
link
see
clinician
within
week
hiv
diagnosi
conclus
analysi
confirm
import
target
ed
popul
hiv
test
ed
popul
larger
proport
heterosexu
male
tradit
hard
reach
group
hiv
screen
high
rate
primari
infect
continu
found
popul
hiv
test
patient
indic
cn
infect
larg
teach
hospit
england
diagnos
late
despit
varieti
indic
ill
uk
european
hiv
test
guidelin
includ
list
indic
condit
hiv
test
includ
aid
defin
neurolog
condit
test
also
recommend
patient
asept
mening
enceph
invas
pneumococc
infect
aim
studi
review
hiv
test
patient
asept
mening
enceph
well
specifi
organ
caus
mening
per
guidelin
method
clinic
laboratori
data
collect
decemb
june
patient
enceph
mening
singl
teach
hospit
also
tertiari
referr
infecti
diseas
unit
patient
recruit
prospect
accord
predefin
definit
mening
enceph
stratifi
accord
aetiolog
data
review
ascertain
whether
hiv
test
perform
outcom
result
patient
recruit
met
inclus
criteria
asept
mening
enceph
patient
infect
includ
pneumococc
varicella
zoster
jc
viru
mycobacterium
tuberculosi
cryptococcu
neoforman
overal
hiv
test
perform
posit
specif
organ
identifi
hiv
test
asept
group
enceph
mening
test
patient
locat
identifi
hiv
test
perform
patient
infecti
diseas
intens
care
gener
medic
team
conclus
modern
guidelin
recommend
hiv
test
patient
asept
mening
enceph
defin
cn
infect
singl
teach
centr
patient
test
gener
ward
compar
specialist
ward
best
patient
proven
cn
infect
test
asept
mening
enceph
test
work
need
promot
hiv
test
gener
medic
emerg
room
set
use
phylogenet
facilit
clinic
case
find
partner
notif
hiv
lesson
systemat
review
use
stigmatis
infecti
diseas
l
mulka
jh
vera
ja
cassel
aj
leighbrown
brighton
sussex
medic
school
uk
univers
edinburgh
uk
background
phylogenet
inform
provid
new
horizon
clinic
case
find
hiv
rais
issu
accept
privaci
even
criminalis
review
studi
describ
use
phylogenet
directli
inform
case
find
undiagnos
contact
commun
acquir
stigmatis
infecti
diseas
method
search
medlin
embas
cinahl
psychinfo
articl
phylogenet
use
facilit
case
find
sexual
transmit
infect
tb
hbv
hcv
publish
juli
english
result
paper
screen
met
inclus
criteria
tb
hiv
addit
studi
report
use
phylogenet
investig
discret
hiv
outbreak
trace
sourc
explicitli
report
role
case
find
case
find
strategi
includ
confirm
sourc
outbreak
prompt
wider
investig
hiv
contact
trace
phylogenet
cluster
case
tb
hiv
combin
cluster
geograph
inform
target
screen
tb
screen
inform
discrep
genotyp
epidemiolog
data
tb
phylogenet
characteris
inform
screen
intervent
hiv
use
link
epidemiolog
data
identifi
sourc
hiv
contact
trace
genotyp
match
case
rapidli
progress
diseas
hiv
facilit
includ
share
molecular
surveil
data
establish
commun
support
target
tb
screen
barrier
includ
delay
result
time
laps
case
refus
access
premis
screen
howev
patient
barrier
rare
report
ethic
issu
includ
media
coverag
hiv
sourc
ident
conclus
phylogeneticsinform
approach
case
find
feasibl
stigmatis
infect
howev
studi
report
use
clinic
public
health
practic
provid
limit
inform
patient
relat
barrier
accept
ethic
challeng
identif
core
transmitt
criminalis
research
patient
view
accept
risk
prefer
approach
use
phylogenet
inform
case
find
hiv
need
inform
futur
intervent
innov
hiv
test
workplac
j
hand
c
evan
h
blake
b
hussain
rowland
lass
leicest
uk
univers
nottingham
uk
design
redefin
east
midland
uk
background
fund
public
health
england
project
provid
hiv
test
part
seri
healthwellb
event
workplac
along
distribut
corridor
target
low
wage
worker
shift
long
hour
although
mani
uk
organis
offer
employe
health
check
includ
hiv
test
one
first
initi
countri
includ
hiv
within
employe
health
check
project
deliv
east
midland
voluntari
sector
organis
took
place
month
period
aim
reach
men
workplac
particularli
migrant
men
subsaharan
africa
eastern
europ
initi
target
undertak
hiv
test
employe
attend
health
event
also
abl
receiv
seri
addit
text
messag
provid
inform
hiv
prep
hep
c
safer
sex
gener
health
wellb
gp
referr
evalu
method
evalu
explor
feasibl
accept
potenti
sustain
workplac
hivwellb
intervent
multipl
stakehold
perspect
employe
compani
project
partner
adopt
mix
method
design
use
questionnair
interview
text
messag
project
monitor
data
result
employe
differ
countri
attend
workplac
health
event
held
differ
compani
one
third
attende
migrant
worker
attende
undertook
hiv
test
attende
never
hiv
test
consid
hiv
test
accept
element
workplac
health
check
felt
learnt
someth
new
health
attende
sign
receiv
follow
text
messag
report
seek
hiv
test
event
conclus
hiv
test
workplac
highli
accept
event
abl
reach
divers
group
employe
includ
previous
test
project
also
suggest
mobil
phone
text
messag
accept
wellreceiv
adjunct
method
motiv
peopl
test
take
action
nation
polici
guidanc
workplac
health
includ
hiv
test
would
also
provid
strong
support
credibl
local
initi
aim
undertak
hiv
test
context
workplac
health
initi
need
research
explor
differ
model
incorpor
hiv
test
workplac
health
wellb
initi
accept
ignor
nation
test
guidelin
current
test
practic
lothian
year
bhiva
nation
test
guidelin
publish
cevik
c
leen
raha
region
infecti
diseas
unit
western
gener
hospit
edinburgh
uk
chalmer
sexual
health
centr
edinburgh
uk
background
uk
almost
patient
diagnos
hiv
initi
art
art
suppress
viral
load
howev
approxim
onefourth
hiv
infect
adult
still
remain
undiagnos
onefourth
newli
diagnos
individu
late
present
aim
assess
newli
diagnos
individu
lothian
preval
agre
polici
screen
hiv
order
understand
current
test
practic
method
use
dedic
hiv
databas
includ
new
present
servic
april
april
data
retrospect
collat
electron
patient
record
descript
statist
perform
examin
demograph
baselin
characterist
treatment
result
identifi
individu
femal
newli
diagnos
hiv
median
age
year
individu
individu
diagnos
gum
clinic
gp
practic
secondari
care
outreach
servic
use
selftest
kit
individu
diagnos
routin
screen
contact
trace
individu
present
clinic
symptom
median
nadir
cell
count
cell
ml
howev
observ
signific
differ
diagnos
variou
set
tabl
individu
diagnos
secondari
care
use
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
home
test
kit
significantli
lower
median
count
cell
ml
respect
half
cohort
count
cell
ml
present
aid
defin
ill
individu
present
health
care
facil
past
year
diagnosi
clinic
indic
hiv
infect
overal
individu
cellsml
die
within
month
diagnosi
due
aid
defin
ill
conclus
earli
diagnosi
critic
improv
morbid
mortal
also
prevent
onward
transmiss
late
diagnosi
associ
longer
hospit
stay
increas
cost
healthcar
servic
cohort
onefourth
patient
count
cellsml
half
cellsml
late
present
contact
health
care
prior
hiv
diagnosi
repres
miss
opportun
earlier
diagnosi
believ
routin
test
relev
set
offer
per
nation
guidelin
order
reduc
undiagnos
hiv
infect
late
diagnosi
late
present
hiv
newcastl
audit
newli
diagnos
hiv
hiv
n
okeef
gentri
e
hurn
daniel
wilkinson
radford
p
falkou
bittin
py
tan
k
gold
n
sankar
e
ong
newcastl
univers
medic
school
uk
newcastl
hospit
nh
trust
uk
background
audit
aim
identifi
late
present
miss
opportun
earlier
hiv
test
year
whether
uk
test
guidelin
impact
earli
diagnosi
method
studi
retrospect
case
note
audit
patient
newli
diagnos
hiv
present
compar
previou
year
sinc
patient
initi
count
class
late
present
count
aid
class
advanc
diseas
result
newlydiagnos
patient
id
depart
gum
patient
present
id
present
late
advanc
diseas
previou
identifi
diseas
gum
present
latether
patient
advanc
diseas
previou
indic
diseas
conclus
late
hiv
present
remain
challeng
newcastl
uk
hiv
test
guidelin
appear
made
impact
past
year
signific
number
newli
diagnos
late
patient
especi
id
depart
miss
opportun
earlier
hiv
test
offer
half
peopl
hiv
care
unit
kingdom
age
year
sourc
id
gum
id
gum
id
gum
id
gum
id
gum
id
gum
id
gum
id
gum
id
gum
id
background
number
peopl
age
year
live
hiv
uk
increas
older
peopl
live
hiv
oplwh
like
diagnos
late
count
aid
defin
ill
within
three
month
diagnosi
inform
sexual
health
servic
utilis
oplwh
prior
hiv
diagnosi
limit
studi
aim
assess
sexual
health
servic
utilis
peopl
live
hiv
plwh
age
compar
prior
hiv
diagnosi
method
studi
conduct
singl
hiv
outpati
centr
uk
plwh
diagnos
within
year
prior
august
identifi
clinic
databas
demograph
hiv
clinic
variabl
includ
baselin
count
date
place
hiv
diagnosi
number
visit
local
sexual
health
clinic
gather
clinic
databas
statist
test
carri
data
determin
differ
signific
defin
result
plwh
includ
remain
plwh
significantli
lower
number
episod
treat
sexual
health
per
person
year
prior
hiv
diagnosi
younger
group
late
diagnosi
seen
compar
tabl
show
facil
hiv
diagnosi
group
plwh
inform
avail
plwh
significantli
like
receiv
diagnosi
primari
secondari
care
wherea
significantli
like
diagnos
sexual
health
ascertain
immedi
caus
death
case
death
directli
relat
hiv
death
directli
relat
hiv
common
immedi
caus
malign
suicid
sepsi
within
hiv
relat
death
common
immedi
caus
multiorgan
endstag
hiv
diseas
lymphoma
sepsi
patient
care
untreat
complic
care
chosen
receiv
treatment
known
hiv
repres
late
diagnos
late
effect
treatment
thu
death
directli
relat
late
diagnosi
compar
nation
previou
audit
overal
patient
diagnos
month
death
compar
across
centr
audit
conclus
compar
audit
period
patient
die
advanc
age
higher
count
frequent
caus
notdirectli
relat
hiv
nonhiv
associ
malign
becom
lead
caus
death
cohort
late
diagnosi
remain
import
contribut
factor
mortal
indic
still
prevent
death
recommend
mortal
review
network
level
meet
chang
made
reduc
prevent
death
trend
prompt
art
initi
among
gay
bisexu
men
diagnos
high
cell
brown
p
kirwan
z
yin
c
chau
v
delpech
public
health
england
london
uk
background
uk
antiretrovir
therapi
art
coverag
art
diagnosi
consid
best
practic
public
health
well
clinic
purpos
gaybisexu
men
start
art
compar
among
heterosexu
suggest
gaybisexu
men
like
start
art
treatment
prevent
tasp
present
demograph
trend
art
initi
among
gay
bisexu
men
sex
men
men
hereaft
method
uk
comprehens
nation
open
cohort
peopl
hiv
point
diagnosi
clinic
updat
site
analys
data
men
start
art
art
start
date
count
prior
art
start
avail
demograph
similar
men
describ
trend
art
uptak
identifi
predictor
prompt
initi
month
diagnosi
among
start
art
men
diagnos
latter
half
exclud
multivari
analys
due
short
follow
time
result
adjust
number
proport
men
start
art
rose
equival
figur
respect
overal
men
start
art
includ
studi
start
art
within
month
within
week
diagnosi
improv
recent
year
figur
factor
associ
prompt
initi
among
includ
recent
year
conclus
trend
art
start
reflect
evolut
nation
treatment
guidelin
impact
tasp
maximis
prompt
art
initi
follow
diagnosi
variat
prompt
initi
diagnosi
region
demograph
factor
requir
investig
ensur
equit
access
art
public
health
purpos
use
technolog
diagnos
hiv
earlier
often
patient
blood
test
year
prior
diagnosi
k
corbett
mann
j
william
chadwick
newcastl
medic
school
uk
jame
cook
univers
hospit
middlesbrough
uk
background
signific
proport
peopl
live
hiv
remain
undiagnos
studi
suggest
mani
patient
present
late
miss
opportun
test
year
prior
diagnosi
one
method
potenti
test
patient
earlier
use
softwar
applic
embed
ordercomm
system
identifi
patient
higher
risk
hiv
patient
attend
clinic
surgeri
hospit
applic
prompt
clinician
add
hiv
test
test
order
howev
applic
effect
patient
undiagnos
hiv
attend
medic
facil
undergo
blood
test
project
aim
determin
case
stabl
local
popul
present
hiv
clinic
northern
england
method
new
diagnos
hiv
present
clinic
review
patient
move
area
within
last
year
exclud
episod
engag
care
result
blood
test
assess
within
webic
ordercomm
system
month
year
diagnosi
reason
order
blood
test
review
determin
indic
condit
potenti
present
subgroup
evalu
result
whether
neutrolymphopaenia
thrombocytopaenia
rais
globulin
present
result
patient
review
median
age
median
count
diagnosi
male
msm
overal
blood
test
order
year
diagnosi
clear
indic
condit
median
year
per
patient
blood
test
done
previou
year
episod
occur
primari
care
hospit
clinic
e
hospit
inpati
episod
late
present
group
median
prior
blood
test
median
year
blood
test
done
indic
condit
subgroup
analys
blood
dyscrasia
rais
globulin
late
present
conclus
high
proport
patient
new
diagnos
hiv
blood
test
year
prior
diagnosi
signific
proport
test
indic
blood
dyscrasia
rais
globulin
technolog
design
prompt
hiv
test
use
algorithm
detect
previou
abnorm
blood
test
amongst
risk
factor
blood
test
order
like
effect
enabl
earlier
diagnosi
hiv
stigma
remain
barrier
test
treatment
adher
associ
sexual
risk
behaviour
compar
stigma
experienc
heterosexu
men
msm
investig
influenc
msm
engag
chemsex
hiv
stigma
method
peopl
live
hiv
stigma
survey
codesign
peopl
live
hiv
advisori
group
nation
expert
peopl
recruit
cross
sector
commun
organis
nh
hiv
clinic
complet
onlin
survey
experi
live
hiv
respons
anonymis
store
secur
analys
engag
commun
member
result
men
complet
survey
identifi
msm
report
engag
chemsex
past
month
msm
white
british
irish
compar
heterosexu
men
msm
less
like
report
relationship
heterosexu
men
respect
multivari
analysi
social
discrimin
variabl
found
msm
twice
like
report
sexual
reject
past
month
compar
heterosexu
men
msm
report
sexual
reject
past
month
compar
heterosexu
men
differ
attribut
reject
hiv
statu
high
group
msm
heterosexu
men
msm
engag
chemsex
past
month
like
report
sexual
reject
compar
msm
report
engag
chemsex
aor
ci
conclus
msm
live
hiv
uk
experienc
greater
stigma
discrimin
term
sexual
reject
compar
heterosexu
men
effect
exagger
msm
engag
chemsex
sexual
discrimin
experienc
group
like
attribut
reject
hiv
statu
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
new
servic
peopl
live
hiv
mental
health
problem
bradshaw
bennett
brighton
sussex
univers
hospit
nh
trust
uk
sussex
partnership
nh
foundat
trust
uk
background
mental
health
problem
mh
p
highli
preval
amongst
peopl
live
hiv
plwh
audit
access
mh
servic
accord
british
psycholog
societi
guidelin
respond
find
method
retrospect
note
review
phone
consult
undertaken
plwh
recent
discharg
hospit
new
servic
establish
respons
find
characterist
servic
user
describ
month
period
statist
analysi
factor
associ
mhp
chisquar
fisher
test
result
male
median
age
year
hiv
vl
undetect
report
alcohol
excess
recreat
inject
drug
use
report
current
mhp
previou
mhp
recreat
drug
use
associ
current
mhp
individu
current
andor
past
mhp
particip
phone
interview
deem
unsuit
call
uncontact
felt
health
care
profession
hcp
given
suffici
opportun
discuss
mhp
experienc
stigma
weekli
pilot
joint
hivpsychiatri
clinic
set
patient
discuss
virtual
face
face
appoint
involv
patient
male
vl
undetect
diagnos
depress
andor
anxieti
disord
person
disordertrait
new
psychiatr
drug
start
dose
chang
individu
onward
referr
made
psycholog
talk
therapi
median
wait
time
appoint
day
versu
day
convent
mh
servic
seventyon
per
cent
individu
complet
feedback
questionnair
satisfi
satisfi
natur
timeli
inform
receiv
prior
attend
appoint
benefici
current
problem
satisfi
satisfi
appoint
locat
conclus
plwh
recent
inpati
high
preval
mhp
signific
minor
felt
suffici
opportun
discuss
mhp
new
servic
led
reduc
wait
time
correspond
high
level
satisfact
hiv
centr
consid
audit
provis
mh
servic
plwh
expand
access
indic
review
patient
fail
disclos
hiv
statu
gp
care
compromis
friday
r
mead
botchey
g
brook
london
northwest
healthcar
nh
trust
uk
background
hiv
posit
peopl
live
long
healthi
live
import
access
gener
practition
gp
experi
treat
wide
rang
day
day
health
condit
bhiva
recommend
patient
encourag
regist
gp
alreadi
regist
hiv
servic
regularli
commun
gp
patient
includ
creation
care
plan
appropri
object
review
determin
mani
patient
within
hiv
servic
fail
disclos
statu
gp
explor
reason
method
retrospect
review
electron
patient
record
epr
conduct
patient
whose
clinic
letter
sent
gp
gp
awar
statu
select
follow
record
demograph
durat
diagnosi
count
viral
load
antiretrovir
therapi
reason
fail
disclos
result
overal
patient
across
two
site
patient
fail
disclos
gp
male
heterosexu
homosexu
bisexu
major
age
origin
subsaharan
africa
almost
patient
diagnos
within
last
five
year
year
greater
year
well
establish
antiretrovir
arv
util
one
three
regimen
averag
count
greater
viral
load
fulli
suppress
anticip
patient
first
diagnos
gum
clinic
remain
special
regist
gp
time
diagnosi
patient
comorbid
includ
hypertens
diabet
asthma
mental
health
ill
obes
other
reason
lack
disclosur
alway
clearli
document
howev
anxieti
around
confidenti
immigr
issu
inabl
find
suitabl
gp
commonli
cite
conclus
overal
major
patient
disclos
gp
howev
review
highlight
need
work
encourag
patient
disclos
patient
mental
health
issu
care
compromis
struggl
adher
drug
use
better
manag
primari
care
level
enabl
barrier
diet
exercis
behaviour
chang
peopl
live
hiv
qualit
investig
duncan
b
peter
l
goff
c
riva
guy
st
thoma
hospit
london
uk
king
colleg
london
uk
univers
southampton
uk
background
peopl
live
hiv
plwh
may
experi
particular
enabl
barrier
lifestyl
chang
report
hivspecif
qualit
investig
aim
characteris
enabl
barrier
method
hiv
patient
prediabet
attend
urban
outpati
clinic
invit
particip
diet
exercis
intervent
complet
drop
declin
take
part
intervent
invit
particip
research
interview
particip
purpos
sampl
ensur
maximum
divers
topic
guid
use
howev
particip
encourag
speak
freeli
interview
digit
record
transcrib
themat
analysi
conduct
lead
research
use
framework
aid
nvivo
softwar
check
collabor
ensur
rigour
result
potenti
particip
consent
interview
took
part
intervent
declin
analysi
interview
identifi
key
theme
fear
disclosur
hiv
statu
particip
felt
happi
disclos
develop
diabet
hiv
declin
particip
achiev
fewer
intervent
goal
exhibit
extern
health
locu
control
blame
diabet
risk
hiv
medicin
believ
behaviour
chang
futil
achiev
goal
consid
prediabet
treatabl
find
practic
way
surmount
barrier
enabl
includ
desir
avoid
ad
pill
diseas
burden
strong
support
network
deliber
weight
loss
lead
loss
cultur
ident
disclosur
hiv
statu
signific
barrier
valoris
overweight
barrier
african
commun
weight
loss
present
loss
ident
gay
men
selfidentifi
bear
subsect
gay
men
reject
norm
idealis
lean
muscular
like
hairier
heavier
conclus
fear
disclosur
hiv
underestim
appear
affect
desir
abil
chang
behaviour
known
fear
loss
ident
among
gay
men
identifi
bear
specif
live
hiv
intervent
treat
metabol
condit
plwh
take
account
enabl
barrier
chang
hivspecif
patient
extern
health
locu
control
may
benefit
psycholog
referr
experi
stigma
discrimin
among
women
live
hiv
uk
find
peopl
live
hiv
stigma
survey
uk
experi
live
hiv
varieti
set
specif
focu
previou
year
examin
live
experi
women
took
part
survey
method
advisori
group
commun
member
expert
help
design
survey
peopl
recruit
commun
organis
hiv
clinic
complet
anonym
onlin
survey
respons
store
secur
analys
phe
commun
engag
univari
multivari
analys
perform
result
women
took
part
women
men
report
rel
high
level
worri
avoid
exclus
social
set
last
year
half
particip
low
selfimag
relat
hiv
overal
fewer
women
report
reject
sexual
partner
vs
p
tran
women
report
worri
verbal
harass
vs
exclus
famili
gather
vs
women
despit
similar
level
disclosur
level
primari
care
women
report
less
control
disclosur
statu
aor
ci
lower
level
support
follow
disclosur
aor
ci
compar
men
adjust
demograph
tran
women
report
treat
differ
patient
gp
cf
women
almost
half
report
hear
neg
comment
healthcar
worker
hiv
statu
peopl
hiv
compar
women
conclus
women
feel
less
control
support
primari
care
regard
disclosur
hiv
tran
women
experi
disproportion
high
level
discrimin
intervent
increas
sensit
support
within
healthcar
requir
experi
stigma
discrimin
healthcar
set
tran
peopl
live
hiv
uk
find
peopl
live
hiv
stigma
survey
uk
hibbert
w
crennajen
l
benton
p
kirwan
lut
okala
wolton
ross
furegato
asbo
k
nambiar
j
roch
c
weerawardhana
hudson
v
delpech
public
health
england
london
uk
famili
plan
associ
london
uk
cliniq
cic
london
uk
chelsea
westminst
hospit
london
uk
brighton
sussex
univers
hospit
nh
trust
uk
queen
univers
belfast
uk
background
tran
umbrella
term
use
refer
peopl
identifi
gender
assign
birth
oppos
cisgend
research
experi
tran
peopl
live
hiv
lack
compar
experi
stigma
discrimin
healthcar
set
report
tran
peopl
live
hiv
uk
cisgend
peopl
method
peopl
live
hiv
stigma
survey
codesign
peopl
live
hiv
advisori
group
nation
expert
peopl
recruit
cross
sector
commun
organis
nh
hiv
clinic
complet
anonym
onlin
survey
respons
store
secur
analys
commun
engag
tran
cisgend
particip
identifi
via
specif
question
current
gender
ident
assign
gender
birth
result
particip
identifi
tran
tran
femal
tran
male
gender
queernonbinari
past
month
compar
cisgend
particip
tran
peopl
significantli
like
report
disclosur
hiv
statu
without
consent
health
care
worker
health
care
colleagu
vs
member
public
vs
p
furthermor
multivari
analys
tran
peopl
significantli
like
report
worri
treat
differ
seek
health
care
vs
aor
ci
report
delay
refus
treatment
vs
past
year
control
demograph
social
factor
almost
half
tran
peopl
live
hiv
avoid
health
care
need
compar
cisgend
peopl
live
hiv
conclus
despit
excel
health
outcom
peopl
live
hiv
uk
especi
tran
peopl
continu
report
high
level
stigma
discrimin
health
care
set
avoid
health
care
due
hiv
statu
potenti
lead
consequ
health
wellb
find
call
increas
transspecif
awar
educ
within
healthcar
set
greater
support
tran
peopl
live
hiv
seek
health
care
nh
investig
intersect
substanc
use
highrisk
sexual
behaviour
associ
mental
health
peopl
live
hiv
e
pool
j
vera
winston
e
bagkeri
c
sabin
p
mallon
sachikony
f
post
pozniak
boffito
brighton
sussex
medic
school
uk
imperi
colleg
london
uk
univers
colleg
london
uk
univeristi
colleg
dublin
school
medicin
ireland
uk
commun
advisori
board
london
uk
king
colleg
london
uk
chelsea
westminst
hospit
london
uk
background
high
preval
smoke
alcohol
recreat
drug
use
report
peopl
live
hiv
addit
higher
risk
sexual
behaviour
investig
associ
risk
behaviour
assess
whether
presenc
multipl
risk
associ
measur
mental
health
among
hivposit
particip
poppi
studi
method
substanc
use
assess
via
detail
patient
questionnair
highrisk
sexual
behaviour
infer
sexual
transmit
diseas
std
diagnosi
last
year
mental
health
assess
patient
report
histori
mental
health
condit
current
depress
symptom
patient
health
questionnair
current
signific
depress
symptom
center
epidemiolog
studi
depress
cesd
associ
presenc
multipl
risk
behaviour
measur
mental
health
men
sex
men
msm
investig
via
logist
regress
adjust
demograph
factor
result
hivposit
poppi
particip
male
msm
mean
rang
age
year
current
smoker
report
drink
unit
alcoholweek
recent
month
drug
use
recent
std
report
behaviour
defin
exhibit
highrisk
phenotyp
preval
phenotyp
declin
age
odd
ratio
year
older
ci
p
seen
age
group
highrisk
phenotyp
msm
adjust
age
msm
time
like
report
highrisk
phenotyp
heterosexu
p
predict
factor
identifi
among
msm
report
mental
health
condit
cesd
msm
report
highrisk
phenotyp
increas
risk
three
measur
mental
health
statu
tabl
conclus
subgroup
particip
report
multipl
riski
behaviour
identifi
strongli
associ
msm
msm
phenotyp
gener
associ
measur
mental
health
modifi
stabl
antiretrovir
therapi
patient
think
lewisham
greenwich
nh
trust
london
uk
background
develop
newer
fixeddos
art
combin
adjust
drug
price
commerci
tender
process
increas
avail
gener
antiretrovir
offer
opportun
reduc
toxic
decreas
pill
burden
manag
cost
hiv
treatment
clinician
patient
comfort
chang
treatment
respons
virolog
failur
unaccept
sideeffect
howev
adapt
otherwis
stabl
treatment
basi
cost
requir
differ
type
convers
may
challeng
clinician
could
provok
patient
anxieti
sought
establish
attitud
toward
chang
art
rang
differ
scenario
amongst
stabl
virologicallysuppress
patient
method
selfcomplet
questionnair
offer
stabl
patient
art
month
undetect
hiv
viral
load
plan
treatment
chang
four
week
period
decemb
elicit
patient
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
level
satisfact
current
medic
level
agreement
rate
scale
strongli
agre
strongli
disagre
chang
treatment
sever
differ
situat
result
questionnair
complet
patient
respond
male
blackafrican
agre
strongli
agre
statement
happi
current
medic
mean
score
patient
amen
chang
medic
novel
medic
reduc
side
effect
take
fewer
tablet
patient
ambival
chang
medic
chang
gener
form
recommend
physician
patient
resist
chang
therapi
base
cost
improv
agreeingstrongli
agre
fall
patient
made
awar
magnitud
save
conclus
patient
happi
current
medic
gener
resist
treatment
chang
circumst
chang
view
posit
involv
associ
direct
benefit
individu
patient
advers
chang
medic
cost
primari
driver
chang
awar
size
save
appear
unlik
influenc
plan
explor
attitud
knowledg
around
treatment
chang
gener
therapi
larger
qualit
project
background
young
peopl
hiv
vulner
group
distinct
need
hiv
may
diagnos
time
huge
transit
live
desir
fit
avoid
stigma
may
increas
influenc
peer
pressur
risk
take
behaviour
use
drug
may
increas
sexual
risk
take
compromis
abil
adher
art
increas
risk
hiv
transmiss
littl
data
drug
use
young
adult
hiv
aim
assess
use
recreat
drug
among
young
peopl
hiv
attend
dedic
young
adult
hiv
servic
larg
inner
citi
hiv
clinic
method
questionnair
design
local
ethic
approv
attain
patient
attend
young
adult
hiv
servic
june
dec
provid
anonym
questionnair
fill
privat
post
secur
box
questionnair
retriev
end
studi
data
analys
result
young
peopl
age
complet
survey
median
age
male
msm
heterosexu
bisexu
report
smoke
current
previous
never
respect
respond
report
use
follow
drug
regularli
cannabi
cocain
mdma
mephedron
ketamin
viagra
ghbgbl
drug
use
common
among
msm
compar
heterosexu
msm
report
regular
occasion
drug
use
compar
heterosexu
p
bisexu
report
drug
use
report
inject
drug
least
felt
drug
use
problem
seek
help
drug
alcohol
problem
report
unprotect
sex
high
drug
respond
art
report
miss
art
result
drug
use
miss
appoint
hiv
clinic
ask
drug
interact
awar
recreat
drug
might
interact
art
conclus
data
show
drug
use
common
among
young
peopl
attend
servic
particularli
msm
drug
use
lead
unprotect
sex
miss
art
case
could
import
factor
onward
hiv
transmiss
support
young
peopl
use
recreat
drug
less
safe
limit
drugdrug
interact
key
keep
vulner
cohort
safe
awar
risk
impact
resili
upon
experi
stigma
find
peopl
live
hiv
stigma
survey
uk
p
kirwan
l
benton
w
crennajen
hibbert
lut
okala
l
thorley
asbo
j
jeffri
l
stackpoolmoor
c
kunda
r
mbew
j
morton
nelson
reev
ross
w
sseruma
g
valioti
wolton
hudson
v
delpech
public
health
england
london
uk
famili
plan
associ
london
uk
stigma
index
uk
advisori
group
london
uk
chelsea
westminst
hospit
london
uk
watipa
london
uk
homerton
univers
hospit
nh
foundat
trust
london
uk
background
psycholog
resili
measur
abil
appropri
adapt
stress
advers
low
resili
link
clinic
depress
anxieti
investig
use
valid
resili
scale
appli
experi
report
peopl
live
hiv
method
peopl
live
hiv
stigma
survey
uk
codesign
commun
member
hiv
expert
peopl
recruit
commun
organis
hiv
clinic
throughout
uk
complet
anonym
onlin
survey
respons
store
secur
analys
phe
activ
commun
engag
valid
connordavidson
resili
scale
cdrisc
includ
survey
score
particip
answer
question
calcul
mean
complet
respons
use
imput
miss
respons
particip
classifi
low
medium
high
resili
use
cluster
analys
experi
stigma
discrimin
compar
low
high
resili
result
major
particip
respond
posit
resili
question
often
nearli
alway
abl
adapt
chang
bounc
back
hardship
mean
resili
score
sd
low
medium
high
resili
past
year
low
resili
like
high
resili
diagnos
depress
vs
experienc
social
discrimin
verbalphys
abus
exclus
vs
anxieti
vs
andor
avoid
socialsexu
experi
vs
p
furthermor
avoid
like
attribut
hiv
factor
vs
signific
correl
observ
resili
age
gender
sexual
ethnic
themat
analysi
particip
experi
live
hiv
identifi
low
resili
commonli
report
social
isol
neg
experi
wherea
high
resili
focus
adopt
healthier
behaviour
empow
experi
conclus
resili
scale
may
nonintrus
way
assess
neg
experi
live
hiv
includ
stigma
discrimin
could
therefor
use
screen
tool
hiv
clinic
referr
counsel
peer
support
support
servic
unchart
territori
report
first
gener
grow
older
hiv
l
scott
laycock
c
blow
terrenc
higgin
trust
london
uk
background
due
incred
advanc
treatment
past
year
see
first
group
peopl
grow
older
hiv
research
explor
grow
older
hiv
mean
peopl
uk
includ
long
term
diagnos
grow
cohort
peopl
diagnos
older
method
project
design
peer
led
piec
research
recruit
peer
research
age
older
live
hiv
peer
team
assist
design
implement
interpret
research
particip
across
great
britain
recruit
complet
comprehens
survey
take
part
indepth
interview
group
workshop
result
individu
includ
analysi
via
survey
respons
interview
workshop
age
rang
median
age
particip
women
wide
rang
experi
requir
concern
observ
factor
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
diagnos
effect
treatment
avail
age
woman
connect
higher
level
self
stigma
benefit
relianc
lower
selfreport
wellb
greater
concern
futur
survey
particip
live
poverti
line
respond
report
moder
high
hiv
self
stigma
report
moder
high
level
loneli
futur
care
key
concern
particip
survey
respond
averag
time
health
condit
addit
hiv
gener
popul
age
made
financi
prepar
futur
care
provis
satisfact
qualiti
care
receiv
hiv
clinic
consist
high
although
frustrat
clinic
longer
onestopshop
health
care
need
qualiti
care
receiv
gp
surgeri
variabl
mainli
due
inconsist
knowledg
around
hiv
conclus
huge
divers
experi
cohort
span
begin
epidem
though
recent
diagnos
mani
peopl
need
littl
support
grow
older
hiv
howev
other
experi
complex
health
care
need
poverti
poor
emot
wellb
addit
servic
support
need
well
equip
inform
primari
healthcar
social
care
sector
support
third
sector
organis
vital
use
feminist
participatori
method
explor
experi
age
hiv
women
london
j
stevenson
e
west
j
smith
p
keogh
univers
greenwich
london
uk
open
univers
milton
keyn
uk
background
age
hiv
grow
issu
rel
recent
gain
attent
research
much
unknown
around
clinic
social
challeng
negoti
older
age
hiv
women
age
hiv
addit
challeng
around
rel
invis
lack
understand
evid
gender
need
experi
cope
hiv
alongsid
age
experi
menopaus
method
three
participatori
creativ
workshop
held
women
age
live
hiv
london
workshop
support
host
third
sector
organis
naz
food
chain
ahpn
women
particip
total
workshop
last
two
hour
record
transcrib
anonymis
addit
record
creativ
output
collect
workshop
structur
flexibl
core
activ
addit
discuss
point
use
depend
group
dynam
flow
discuss
workshop
vari
slightli
key
creativ
activ
bodi
map
adapt
use
research
techniqu
support
women
explor
share
experi
creativ
mean
intent
facilit
greater
share
offer
altern
discuss
particip
prefer
result
isol
emerg
major
theme
workshop
particip
describ
loneli
physic
isol
lack
social
support
famili
friendship
network
well
lack
access
support
servic
describ
fear
increas
grew
older
addit
particip
describ
impact
physic
challeng
age
menopaus
manag
hiv
treatment
side
effect
stigma
discrimin
associ
age
hiv
separ
combin
disclosur
social
relationship
particularli
challeng
bodi
map
exercis
particip
describ
fear
uncertainti
futur
depend
formal
sourc
support
particularli
peer
support
support
identifi
key
concern
context
diminish
resourc
cut
servic
conclus
workshop
demonstr
women
valu
opportun
space
share
experi
challeng
fear
hope
around
age
use
innov
participatori
creativ
assetsbas
method
includ
bodymap
enabl
greater
share
particip
descript
chang
need
inpati
care
hiv
patient
modern
antiretrovir
therapi
era
n
smati
de
saram
bower
nelson
imperi
colleg
london
uk
chelsea
westminst
hospit
london
uk
aim
assess
reason
inpati
admiss
tertiari
hiv
care
centr
impact
need
consult
special
deliv
optim
care
method
retrospect
review
inpati
admiss
care
hiv
team
januari
decemb
carri
use
electron
patient
record
data
collect
reason
admiss
length
admiss
level
immunosuppress
admiss
categoris
relat
unrel
hiv
two
independ
physician
disagr
third
clinician
assess
adjud
result
studi
period
inpati
episod
relat
patient
admiss
classifi
hivrel
hivrel
hivrel
admiss
oncolog
aid
defin
malign
opportunist
infect
investig
symptom
patient
count
cll
antiretrovir
toxic
investig
symptom
patient
advanc
hiv
antiretrovir
manag
admiss
relat
hiv
respiratori
condit
hepat
problem
oncolog
relat
substanc
abus
neurolog
renal
gastrointestin
orthopaed
haematolog
mental
health
urolog
dermatolog
geriatr
relat
problem
rheumatolog
gener
surgic
social
need
medic
reason
literatur
review
effect
programm
deliv
antiretrovir
therapi
nonfacil
base
set
subsaharan
africa
follow
ltfu
mortal
includ
data
extract
qualit
quantit
analysi
perform
riskratio
calcul
forest
plot
creat
major
clinic
outcom
use
rstudio
appli
random
effect
model
background
respond
evolv
climat
antiretrovir
arv
prescrib
cost
pressur
midland
east
england
arv
write
group
devis
prescrib
strategi
frame
around
innov
visual
arv
regimen
band
tool
consid
whole
regimen
cost
per
month
clinic
context
whilst
remain
commerci
sensit
nh
england
commiss
statement
nation
guidelin
tender
price
taken
account
averag
band
valu
band
cost
increas
greater
level
teammdt
discuss
requir
look
ascertain
real
world
feasibl
region
strategi
method
new
tool
went
live
timefram
observ
centr
submit
data
captur
region
audit
form
within
timefram
anonymis
data
collat
analys
result
centr
provid
data
west
mid
east
mid
east
england
give
dataset
male
count
cellsmm
hiv
viral
load
cml
region
estim
cost
regimen
per
month
region
band
use
percentag
total
expens
band
repres
seen
data
set
exclud
prescrib
strategi
correctli
implement
case
popular
band
although
band
regimen
made
case
account
total
expens
overal
patient
start
band
regimen
rise
review
group
follow
strategi
observ
regimen
singl
tablet
conclus
centr
contribut
data
demonstr
high
level
adher
region
strategi
data
provid
use
baselin
futur
analysi
arv
band
tool
simpl
method
allow
clinician
view
data
format
prescrib
stratifi
cost
band
allow
comparison
similar
regimen
significantli
differ
price
region
strategi
feasibl
flexibl
way
translat
prescrib
initi
format
clinic
relev
whilst
remain
costeffect
respons
chang
drug
price
attitud
share
electron
patient
record
system
surrey
hiv
clinic
atefi
sy
chan
homerton
sexual
health
servic
london
uk
ashford
st
peter
hospit
surrey
uk
background
electron
patient
record
epr
system
becom
commonplac
mani
part
nh
transit
prompt
us
consid
whether
share
epr
gumhiv
servic
nh
servic
accept
patient
staff
method
conduct
paper
survey
patient
attend
routin
hiv
clinic
appoint
june
septemb
furthermor
conduct
electron
staff
survey
concurr
result
receiv
patient
staff
respons
survey
major
patient
accept
gp
access
hiv
clinic
note
less
half
agre
share
epr
system
gp
gumhiv
hospit
servic
staff
survey
felt
healthcar
provid
outsid
gumhiv
depart
access
note
mani
concern
around
share
epr
stem
fear
stigmatis
although
confidenti
effect
patientphysician
relationship
implic
travel
also
cite
staff
respond
recognis
mani
benefit
share
epr
well
potenti
limit
disadvantag
conclus
shown
consider
accept
princip
share
epr
hiv
primari
care
servic
studi
show
share
data
secondarytertiari
servic
less
readili
accept
strategi
mitig
concern
regard
may
possibl
investig
preval
abnorm
result
baselin
investig
patient
attend
hiv
outpati
servic
method
infect
patient
attend
hiv
depart
januari
octob
includ
studi
cohort
includ
hiv
infect
patient
transfer
care
depart
attend
clinic
first
time
studi
period
result
first
measur
haematolog
renal
liver
cholesterollipid
profil
patient
review
use
actg
grade
identifi
abnorm
result
result
total
patient
attend
clinic
first
time
studi
interv
includ
newli
diagnos
hiv
infect
patient
patient
transfer
hiv
care
centr
newli
diagnos
patient
avid
index
consist
recent
hiv
infect
first
investig
six
patient
grade
renal
failur
three
case
renal
function
normalis
e
gfr
mlmin
within
four
week
start
combin
antiretrovir
treatment
cart
two
patient
hypertens
grade
transamin
detect
patient
hepat
c
infect
nonalcohol
fatti
liver
diseas
diagnos
four
patent
total
cholesterol
hdl
ratio
equal
detect
patient
haemoglobin
electrophoresi
patient
ethnic
northern
european
identifi
sickl
cell
trait
defici
six
four
patient
respect
conclus
major
newli
diagnos
patient
normal
screen
gener
physiolog
baselin
investig
provid
good
measur
patient
gener
physiolog
may
benefici
longitudin
observ
capac
build
senior
clinician
improv
health
care
resourcepoor
set
p
olupotolupot
j
meadway
busitema
univers
mbale
uganda
medicin
muheza
london
uk
background
uk
physician
undertook
survey
hiv
servic
eastern
region
uganda
becam
awar
lack
appropri
postgradu
train
hiv
senior
clinician
support
carri
train
grade
health
worker
clinic
resourc
avail
includ
antiretrovir
therapi
use
effect
patient
deni
treatment
avail
clinic
lack
knowledg
amongst
clinic
staff
method
small
uk
chariti
fund
postgradu
cours
senior
clinician
updat
session
hiv
develop
entir
partnership
local
clinician
annual
confer
develop
occur
year
plan
particip
present
lectur
workshop
clinic
hiv
updat
improv
skill
modern
adult
educ
techniqu
make
present
audit
research
increasingli
studi
area
work
made
present
confer
local
guidelin
develop
confer
session
particip
also
could
appli
fund
undertak
small
research
project
audit
take
train
session
staff
remot
area
educ
facil
result
last
year
follow
achiev
individu
encount
senior
clinician
annual
confer
senior
nurs
local
clinician
rsn
larg
mentorship
workshop
annual
health
care
rural
area
improv
train
workshop
staff
senior
clinician
made
hiv
present
work
place
clinician
conduct
four
hiv
studi
public
nation
guidelin
guidelin
roll
emtct
local
guidelin
place
implement
guidelin
post
exposur
prophylaxi
develop
local
use
plan
nation
guidelin
clinician
set
hiv
clinic
three
rural
set
overal
care
hiv
patient
improv
conclus
resourcelimit
set
empow
local
clinician
regular
train
brought
import
chang
everi
level
health
care
evalu
beyou
mhealth
applic
support
selfmanag
strategi
peopl
live
hiv
brown
waugh
busson
stumpf
chelsea
westminst
hospit
nh
foundat
trust
london
uk
centr
human
comput
interact
design
univers
london
uk
background
beyou
newli
develop
app
design
provid
user
reliabl
inform
bodi
mind
life
known
mobil
health
mhealth
app
support
selfmanag
strategi
peopl
live
hiv
app
give
user
abil
set
goal
achiev
reward
input
health
inform
set
calendar
remind
method
juli
decemb
usabl
use
beyou
evalu
expert
heurist
evalu
b
expert
review
exist
research
public
relat
system
design
use
peopl
live
hiv
c
feedback
potenti
user
feedback
current
user
e
endus
evalu
use
download
beyou
feedback
user
obtain
via
anonym
onlin
questionnair
endus
evalu
includ
beyou
screenshot
omit
question
selfmanag
qualiti
life
wellb
particip
recruit
onlin
via
social
media
platform
push
notif
within
beyou
app
one
interview
conduct
indepth
understand
perspect
result
total
recommend
made
expert
review
overal
app
good
usabl
app
design
could
improv
even
attend
issu
structur
inform
consist
clearer
label
inform
content
perceiv
use
ad
valu
inform
paidfor
app
need
clarif
track
lab
result
appreci
extend
health
data
eg
symptom
suggest
medic
adher
potenti
interact
great
import
respond
aspect
could
improv
app
set
goal
import
user
want
flexibl
frequenc
goal
notifi
conclus
beyou
design
well
present
usabl
issu
relat
structur
inform
consist
clearer
label
could
address
quickli
updat
version
beyou
consid
use
peopl
live
hiv
sever
avenu
improv
includ
clarifi
ad
valu
expand
health
inform
track
medic
adher
support
flexibl
goal
frequenc
notif
explor
onlin
peer
support
peopl
live
hiv
sparrowhawk
lang
terrenc
higgin
trust
london
uk
background
live
digit
age
increasingli
live
live
onlin
via
digit
devic
report
peopl
hiv
access
onlin
peer
support
outcom
achiev
method
activ
user
onlin
peerl
forum
invit
take
part
smallscal
survey
regard
onlin
peer
support
data
collect
undertaken
novemb
decemb
secondari
servic
data
review
period
april
septemb
result
sampl
size
respond
advis
join
servic
talk
peopl
hiv
find
inform
hiv
two
respond
advis
local
servic
area
four
said
servic
area
meet
need
regard
access
onlin
peer
support
volunt
live
experi
hiv
agreedstrongli
agre
increas
mental
wellb
compar
relat
physic
wellb
agreedstrongli
agre
increas
confid
selfmanag
diagnosi
agreedstrongli
agre
reduc
need
contact
gp
health
care
worker
primari
care
set
agreedstrongli
agre
increas
confid
discuss
consult
specialist
nurs
agre
strongli
agre
increas
knowledg
hiv
treatment
care
whilst
agreedstrongli
agre
increas
confid
talk
hiv
peopl
condit
agre
strongli
agre
reduc
feel
social
isol
reduc
feel
loneli
increas
sens
selfworth
analysi
found
respond
live
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
rural
locat
report
less
posit
outcom
diagnos
gay
bisexu
men
report
posit
outcom
six
month
period
april
hour
support
deliv
volunt
result
intervent
chief
categori
live
hiv
recent
diagnos
treatment
basic
inform
emot
support
access
servic
conclus
despit
absenc
facetofac
contact
challeng
digit
commun
user
report
good
outcom
smallscal
studi
onlin
peer
support
provid
peopl
confid
selfmanag
hiv
increas
confid
knowledg
condit
frequent
stabl
attend
har
miss
true
complex
stabl
patient
patel
georg
roch
churchil
e
nixon
gilleec
brighton
sussex
univers
hospit
nh
trust
uk
background
har
introduc
categoris
hiv
patient
group
complex
c
new
stabl
collect
real
time
har
may
use
hiv
commiss
tool
therefor
import
assess
accuraci
first
pilot
concern
rais
har
subcategori
specif
would
captur
complex
hiv
attend
bhiva
guidelin
recommend
stabl
patient
follow
everi
month
review
appoint
activ
identifi
mani
stabl
patient
seen
frequent
therefor
perform
pilot
studi
investig
reason
increas
attend
within
stabl
patient
categori
standard
care
help
achiev
better
outcom
patient
researchact
depart
offer
opportun
particip
rang
intervent
observ
studi
last
ten
year
high
level
engag
patient
sought
judg
current
level
interest
research
amongst
clinic
cohort
determin
type
research
patient
would
happi
particip
inform
futur
strategi
method
selfadminist
questionnair
offer
individu
attend
care
fourweek
period
august
consist
question
design
determin
patient
interest
differ
type
research
prefer
access
inform
research
opportun
result
patient
complet
questionnair
femal
blackafrican
median
age
year
patient
current
art
previous
taken
part
clinic
trial
patient
agre
contact
clinic
suitabl
research
opportun
aris
patient
interest
trial
involv
chang
treatment
new
drug
would
consid
chang
novel
experiment
new
type
treatment
inject
therapi
patient
interest
trial
involv
simpli
take
extra
blood
test
use
blood
result
routin
health
inform
research
gener
men
appear
inclin
particip
trial
appear
signific
differ
attitud
toward
research
particip
regard
age
ethnic
patient
report
use
clinic
websit
sourc
inform
conclus
snapshot
demonstr
high
level
interest
clinic
research
surpris
support
particip
drug
trial
although
observ
studi
qualit
research
also
attract
support
continu
collect
inform
help
inform
futur
choic
studi
open
allow
us
develop
databas
patient
would
consid
clinic
trial
particip
current
evalu
use
sm
direct
patient
research
page
websit
mean
improv
recruit
studi
healthcar
profession
questionnair
evalu
educ
intervent
strengthen
hiv
test
high
hiv
preval
gener
practic
citi
within
southwest
england
c
davi
j
kesten
j
horwood
may
gompel
croft
b
coleman
bill
univers
bristol
uk
southmead
hospit
bristol
uk
central
health
clinic
bristol
uk
bristol
citi
council
uk
background
encourag
appropri
hiv
test
citi
council
commiss
educ
intervent
gppractic
high
hiv
preval
within
citi
southwest
england
report
questionnair
administ
obtain
feedback
appropri
use
train
particip
healthcar
profession
hcp
method
educ
session
base
medfash
hiv
test
practic
onlin
educ
tool
deliv
steppedwedg
randomis
control
trial
gppractic
high
hiv
practic
popul
preval
feedback
train
via
paperbas
evalu
questionnair
complet
immedi
train
mean
score
seven
statement
calcul
use
point
scale
disagre
agre
result
train
session
attend
hcp
gp
nurs
other
eg
practic
manag
evalu
questionnair
complet
mean
score
follow
statement
appli
inform
gain
train
practic
set
trainer
activ
involv
learn
process
score
highest
mean
score
statement
particip
awar
bhiva
nice
guidelin
hiv
test
score
lowest
mean
score
three
statement
train
met
profession
educ
need
result
train
feel
confid
abil
discuss
hiv
test
patient
confid
abil
conduct
hiv
test
receiv
mean
score
particip
ask
feel
strength
train
exampl
freetext
respons
includ
interact
summaris
risk
factor
test
refer
rais
awar
inform
preval
present
symptom
awar
ask
would
anyth
differ
practic
set
result
train
respons
includ
ye
offer
test
patient
awar
need
test
ye
like
offer
part
routin
test
method
onlin
survey
undertaken
peopl
live
hiv
plhiv
across
england
respond
predominantli
gay
men
age
rang
year
old
median
year
live
hiv
focu
group
held
posit
uk
london
particip
women
three
men
age
result
commun
gp
hiv
clinic
report
gp
hiv
clinician
identifi
commun
unsatisfactori
plhiv
state
hiv
clinic
commun
gp
gp
commun
hiv
clinic
clinic
govern
found
mani
patient
current
confid
gp
knowledg
hiv
state
gp
abl
manag
health
gp
good
understand
hiv
issu
often
patient
know
hiv
relat
draw
line
lead
confus
manag
aspect
care
confidenti
today
respond
felt
inform
held
confidenti
gp
improv
percept
fear
confidenti
breach
common
amongst
plhiv
sexual
health
survey
respond
perceiv
gp
comfort
talk
sexual
health
implic
sexual
health
manag
plhiv
primari
care
also
pose
greater
risk
earli
identif
diagnosi
treatment
model
care
major
plhiv
want
gp
situat
within
hiv
clinic
mirror
studi
smaller
cohort
want
access
gp
local
howev
overrid
issu
one
knowledg
educ
gp
conclus
six
year
studi
progress
term
gp
support
plhiv
notabl
manag
confidenti
howev
poor
commun
knowledg
burden
patient
manag
care
ensur
aspect
join
much
work
still
need
improv
care
peopl
live
hiv
promot
support
selfmanag
hiv
test
practic
local
genitourinari
cancer
servic
qualiti
improv
project
evalu
current
practic
throughout
cheshir
merseysid
regard
offer
hiv
test
earli
neoplast
lesion
diagnos
use
nonvalid
questionnair
via
telephon
interview
nurs
staff
offer
colposcopi
servic
within
region
gynaecolog
specialist
nurs
tertiari
cancer
centr
consist
averag
five
minut
discuss
colposcopi
nurs
specialist
centr
gynaecolog
colorect
cancer
nurs
specialist
clarifi
whether
test
hiv
routin
whether
offer
test
whether
awar
guidelin
regard
result
survey
hospit
across
region
includ
cancer
centr
cin
vin
none
hospit
survey
current
offer
hiv
test
new
cin
vin
diagnos
one
hospit
report
awar
guidanc
cin
vin
consid
chang
pathway
reflect
conclus
direct
despit
guidanc
bhiva
local
servic
routin
offer
hiv
test
individu
new
squamou
genit
neoplast
diagnosi
one
hospit
within
region
awar
bhiva
guidelin
action
go
forward
evalu
includ
explor
perceiv
barrier
educ
depart
local
set
pathway
referr
aim
develop
patient
inform
leaflet
support
encourag
patient
staff
improv
hiv
care
larg
prison
cluster
kegg
j
clark
lewisham
greenwich
nh
trust
london
uk
background
provid
comprehens
inreach
servic
hiv
larg
prison
cluster
sinc
previous
provid
similar
servic
highlight
chang
prison
hiv
popul
describ
improv
made
manag
method
obtain
inform
prison
healthcar
electron
patient
record
epr
system
hiv
posit
prison
seen
servic
april
decemb
result
previou
experi
involv
rel
small
heterosexu
popul
modest
level
ivdu
patient
transport
previou
treat
centr
hiv
care
ad
hoc
care
given
session
hiv
physician
art
seen
hiv
servic
preced
six
month
gener
prior
detent
inform
regard
hiv
care
prison
healthcar
epr
major
experienc
treatment
interrupt
date
provid
care
hiv
peopl
individu
diagnos
hiv
posit
whilst
prison
major
patient
held
categori
b
prison
smaller
number
categori
prison
yoi
msm
known
hcv
coinfect
prison
last
month
msm
offend
behaviour
associ
drug
misus
patient
art
undetect
vl
report
unschedul
treatment
interrupt
usual
around
time
come
prison
patient
refus
opt
defer
treatment
obtain
clinic
summari
patient
made
avail
epr
facilit
care
prison
move
within
prison
system
patient
left
prison
done
suppli
art
identifi
servic
ongo
care
major
conclus
number
hiv
posit
prison
increas
signific
number
msm
offend
behaviour
associ
drug
use
major
patient
awar
hiv
statu
prior
arriv
prison
improv
prison
engag
hiv
care
uptak
art
made
number
intervent
minimis
risk
unschedul
treatment
interrupt
streamlin
care
patient
move
prison
engag
hiv
servic
releas
key
part
offend
resettl
intervent
improv
manag
hepat
c
infect
sexual
health
clinic
patient
seen
hepatologist
within
month
diagnos
offer
treatment
implement
clinic
proforma
improv
document
manag
patient
acut
hcv
infect
complet
phe
notif
form
partner
notif
hiv
neg
individu
identifi
area
improv
implement
proforma
electron
patient
record
time
manag
patient
improv
outcom
prevent
onward
transmiss
peer
mentor
impact
posit
uk
project
train
programm
j
morri
anderson
g
brough
thompson
posit
uk
london
uk
background
review
highlight
outcom
posit
uk
project
peer
mentor
train
programm
project
aim
train
peopl
across
uk
provid
coverag
peer
mentor
hiv
servic
clinic
set
peer
mentor
peopl
live
hiv
train
cover
skill
safeguard
treatment
transmiss
hiv
action
plan
goal
set
three
day
particip
abl
complet
nvq
level
peer
mentor
evalu
taken
place
demonstr
impact
train
provid
support
mentor
method
data
cover
train
session
londonbas
outsid
london
month
data
collect
use
likert
scale
aim
identifi
effect
train
deliveri
potenti
outcom
individu
move
forward
peer
mentor
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
cohort
contain
individu
particip
male
femal
age
rang
year
age
almost
even
split
heterosexu
gaymsmlesbian
particip
complet
form
contain
question
around
variou
aspect
peer
mentoringpretrain
posttrain
knowledg
hiv
relat
issu
understand
use
wellb
measur
abil
use
action
plan
problem
solv
abil
use
activ
listen
understand
attitud
valu
understand
stage
mentor
relationship
understand
boundari
polici
confidenti
knowledg
refer
mentor
relationship
result
data
shown
increas
eight
area
biggest
increas
point
area
directli
applic
peer
mentor
understand
boundari
polici
confidenti
role
abil
use
action
plan
problem
solv
increas
point
pretrain
posttrain
increas
measur
area
show
favour
set
outcom
train
qualit
evalu
educ
intervent
healthcar
profession
appropri
hiv
test
higher
preval
gener
practic
citi
southwest
england
j
kesten
c
davi
j
horwood
may
gompel
bill
b
coleman
croft
univers
bristol
uk
north
bristol
nh
trust
uk
bristol
citi
council
uk
univers
hospit
bristol
uk
introduct
approxim
peopl
infect
hiv
undiagnos
late
diagnosi
occur
neg
consequ
patient
public
health
nh
encourag
appropri
hiv
test
citi
council
commiss
educ
intervent
gppractic
qualit
studi
examin
healthcar
profession
hcp
experi
perceiv
impact
educ
intervent
hiv
test
method
educ
session
base
medfash
hiv
test
practic
onlin
educ
tool
deliv
steppedwedg
randomis
control
trial
gppractic
high
hiv
practic
popul
preval
semistructur
interview
conduct
hcp
attend
train
approxim
posttrain
sexual
health
clinician
deliv
train
interview
explor
pretrain
hiv
test
practic
factor
influenc
test
view
train
impact
knowledg
confid
test
practic
gppractic
reimburs
per
interview
interview
audio
record
transcrib
verbatim
analys
themat
result
interview
last
minut
averag
conduct
across
practic
gp
nurs
sexual
health
clinician
particip
appreci
opportun
updat
hiv
knowledg
tailor
interact
session
deliv
knowledg
sexualhealth
clinician
posttrain
hcp
increas
awar
hiv
indic
condit
confidenceselfefficaci
offer
hiv
test
effici
consider
hiv
test
whilst
felt
increas
hiv
test
other
continu
barrier
test
includ
perceiv
lack
opportun
test
consid
hiv
consult
optimis
intervent
impact
followup
session
recommend
discuss
find
suggest
hiv
train
experienc
posit
improv
perceiv
awar
confid
consider
hiv
test
whilst
percept
test
rate
mix
studi
highlight
hiv
educ
perceiv
valuabl
increas
awar
hiv
test
opportun
repetit
may
need
sustain
impact
reaudit
antiretrovir
drug
wastag
teach
hospit
sexual
health
infecti
diseas
clinic
b
singh
k
michi
wheeler
trotman
best
neari
j
clough
n
beveridg
chaponda
royal
liverpool
univers
hospit
uk
background
audit
hiv
clinic
larg
citi
centr
teach
hospit
show
antiretrovir
arv
drug
wastag
patient
stabl
art
switch
new
regimen
bhiva
confer
identifi
strategi
reduc
wastag
includ
limit
art
suppli
time
start
switch
art
one
month
limit
prescript
outsid
routin
clinic
visit
one
month
encourag
remain
arv
use
nonurg
regimen
switch
enhanc
adher
support
commun
nurs
poorli
adher
patient
reaudit
assess
impact
method
pharmaci
record
period
screen
patient
stabl
one
arv
regimen
b
patient
switch
therapi
electron
hiv
databas
also
interrog
case
note
review
determin
reason
switch
confirm
overprescrib
arv
pharmaci
data
use
confirm
amount
wastag
correspond
cost
oneyear
period
result
total
patient
prescrib
arv
initi
screen
stabl
patient
appear
month
excess
review
hepat
b
hiv
infect
appropri
total
dispens
insuffici
data
record
overprescrib
patient
annual
total
wastag
month
arv
cost
patient
screen
switch
therapi
common
reason
simplif
toler
toxic
interact
failur
adher
less
frequent
wastag
demonstr
case
unclear
total
new
arv
prescrib
month
occas
quantiti
cost
calcul
least
two
assessor
interand
intraobserv
agreement
test
three
switch
patient
conclus
compar
previou
audit
excess
stabl
arv
prescript
remain
similar
despit
increas
cohort
size
wastag
switch
decreas
significantli
reduct
quantiti
new
regimen
prescrib
may
respons
reduct
wastag
follow
simpl
clinician
feedback
intervent
howev
signific
annual
wastag
still
observ
subsequ
electron
prescrib
system
integr
hiv
databas
support
requirementbas
prescrib
screen
hiv
patient
cardiovascular
diseas
coordin
better
primari
care
h
alexand
c
kirbi
bradi
king
colleg
hospit
london
uk
background
bhiva
guidelin
recommend
screen
monitor
age
relat
condit
cardiovascular
health
consider
overlap
recommend
hiv
guidelin
screen
undertaken
primari
care
project
aim
determin
whether
duplic
occur
monitor
cardiovascular
health
hiv
patient
whether
servic
achiev
bhiva
audit
standard
method
gp
qualiti
outcom
framework
qof
crossreferenc
bhiva
monitor
guidelin
identifi
area
recommend
primari
care
hiv
set
contact
local
gp
hiv
patient
age
care
regist
data
collect
patient
disclos
gp
agre
third
parti
inform
share
retrospect
case
note
review
conduct
emi
gp
electron
databas
clinic
record
data
collect
three
area
assess
smoke
statu
onward
referr
blood
pressur
bp
monitor
cardiovascular
diseas
cvd
risk
assess
also
look
whether
hiv
servic
accur
record
comorbid
medic
suppli
dispens
collect
hiv
medicin
commun
pilot
servic
v
gordon
brawley
nh
grampian
aberdeen
uk
background
hiv
medic
suppli
dispens
commun
pharmaci
current
exempt
vat
save
essenti
hiv
cohort
grow
furthermor
servic
cover
rural
area
provid
improv
access
medic
especi
newer
less
toxic
regim
requir
less
frequent
review
servic
cover
larg
rural
area
includ
island
care
approxim
hiv
posit
patient
signific
proport
patient
live
rural
area
often
share
care
arrang
primari
care
andor
televideoconferenc
option
commun
suppli
dispens
hiv
medic
seen
opportun
provid
localis
patient
centr
care
method
patient
treatment
survey
opt
commun
pharmaci
elig
patient
commun
suppli
arrang
put
place
drug
compani
wholesal
nomin
pharmaci
contact
andor
visit
hiv
pharmacist
provid
transfer
pack
contain
order
instruct
regimen
drug
stabil
data
interact
resourc
secondari
care
contact
inform
hospit
base
prescript
post
commun
pharmaci
drug
order
dispens
accordingli
patient
inform
medic
readi
collect
result
patient
current
receiv
medic
commun
pharmaci
date
affect
clinic
attend
complianc
request
patient
return
hospit
dispens
addit
feedback
commun
pharmacist
posit
conclus
commun
pharmaci
suppli
dispens
rel
simpl
option
establish
provid
increas
access
care
patient
furthermor
model
use
chronic
condit
view
forward
step
normalis
hiv
care
pneumococc
vaccin
patient
live
hiv
knowledg
number
p
gallogli
lynn
guy
st
thoma
nh
trust
london
uk
background
streptococcu
pneumonia
infect
signific
caus
pneumonia
invas
pneumococc
diseas
ipd
hivposit
adult
time
higher
risk
infect
associ
greater
morbid
mortal
compar
agedmatch
hivneg
adult
bhiva
recommend
hiv
posit
adult
receiv
singl
dose
pneumococc
conjug
vaccin
irrespect
count
antiretrovir
arv
use
viral
load
vl
age
year
comorbid
also
receiv
singl
dose
pneumococc
polysaccharid
vaccin
local
bhiva
recommend
includ
written
hiv
correspond
gp
present
main
provid
pneumococc
vaccin
aim
studi
establish
current
patient
knowledg
vaccin
adher
bhiva
guidelin
demonstr
number
patient
confirm
vaccin
method
conduct
crosssect
studi
use
questionnair
outpati
attend
hiv
clinic
one
week
period
medic
histori
vaccin
statu
confirm
use
hospit
gp
electron
note
result
male
femal
complet
questionnair
age
rang
year
durat
hiv
diagnosi
rang
month
year
patient
prescrib
arv
therapi
mean
count
rang
patient
latest
vl
level
patient
histori
aidsdefin
ill
gp
awar
patient
hiv
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
diagnosi
patient
comorbid
diabet
mellitu
lung
diseas
liver
diseas
previou
pneumonia
current
smoker
alcohol
histori
patient
prior
knowledg
pneumococc
vaccin
patient
awar
vaccin
patient
report
vaccin
gp
record
confirm
patient
total
vaccin
patient
also
receiv
patient
vaccin
statu
clearli
document
hospit
hiv
electron
note
patient
knowledg
vaccin
patient
unvaccin
conclus
studi
show
gener
hiv
clinic
popul
signific
number
patient
knowledg
pneumococc
vaccin
major
patient
remain
unvaccin
risk
increas
mortal
associ
pneumococc
diseas
health
promot
strategi
need
improv
vaccin
awar
import
patient
popul
fund
pneumococc
vaccin
administr
hiv
clinic
oppos
current
practic
reli
gp
administr
may
increas
uptak
vaccin
line
bhiva
recommend
benchmark
standard
ensur
high
qualiti
effect
hiv
peer
support
servic
posit
uk
london
uk
background
grow
demand
peer
support
commun
live
hiv
recognit
within
nh
role
peer
support
support
clinic
outcom
improv
health
wellb
identifi
role
third
sector
provid
commun
led
support
address
need
peopl
live
hiv
access
peersupport
promot
wellb
treatment
adher
selfmanag
develop
evid
base
standard
hiv
peer
support
essenti
benchmark
hiv
commun
health
social
care
provid
decis
maker
ensur
consist
approach
promot
good
practic
deliveri
peer
support
method
standard
develop
steer
group
peopl
live
hiv
repres
ngo
provid
peer
support
british
hiv
associ
nation
hiv
nurs
associ
children
hiv
associ
chiva
target
consult
undertaken
group
peopl
live
hiv
london
liverpool
youth
group
leader
chiva
summer
camp
individu
across
sector
august
septemb
standard
open
consult
eforum
includ
ukcab
ngo
across
uk
result
format
standard
identifi
includ
titl
rational
compet
skill
need
achiev
standard
expect
outcomesth
chang
hope
achiev
standard
audit
indicatorsto
demonstr
standard
implement
standard
identifi
everybodi
live
hiv
access
peer
support
peopl
provid
peer
support
live
hiv
access
train
support
person
develop
peer
support
includ
robust
monitor
measur
evalu
process
children
young
peopl
hiv
access
child
youth
centr
peersupport
conclus
standard
launch
earli
impact
ukcab
repres
guidelin
write
committe
academicclin
research
studi
board
l
kwardem
r
jame
j
shepherd
reshap
london
uk
ukcab
uk
background
hiv
commun
engag
health
care
sector
long
histori
uk
commun
advisori
board
ukcab
network
hiv
advoc
member
hiv
group
sourc
commun
repres
cr
method
semistructur
interview
conduct
multidisciplinari
england
base
clinician
experi
bhiva
nhvna
committe
trial
steer
group
scientif
advisori
board
hiv
cr
transcript
analysi
done
use
primari
code
preset
emerg
code
clinician
experi
cr
impact
result
frequent
cite
benefit
live
experi
whole
pathway
perspect
cr
brought
other
nonclin
advocaci
empathi
patient
centered
research
initi
direct
develop
patient
inform
dissemin
strategi
commun
prioritis
lobbi
studiesguidelin
realiti
check
media
manag
increas
learn
clinician
interviewe
valu
contribut
cr
committe
identifi
uniqu
impact
ukcab
seen
valuabl
formal
resourc
provid
skill
cr
fund
commonli
describ
challeng
commun
engag
particip
felt
train
mentorship
apprenticeship
induct
shadow
valuabl
profession
cr
join
committe
repres
cr
vari
view
impress
cr
abil
bring
rang
view
hiv
commun
other
uncertain
exist
feedback
system
concern
viewpoint
group
unheard
observ
peopl
newli
diagnos
may
differ
need
long
term
diagnos
concern
express
cr
select
process
provis
opportun
newer
less
experienc
cr
number
innov
best
practic
exampl
commun
involv
identifi
conclus
cr
highli
valu
seen
effectiveimpact
profession
studi
benefit
individu
profession
organ
health
system
constant
reflect
need
organ
commun
ensur
effect
represent
mechan
within
stakehold
ukcab
bhiva
nhivna
tsc
need
sustain
cr
model
unanim
peopl
live
hiv
must
directli
involv
decis
make
servic
deliveri
clinic
care
direct
impact
live
women
inspir
support
empow
unleash
posit
potenti
wise
workshop
hivposit
women
uk
background
wise
workshop
aim
provid
advocaci
skill
women
live
hiv
well
opportun
meet
collect
analys
current
situat
begin
develop
advocaci
strategi
follow
huge
success
first
wise
workshop
sophia
forum
ran
second
workshop
new
group
advoc
octob
sophia
forum
engag
posit
uk
help
design
deliveri
method
workshop
took
place
manchest
day
attend
women
differ
part
england
women
select
base
interest
desir
particip
advocaci
group
divers
black
african
women
black
women
caribbean
russian
european
age
rang
facilit
women
live
hiv
one
attend
first
workshop
particip
extern
speaker
also
invit
facilit
specif
session
session
power
control
women
resist
imkaan
activ
direct
action
act
poetri
advocaci
dorothea
smart
sophia
forum
recent
publish
collect
poetri
session
result
evalu
workshop
overwhelmingli
posit
particip
ask
evalu
session
individu
score
poor
satisfactori
good
excel
ninetynin
per
cent
rate
session
either
good
excel
conclus
second
wise
workshop
highlight
import
women
space
women
hiv
reflect
live
develop
confid
skill
move
activ
discuss
show
perceiv
stigma
prevent
peopl
live
openli
hiv
fear
famili
member
friend
employ
employe
respond
neg
combin
poverti
isol
issu
unresolv
immigr
case
lack
skill
still
creat
huge
obstacl
women
full
particip
advocaci
howev
throughout
workshop
women
explor
myriad
way
drew
strength
effect
chang
live
could
drawn
catalyz
wider
transform
suffer
thing
keep
go
backward
forward
experi
menopaus
among
women
live
hiv
unit
kingdom
j
mcgregorread
f
pettitt
f
burn
r
gilson
c
sabin
tariq
petretti
ukcab
london
uk
univers
colleg
london
uk
posit
uk
london
uk
background
improv
surviv
due
antiretrovir
therapi
art
led
shift
age
distribut
peopl
live
hiv
increas
number
women
live
hiv
wlhiv
reach
menopaus
age
present
result
qualit
studi
explor
experi
menopaus
among
wlhiv
uk
method
collabor
hiv
chariti
two
peer
research
conduct
three
focu
group
discuss
fgd
wlhiv
age
fgd
transcrib
verbatim
analys
themat
nvivo
work
part
prime
studi
mixedmethod
observ
studi
explor
impact
menopaus
wlhiv
health
wellb
result
women
describ
lack
prior
knowledg
leav
underprepar
menopaus
symptom
women
born
subsaharan
africa
exacerb
cultur
taboo
around
discuss
menopaus
loss
kinship
network
migrat
menopaus
context
hiv
brought
particular
challeng
particip
concern
menopaus
could
precipit
hivinfect
art
whilst
reluct
take
medic
hormon
replac
therapi
alreadi
art
common
symptom
hot
flush
mood
chang
poor
sleep
sometim
impact
abil
adher
art
mani
particip
recognis
menopaus
symptom
instead
attribut
art
sideeffect
hiv
furthermor
found
go
backward
forward
primari
healthcar
provid
hcp
hivphysician
seek
advic
clinic
care
often
lead
frustrat
delay
particip
highlight
import
support
hcp
access
inform
hiv
menopaus
need
ongo
peersupport
mani
describ
particip
fgd
often
first
opportun
discuss
menopaus
wlhiv
empow
conclus
one
first
qualit
studi
explor
experi
menopaus
wlhiv
particip
encount
particular
challeng
recognit
manag
menopaus
result
also
hivposit
increas
awar
among
patient
hcp
develop
hivspecif
patient
resourc
peersupport
network
may
help
support
wlhiv
stage
live
limit
neg
impact
hiv
care
women
hivaid
antiretrovir
therapi
lower
incid
symptom
associ
menstrual
dysfunct
hapangama
n
tempest
edirisingh
univers
liverpool
uk
royal
liverpool
univers
hospit
uk
background
symptom
associ
endometriosi
menstrual
disord
common
amongst
women
reproduct
age
pathogenesi
ill
postul
due
aberr
endometri
regener
immun
respons
endometri
stem
cell
highli
activ
antiretrovir
therapi
haart
shown
enhanc
event
seen
biolog
age
tissu
ill
associ
stemcel
age
appear
prematur
hivaid
patient
specif
compon
haart
caus
featur
resembl
age
thought
nucleosid
revers
transcriptas
inhibitor
nrti
antitelomeras
activ
recent
shown
high
telomeras
activ
featur
endometri
epitheli
progenitor
cell
endometriosi
aim
examin
women
haart
lower
incid
symptom
associ
menstrual
irregular
endometriosi
method
hiv
posit
women
group
attend
specialist
hiv
clinic
royal
liverpool
univers
hospit
consent
complet
questionnair
attend
doctor
record
patient
hiv
relat
histori
includ
recent
blood
test
result
non
hiv
posit
patient
use
control
result
women
slightli
older
vs
year
p
higher
bmi
vs
p
like
parou
vs
noncaucasian
vs
p
compar
mean
durat
diagnosi
hiv
year
patient
diagnos
aid
count
viral
load
median
durat
haart
year
similar
proport
women
group
use
contracept
vs
women
use
condom
vs
women
report
light
normal
flow
vs
shorter
durat
day
bleed
commonli
compar
control
vs
women
less
like
rate
menstrual
pain
moder
sever
compar
control
vs
conclus
data
suggest
women
hiv
nrti
decreas
incid
menstrual
flow
durat
pain
support
hypothesi
possibl
due
benefici
side
effect
nrti
endometri
telomeras
activ
studi
warrant
examin
effect
nrti
treat
patient
menstrual
problem
endometriosi
nrti
uniqu
advantag
exist
treatment
allow
patient
retain
fertil
provid
holist
sexual
reproduct
health
srh
care
hiv
outpati
set
improv
srh
outcom
hiv
posit
women
r
metcalf
p
anderson
v
smith
f
fargi
brownle
centr
infecti
diseas
glasgow
uk
background
urban
hiv
servic
provid
preconcept
advic
multidisciplinari
obstetricpaediatrichiv
care
pregnanc
contracept
servic
includ
long
act
revers
contracept
larc
cervic
screen
femal
cohort
mostli
area
high
depriv
low
cervic
screen
uptak
high
unintend
pregnanc
rate
well
recognis
aim
enabl
women
safe
plan
pregnanc
prevent
hiv
mother
child
transmiss
prevent
cervic
cancer
enhanc
srh
servic
provid
sought
evalu
use
servic
assess
pregnanc
plan
pregnanc
outcom
contracept
use
cervic
screen
women
method
two
year
retrospect
review
pregnanc
juli
aug
snapshot
analysi
contracept
use
via
citywid
hospit
sexual
health
servic
case
note
review
oct
scottish
cervic
callrecal
system
access
assess
cervic
screen
uptak
recent
result
dec
result
pregnanc
result
termin
spontan
abort
women
disclos
servic
pregnanc
term
women
median
age
year
cf
nation
averag
year
prior
conceiv
report
plan
pregnanc
document
use
contracept
concept
report
unplan
cf
nation
averag
pregnanc
woman
establish
antiretrovir
arv
prior
concept
hiv
vl
copiesml
new
diagnos
pregnanc
previous
diagnos
arv
achiev
vl
copiesml
term
caesarean
section
nonobstetr
reason
postpartum
larc
use
condom
contracept
figur
show
overal
contracept
use
cohort
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
cervic
screen
previou
month
cf
nation
rate
neg
result
conclus
poor
uptak
preconcept
servic
disclosur
pregnanc
plan
unplan
pregnanc
rate
high
larc
rate
low
includ
post
partum
despit
contracept
offer
cervic
screen
uptak
higher
scottish
nation
averag
plan
increas
patient
awar
srh
servic
conduct
qualit
research
determin
women
avail
full
srh
servic
current
offer
hormon
replac
therapi
hrt
benefici
hiv
posit
women
symptomat
andor
earli
menopaus
may
improv
bone
health
centr
hiv
posit
patient
femal
age
year
postmenopaus
women
may
refer
hiv
medic
gynaecolog
clinic
review
hrt
counsel
aim
assess
uptak
hrt
hiv
posit
postmenopaus
women
effect
hrt
treat
menopaus
symptom
demograph
hiv
characterist
earli
prematur
natur
menopaus
method
retrospect
case
note
review
postmenopaus
women
hiv
attend
medic
gynaecolog
clinic
jan
dec
menopaus
classifi
age
menopaus
prematur
year
earli
year
natur
baselin
characterist
manag
describ
result
women
refer
medic
gynaecolog
postmenopaus
black
ethnic
undetect
treatment
median
iqr
current
nadir
cellsll
respect
age
rang
menopaus
year
prematur
earli
menopaus
evid
differ
demographichiv
characterist
menopaus
categori
p
trend
higher
pariti
among
natur
menopaus
compar
earli
prematur
median
iqr
pariti
vs
respect
women
attend
discuss
menopaus
manag
symptom
control
accept
hrt
prescrib
system
hrt
continu
sequenti
oestrogen
patch
gel
plu
micron
progestogen
requir
oestrogen
uptitr
improv
symptom
experienc
side
effect
bleed
mood
disturb
women
symptomat
relief
within
month
start
hrt
discontinu
due
side
effect
anxieti
breast
cancer
underw
bone
miner
densiti
evalu
osteopen
osteoporosi
conclus
hrt
accept
major
women
hiv
counsel
offer
treatment
women
symptomat
improv
advers
effect
rare
dose
adjust
requir
major
patient
preval
asymptomat
sti
patient
high
risk
hiv
acquisit
transmiss
ugandan
clinic
set
e
mabonga
l
hamzah
c
gaydo
manab
elbir
j
kisaky
r
parkesratanshi
king
colleg
hospit
london
uk
john
hopkin
univers
baltimor
usa
infecti
diseas
institut
kampala
uganda
univers
cambridg
uk
background
manag
sexual
transmit
infect
sti
subsaharan
africa
util
syndrom
manag
asymptomat
patient
high
risk
sti
therefor
routin
test
aim
studi
establish
preval
asymptomat
chlamydia
ct
gonorrhea
ng
key
popul
increas
risk
acquisit
transmiss
hiv
risk
factor
sti
materi
method
studi
carri
infecti
diseas
institut
mulago
hospit
kampala
marchjuli
asymptomat
patient
follow
categori
offer
sti
test
hiv
discord
coupl
hiv
young
adult
hiv
pregnant
patient
attend
risk
popul
clinic
patient
examin
provid
urin
selftaken
vulval
swab
test
ng
ct
polymeras
chain
reaction
pcr
use
bd
probetec
tm
result
patient
screen
women
median
age
year
iqr
median
cellsll
iqr
hiv
posit
antiretrovir
sti
diagnos
women
hiv
posit
hiv
neg
preval
ng
ct
sti
associ
age
year
ci
employ
partner
unknown
hiv
statu
compar
hiv
posit
partner
sti
associ
histori
previou
sti
condom
use
number
partner
patient
treat
screen
contact
follow
call
back
partner
report
receiv
treatment
conclus
signific
preval
asymptomat
sti
femal
year
patient
would
gone
undiagnos
use
syndrom
manag
untreat
asymptomat
sti
may
facilit
increas
hiv
transmiss
asymptomat
key
hiv
posit
popul
selfcollect
ngct
test
investig
sexual
health
peopl
live
hiv
r
thomsonglov
f
alloba
j
ruffl
sempl
c
bate
royal
liverpool
broadgreen
univers
hospit
nh
trust
uk
background
british
hiv
associ
bhiva
issu
standard
care
peopl
live
hiv
state
specif
audit
outcom
relat
sexual
health
advis
annual
sexual
health
histori
screen
monthli
syphili
hepat
c
serolog
annual
cervic
cytolog
screen
women
audit
evalu
perform
inner
citi
hiv
clinic
meet
target
compar
previou
audit
method
retrospect
studi
hiv
patient
attend
appoint
may
exclus
criteria
includ
recent
hiv
diagnosi
patient
attend
within
preced
year
sampl
size
femal
male
patient
exclud
inform
gather
clinic
letter
case
note
gumhiv
aid
report
databas
har
domain
evalu
evid
sexual
health
histori
sexual
health
screen
syphili
serolog
hepat
c
serolog
cervic
cytolog
evid
contracept
discuss
evalu
qualiti
improv
purpos
result
show
overal
improv
meet
bhiva
standard
care
sinc
particular
uptak
syphili
serolog
audit
limit
includ
unavail
case
note
handwrit
legibl
lack
document
clinic
move
away
paper
note
improv
outcom
area
chang
har
databas
implement
aid
document
sexual
health
histori
screen
uptak
annual
cytolog
decreas
sinc
result
audit
aidem
emoir
creat
remind
clinician
address
overdu
smear
patient
low
uptak
record
contracept
discuss
highlight
need
improv
area
contracept
discuss
could
includ
bhiva
sexual
health
audit
outcom
healthcar
practition
discuss
parenthood
possibl
hivposit
msm
preliminari
find
mail
studi
method
qualit
interview
conduct
hivposit
msm
across
four
hiv
outpati
clinic
men
age
two
selfidentifi
gay
none
children
part
interview
patient
ask
whether
want
becom
parent
futur
whether
ever
talk
parenthood
possibl
clinician
whether
thought
parenthood
reproduct
health
discuss
part
hiv
care
result
msm
express
parent
desir
four
patient
recal
talk
parenthood
possibl
healthcar
practition
case
men
briefli
reassur
time
hiv
diagnosi
possibl
hivposit
peopl
becom
parent
saw
signific
suffici
inform
men
said
would
like
would
like
discuss
issu
relat
parenthood
context
hiv
direct
relev
inform
sourc
minor
case
live
hiv
seem
direct
impact
men
parent
intent
frequent
given
suggest
highlight
parenthood
possibl
time
hiv
diagnosi
signpost
inform
sourc
potenti
interest
men
said
would
feel
comfort
ask
clinic
staff
parenthood
possibl
especi
specif
question
implic
hiv
biolog
parenthood
conclus
find
suggest
signific
number
hivposit
msm
would
like
children
futur
time
hiv
diagnosi
especi
crucial
reassur
possibl
peopl
live
hiv
becom
parent
detail
reliabl
inform
avail
clinician
abl
direct
patient
relev
resourc
need
import
healthcar
practition
assum
issu
relat
parenthood
reproduct
health
relev
msm
popul
author
hiv
medicin
british
hiv
associ
hiv
medicin
suppl
